
<html lang="en"     class="pb-page"  data-request-id="d171b71a-1e5f-46c3-8556-59404d8d4495"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2017.60.issue-21;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.7b01223;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen" /></meta><meta name="dc.Creator" content="Jennifer R.  Riggs" /></meta><meta name="dc.Creator" content="Mark  Nagy" /></meta><meta name="dc.Creator" content="Jan  Elsner" /></meta><meta name="dc.Creator" content="Paul  Erdman" /></meta><meta name="dc.Creator" content="Dan  Cashion" /></meta><meta name="dc.Creator" content="Dale  Robinson" /></meta><meta name="dc.Creator" content="Roy  Harris" /></meta><meta name="dc.Creator" content="Dehua  Huang" /></meta><meta name="dc.Creator" content="Lida  Tehrani" /></meta><meta name="dc.Creator" content="Gordafaried  Deyanat-Yazdi" /></meta><meta name="dc.Creator" content="Rama Krishna  Narla" /></meta><meta name="dc.Creator" content="Xiaohui  Peng" /></meta><meta name="dc.Creator" content="Tam  Tran" /></meta><meta name="dc.Creator" content="Leo  Barnes" /></meta><meta name="dc.Creator" content="Terra  Miller" /></meta><meta name="dc.Creator" content="Jason  Katz" /></meta><meta name="dc.Creator" content="Yang  Tang" /></meta><meta name="dc.Creator" content="Ming  Chen" /></meta><meta name="dc.Creator" content="Mehran F.  Moghaddam" /></meta><meta name="dc.Creator" content="Sogole  Bahmanyar" /></meta><meta name="dc.Creator" content="Barbra  Pagarigan" /></meta><meta name="dc.Creator" content="Silvia  Delker" /></meta><meta name="dc.Creator" content="Laurie  LeBrun" /></meta><meta name="dc.Creator" content="Philip P.  Chamberlain" /></meta><meta name="dc.Creator" content="Andrew  Calabrese" /></meta><meta name="dc.Creator" content="Stacie S.  Canan" /></meta><meta name="dc.Creator" content="Katerina  Leftheris" /></meta><meta name="dc.Creator" content="Dan  Zhu" /></meta><meta name="dc.Creator" content="John F.  Boylan" /></meta><meta name="dc.Description" content="Triple negative breast cancer (TNBC) remains a serious unmet medical need with discouragingly high relapse rates. We report here the synthesis and structure–activity relationship (SAR) of a novel s..." /></meta><meta name="Description" content="Triple negative breast cancer (TNBC) remains a serious unmet medical need with discouragingly high relapse rates. We report here the synthesis and structure–activity relationship (SAR) of a novel s..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 27, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01223" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01223" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01223" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01223" /></link>
        
    
    

<title>The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01223" /></meta><meta property="og:title" content="The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0015.jpeg" /></meta><meta property="og:description" content="Triple negative breast cancer (TNBC) remains a serious unmet medical need with discouragingly high relapse rates. We report here the synthesis and structure–activity relationship (SAR) of a novel series of 2,4,5-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines with potent activity against TNBC tumor cell lines. These compounds were discovered from a TNBC phenotypic screen and possess a unique dual inhibition profile targeting TTK (mitotic exit) and CLK2 (mRNA splicing). Design and optimization, driven with a TNBC tumor cell assay, identified potent and selective compounds with favorable in vitro and in vivo activity profiles and good iv PK properties. This cell-based driven SAR produced compounds with strong single agent in vivo efficacy in multiple TNBC xenograft models without significant body weight loss. These data supported the nomination of CC-671 into IND-enabling studies as a single agent TNBC therapy." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01223"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01223">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01223&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01223&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01223&amp;href=/doi/10.1021/acs.jmedchem.7b01223" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 8989-9002</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01221" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01237" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer+R.++Riggs">Jennifer R. Riggs</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-9012-1428" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Nagy">Mark Nagy</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jan++Elsner">Jan Elsner</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Erdman">Paul Erdman</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dan++Cashion">Dan Cashion</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dale++Robinson">Dale Robinson</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Roy++Harris">Roy Harris</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dehua++Huang">Dehua Huang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lida++Tehrani">Lida Tehrani</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gordafaried++Deyanat-Yazdi">Gordafaried Deyanat-Yazdi</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rama+Krishna++Narla">Rama Krishna Narla</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaohui++Peng">Xiaohui Peng</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tam++Tran">Tam Tran</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Leo++Barnes">Leo Barnes</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Terra++Miller">Terra Miller</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Katz">Jason Katz</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yang++Tang">Yang Tang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ming++Chen">Ming Chen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mehran+F.++Moghaddam">Mehran F. Moghaddam</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sogole++Bahmanyar">Sogole Bahmanyar</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Barbra++Pagarigan">Barbra Pagarigan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Silvia++Delker">Silvia Delker</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Laurie++LeBrun">Laurie LeBrun</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philip+P.++Chamberlain">Philip P. Chamberlain</a></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-6407-7344" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Calabrese">Andrew Calabrese</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stacie+S.++Canan">Stacie S. Canan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Katerina++Leftheris">Katerina Leftheris</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dan++Zhu">Dan Zhu</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+F.++Boylan">John F. Boylan</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Celgene Corporation, 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 858-795-4854. E-mail: <a href="/cdn-cgi/l/email-protection#c1abb3a8a6a6b281a2a4ada6a4afa4efa2aeac"><span class="__cf_email__" data-cfemail="244e564d4343576447414843414a410a474b49">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01223&amp;href=/doi/10.1021%2Facs.jmedchem.7b01223" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 8989–9002</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 9, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>18 August 2017</li><li><span class="item_label"><b>Published</b> online</span>27 October 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 November 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01223" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01223</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8989%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJennifer%2BR.%2BRiggs%252C%2BMark%2BNagy%252C%2BJan%2BElsner%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D21%26contentID%3Dacs.jmedchem.7b01223%26title%3DThe%2BDiscovery%2Bof%2Ba%2BDual%2BTTK%2BProtein%2BKinase%252FCDC2-Like%2BKinase%2B%2528CLK2%2529%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BTriple%2BNegative%2BBreast%2BCancer%2BInitiated%2Bfrom%2Ba%2BPhenotypic%2BScreen%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9002%26publicationDate%3DNovember%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01223"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3263</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">21</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01223" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;R. Riggs&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Nagy&quot;},{&quot;first_name&quot;:&quot;Jan&quot;,&quot;last_name&quot;:&quot;Elsner&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Erdman&quot;},{&quot;first_name&quot;:&quot;Dan&quot;,&quot;last_name&quot;:&quot;Cashion&quot;},{&quot;first_name&quot;:&quot;Dale&quot;,&quot;last_name&quot;:&quot;Robinson&quot;},{&quot;first_name&quot;:&quot;Roy&quot;,&quot;last_name&quot;:&quot;Harris&quot;},{&quot;first_name&quot;:&quot;Dehua&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Lida&quot;,&quot;last_name&quot;:&quot;Tehrani&quot;},{&quot;first_name&quot;:&quot;Gordafaried&quot;,&quot;last_name&quot;:&quot;Deyanat-Yazdi&quot;},{&quot;first_name&quot;:&quot;Rama&quot;,&quot;last_name&quot;:&quot;Krishna Narla&quot;},{&quot;first_name&quot;:&quot;Xiaohui&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Tam&quot;,&quot;last_name&quot;:&quot;Tran&quot;},{&quot;first_name&quot;:&quot;Leo&quot;,&quot;last_name&quot;:&quot;Barnes&quot;},{&quot;first_name&quot;:&quot;Terra&quot;,&quot;last_name&quot;:&quot;Miller&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Katz&quot;},{&quot;first_name&quot;:&quot;Yang&quot;,&quot;last_name&quot;:&quot;Tang&quot;},{&quot;first_name&quot;:&quot;Ming&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Mehran&quot;,&quot;last_name&quot;:&quot;F. Moghaddam&quot;},{&quot;first_name&quot;:&quot;Sogole&quot;,&quot;last_name&quot;:&quot;Bahmanyar&quot;},{&quot;first_name&quot;:&quot;Barbra&quot;,&quot;last_name&quot;:&quot;Pagarigan&quot;},{&quot;first_name&quot;:&quot;Silvia&quot;,&quot;last_name&quot;:&quot;Delker&quot;},{&quot;first_name&quot;:&quot;Laurie&quot;,&quot;last_name&quot;:&quot;LeBrun&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;P. Chamberlain&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Calabrese&quot;},{&quot;first_name&quot;:&quot;Stacie&quot;,&quot;last_name&quot;:&quot;S. Canan&quot;},{&quot;first_name&quot;:&quot;Katerina&quot;,&quot;last_name&quot;:&quot;Leftheris&quot;},{&quot;first_name&quot;:&quot;Dan&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;F. Boylan&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;8989-9002&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01223&quot;},&quot;abstract&quot;:&quot;Triple negative breast cancer (TNBC) remains a serious unmet medical need with discouragingly high relapse rates. We report here the synthesis and structure–activity relationship (SAR) of a novel series of 2,4,5-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines with potent activity against TNBC tumor cell lines. These compounds were discovered from a TNBC phenotypic screen and possess a unique dual inhibition profile targeting TTK (mitotic exit) and CLK2 (mRNA splicing). Design and optimization, driven with a TNBC tumor cell assay, identified potent and selective compounds with favorable in vitro and in vivo activity profiles and good iv PK properties. This cell-based driven SAR produced compounds with strong single agent in vivo efficacy in multiple TNBC xenograft models without significant body weight loss. These data supported the nomination of CC-671 into IND-enabling studies as a single agent TNBC therapy.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01223&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01223" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01223&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01223" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01223&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01223" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01223&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01223&amp;href=/doi/10.1021/acs.jmedchem.7b01223" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01223" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01223" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01223%26sid%3Dliteratum%253Aachs%26pmid%3D28991472%26genre%3Darticle%26aulast%3DRiggs%26date%3D2017%26atitle%3DThe%2BDiscovery%2Bof%2Ba%2BDual%2BTTK%2BProtein%2BKinase%252FCDC2-Like%2BKinase%2B%2528CLK2%2529%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BTriple%2BNegative%2BBreast%2BCancer%2BInitiated%2Bfrom%2Ba%2BPhenotypic%2BScreen%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D21%26spage%3D8989%26epage%3D9002%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291465" title="Structure activity relationship">Structure activity relationship</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/jmcmar.2017.60.issue-21/20171109/jmcmar.2017.60.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Triple negative breast cancer (TNBC) remains a serious unmet medical need with discouragingly high relapse rates. We report here the synthesis and structure–activity relationship (SAR) of a novel series of 2,4,5-trisubstituted-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidines with potent activity against TNBC tumor cell lines. These compounds were discovered from a TNBC phenotypic screen and possess a unique dual inhibition profile targeting TTK (mitotic exit) and CLK2 (mRNA splicing). Design and optimization, driven with a TNBC tumor cell assay, identified potent and selective compounds with favorable in vitro and in vivo activity profiles and good iv PK properties. This cell-based driven SAR produced compounds with strong single agent in vivo efficacy in multiple TNBC xenograft models without significant body weight loss. These data supported the nomination of CC-671 into IND-enabling studies as a single agent TNBC therapy.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77542" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77542" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Phenotypic-based drug discovery has proven successful in the generation of novel, first-in-class drugs as compared to target-based approaches.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> Although triple negative breast cancer (TNBC) patients have a reasonable response rate to current standard of care chemotherapy, the relapse rates are high and treatment options remain limited. Because of the heterogeneous nature of TNBC, attempts have been made to further categorize TNBC into as many as 10 different subtypes.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Because of this heterogeneity and lack of well-defined clinical targets, we used a phenotypic approach to identify a novel treatment for TNBC. By targeting preferential induction of apoptosis in TNBC cell lines over luminal breast cancer cell lines, we identified a series of 2,4,5-trisubstituted-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidines with the desired phenotypic profile.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a></div><div class="NLM_p">During the phenotypic SAR chemistry campaign, we established two kinases that were selectively inhibited by our molecules and likely responsible for the cellular activity: monopolar spindle 1 (Mps1), also known as TTK protein kinase, and CDC2-like kinase (CLK2). TTK is a dual serine/threonine kinase that regulates the spindle assembly checkpoint (SAC), thereby controlling the progression of cells through mitosis.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> TTK siRNA knockout accelerates mitotic progression and induces cell death in TNBC cell lines.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> TTK also phosphorylates key oncogenic proteins such as p53, CHK2, and MDM2, critical to DNA damage repair.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> TTK has been shown in the literature to be a promising TNBC targeting opportunity. TTK mRNA and protein are overexpressed in a TNBC cohort of breast cancer primary tumors, and high TTK expression in TNBC patients is linked to a poor patient prognosis.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> These data provided sufficient rationale to gain the interest of a number of pharmaceutical companies and academic institutions leading to the publication of multiple, potent TTK inhibitors.<a onclick="showRef(event, 'ref9 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref9 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23">(9, 13-23)</a> Thus far, four TTK inhibitors have reportedly entered phase I clinical trials: BAY 1161909 (clinical trials.gov ID: NCT02138812), BAY 1217389 (clinical trials.gov ID: NCT02366949), S 81694 (EudraCT no: 2014-002023-10), and CFI-402257 (clinicaltrials.gov ID: NCT02792465) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). While all are potent TTK inhibitors, they differ in several aspects including kinase selectivity profiles, route of administration, preclinical efficacy model type, ability to produce single agent efficacy with tolerated doses, dosing paradigm, PK, and likely mean resonance time on the target protein. The novel kinase profile, the long time on target which allows for intermittent dosing, and strong single agent efficacy provide possible competitive advantages for our series of TTK inhibitors.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of TTK inhibitors reportedly in phase I clinical trials. The structure of S 81694 has not been published.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">SR specific kinases (SRPKs) and CLK2 phosphorylate serine- and arginine-rich proteins (SR) within the spliceosome and modulate mRNA splicing activity and consequently protein synthesis.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> The high level of cancer associated mutations or overexpression across the splicing process highlights the growth and survival advantage obtained when tumor cells co-opt this pathway. Downregulation of CLK2 alters splicing patterns and inhibits breast cancer growth in vitro and in vivo.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Consistent with these data, small molecule CLK2 inhibition alters expression of SR proteins by changing the splicing pattern in mRNAs involved in growth and survival leading to cancer cell apoptosis.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p">A dual TTK/CLK2 inhibitor would produce mitotic acceleration and RNA splicing modification. Given the rapid adaptation and growth requirements of a tumor cell, this unique kinase combination profile should prove impactful in a number of cancer subtypes including high unmet medical need indications such as TNBC. Here we describe the optimization of a phenotypic hit (<b>1</b>, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) and SAR exploration, leading to favorable in vivo iv PK profiles and the selection of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (CC-671) for IND-enabling studies.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of phenotypic hit <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05305" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05305" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of 2,4,5-trisubstituted-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidines is outlined in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Commercially available 2,4-dichloro-5-iodo-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine was converted to the SEM-protected intermediate <b>2</b> using 2-(trimethylsilyl)ethoxymethyl chloride (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The C-4 substituent was introduced by displacement of the chloride with appropriate alcohols to give <b>3a</b>–<b>3c</b>. Suzuki–Mukiyama cross coupling reaction of iodide <b>3</b> with aryl boronic acids or esters resulted in disubstituted pyrrolopyrimidines <b>4a</b>–<b>4u</b>. Alternatively, the C-5 substituent could be installed first from intermediate <b>2</b>. Suzuki–Mukiyama coupling with appropriate aryl boronic esters or acids affords <b>5</b>. Chloride displacement at C-4 with alkyl and cycloalkyl alcohols provides disubstituted pyrrolopyrimidines <b>6a</b>–<b>6g</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Disubstituted Pyrimidine Intermediates <b>4a</b>–<b>4u</b> and <b>6a</b>–<b>6g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) SEM-Cl, NaH, DMF, 0–22 °C; (b) R<sub>2</sub>-alcohol, 1, 4-dioxane, NaOtBu, 70–90 °C; (c) R<sub>1</sub>-boronate ester or acid, sodium carbonate in water, PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub> or Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, 1, 4-dioxane, 70–90 °C.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 2,4,5-Trisubstituted-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidines <b>7</b>–<b>44</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R<sub>3</sub>-amine, Pd<sub>2</sub>(dba)<sub>3</sub>, Xanphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, MW 150 °C; (b) TFA, DCM; (c) NH<sub>4</sub>OH, MeOH; (d) TBAF, THF, 50 °C.</p></p></figure><div class="NLM_p last">The C-2 substituent was installed using Pd-catalyzed Buchwald coupling to afford <b>7–44</b> SEM (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Final analogues (<b>7</b>–<b>44</b>) were obtained after deprotection using either TBAF or a two-step process of TFA followed by NH<sub>4</sub>OH-assisted cleavage of the hemiaminal intermediate.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25843" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25843" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our desired profile for TNBC therapy from this phenotypic approach was to retain TNBC sensitivity while sparing luminal cancer cell lines to ensure a lack of general cytotoxicity. With this in mind, two cellular assays, Cal-51, a TNBC cell line, and BT-474, a luminal breast cancer cell line, were utilized to evaluate analogues. Potency in the Cal-51 assay was primarily used to drive the SAR. While the phenotypic activity of hit <b>1</b> exhibited the desired phenotypic profile, it was metabolically unstable in liver S9 fractions. Glucuronidation and sulfation of the phenol were the major metabolites. Our first goal was to replace the metabolically labile phenol at C-5 of <b>1</b>. The contribution of the phenol moiety to the metabolic instability of <b>1</b> is further illustrated by the significant improvement in S9 stability of the unsubstituted phenyl <b>7</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). The dramatic loss in potency of <b>7</b> suggests the phenol in <b>1</b> is making a key interaction, contributing to the observed cellular effect. We further examined the hydrogen bonding requirements and the positioning of the phenol. The <i>m</i>-phenol <b>8</b> suffered from a slight reduction in potency as compared to the <i>p</i>-phenol <b>1</b>. Replacement of the phenol with an unsubstituted 4- or 3-pyridyl (<b>9</b> and <b>10</b>) afforded analogues with similar potency to their respective phenol counterparts (<b>9</b> vs <b>1</b> and <b>10</b> vs <b>8</b>), suggesting the hydrogen bond donor is not necessary, but a hydrogen bond acceptor is contributing significantly to potency. Five-membered heterocycles were tolerated as in pyrazole <b>12</b>, but isomeric pyrazole <b>11</b> resulted in a loss of potency, suggesting the correct orientation of the H-bond acceptor is critical. Interestingly, capping the phenol to give the <i>p</i>-methoxy <b>13</b> resulted in a loss in potency. Extending the alcohol by adding a methylene as in <b>14</b> and <b>15</b> was tolerated, and the proper positioning of the H-bond acceptor (<b>15</b>) resulted in improved potency. The <i>p</i>-carboxamide, <b>16</b>, was equipotent to the original hit <b>1</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. C-5 Position Potency and Metabolic Stability SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Mean ± SEM.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Percent remaining at 60 min.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Not determined.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last"><i>n</i> = 2.</p></div></div><div></div></div><div class="NLM_p">In an effort to replace the carboxamide, substituting the aryl ring at the <i>para</i> position with five-membered heterocycles was explored. Again, the positioning of the H-bond acceptor in the pyrazole, imidazole, and triazole compounds (<b>17</b>–<b>19</b>) impacted the potency. Fused 6,5-heterocycles <b>20</b>–<b>23</b> gave mixed results, as expected from the H-bond acceptor SAR presented thus far. Depending on the position of the nitrogen H-bond acceptor, analogues either maintained potency (<b>20</b>, <b>23</b>), or lost potency (<b>21</b>, <b>22</b>). On the basis of the overall profile of potency in Cal-51, selectivity over the luminal line BT-474, and high S9 stability, the 2-methyl benzoxazole <b>23</b> was held constant at C-5 in the exploration of C-4 and C-2.</div><div class="NLM_p">Our exploration at C-4 revealed a general tolerance for a variety of cycloalkyl and oxygen-containing functional groups for Cal-51 potency (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). We first explored contraction of the cyclopentyl ring, resulting in equipotent cyclobutyl <b>24</b> and cyclopropyl <b>25</b>. Small alkyl substituents such as isopropyl (<b>26</b>), hydroxy-ethyl (<b>27</b>), or methoxy-ethyl (<b>28</b>) also maintained Cal-51 potency although a general erosion of selectivity was seen in BT-474 with the smaller cyclopropyl and alkyl substituents. The free OH at C-4, <b>29</b>, caused a complete loss in potency. Introduction of heteroatoms into the cyclic C-4 substituent generally led to a slight improvement in Cal-51 potency (<b>30</b> vs <b>24</b> and <b>31</b> vs <b>23</b>). The six-membered THP and cyclohexanols <b>32</b>–<b>34</b> generally led to an increase in potency as compared to the cyclopentyl <b>23</b>. Overall, the C-4 position was tolerant of various groups with respect to potency and reasonable rat S9 stability was maintained (data not shown). We felt this position could be used to improve properties, such as lowering lipophilicity. Considering the potency, selectivity against BT-474, and synthetic ease, we chose the cyclopentyl at C-4 to hold constant for SAR studies at C-2.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. C-4 Position Potency SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0011.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Mean ± SEM.</p></div></div><div></div></div><div class="NLM_p">On the C-2 aryl group, we extensively explored the <i>para</i> substituents (R4) while holding the <i>ortho</i>-methoxy constant (R5). A subset of these analogues are shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. Removal of the R4 substituent (<b>35</b>) resulted in a loss of potency as compared to the methyl carboxamide <b>23</b>. The dimethyl tertiary carboxamide <b>36</b> maintained potency. Cyclic tertiary amides such as piperazine <b>37</b> and morpholine <b>38</b> were explored with mixed results. Piperazine <b>37</b> maintained good Cal-51 potency, while the corresponding morpholine <b>38</b> was ∼6-fold less potent. Secondary amides (oxetane <b>39</b> and alcohols <b>40</b>–<b>42</b>), explored to decrease lipophilicity and increase solubility, generally maintained potency.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. C-2 Position Potency SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0013.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0014.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Mean ± SEM.</p></div></div><div></div></div><div class="NLM_p">SAR at R5 of the C-2 aryl group was also explored. Hydrogen substitution at this position led to an erosion of kinase selectivity (data not shown), therefore small changes were assessed. While replacement of the methoxy with a methyl (<b>43</b>) was not well tolerated, with a ∼6-fold loss in potency, the corresponding chloro analogue (<b>44</b>) provided an equipotent analogue to <b>23</b>. Extending the alkyl chain, such as ethoxy at R5, resulted in a loss of potency (data not shown).</div><div class="NLM_p">With multiple analogues in hand that met the desired TNBC potency, selectivity against BT-474, and metabolic stability, the iv PK properties of a number of compounds were assessed. The results of both rat and mouse iv PK are provided in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. Comparing analogue <b>23</b> to analogue <b>16</b>, the clearance in both rat and mouse are lower for the C-5 methyl benzoxazole (<b>23</b>) vs methyl amide (<b>16</b>), leading to a longer MRT. Compounds containing C-4 alkyl and cycloalkyl substituents <b>23</b>, <b>25</b>, <b>26</b>, <b>31</b>, <b>32</b>, and <b>34</b> have slow to moderate clearance in rat, but THP <b>32</b> and methylcyclohexanol <b>34</b> suffer from rapid clearance in mouse. Substitution of the amide at C-2 with the solubilizing hydroxy-ethyl group (<b>40</b>) showed increased clearance as compared to <b>23</b> in both rat and mouse. The oxetane <b>39</b> displayed low clearance in both rat and mouse, resulting in a longer MRT.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. PK Properties of Selected Analogues</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="±"> </th><th class="colsep0 rowsep0" align="center" char="±"> </th><th class="rowsep1 colsep0" colspan="3" align="center">rat IV PK<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="rowsep1 colsep0" colspan="2" align="center">mouse IV PK<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a>,<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">analogue</th><th class="colsep0 rowsep0" align="center" char="±">rat S9 met. stability<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±">human S9 met. stability<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">CL<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">Vss<a class="ref internalNav" href="#t4fn7" aria-label="g">g</a></th><th class="colsep0 rowsep0" align="center">MRT<a class="ref internalNav" href="#t4fn8" aria-label="h">h</a></th><th class="colsep0 rowsep0" align="center">CL<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center" char=".">MRT<a class="ref internalNav" href="#t4fn8" aria-label="h">h</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="char" char="±">87 ± 10</td><td class="colsep0 rowsep0" align="char" char="±">79 ± 13</td><td class="colsep0 rowsep0" align="center">61.3<a class="ref internalNav" href="#t4fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">4.0<a class="ref internalNav" href="#t4fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">1.1<a class="ref internalNav" href="#t4fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="left">63.1</td><td class="colsep0 rowsep0" align="char" char=".">0.36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="char" char="±">98 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">91 ± 11</td><td class="colsep0 rowsep0" align="center">9.30 ± 1.31</td><td class="colsep0 rowsep0" align="center">2.3 ± 0.22</td><td class="colsep0 rowsep0" align="center">4.1 ± 0.3</td><td class="colsep0 rowsep0" align="left">8.48<a class="ref internalNav" href="#t4fn10" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="char" char=".">5.2<a class="ref internalNav" href="#t4fn10" aria-label="j">j</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="char" char="±">63 ± 8</td><td class="colsep0 rowsep0" align="char" char="±">75 ± 9</td><td class="colsep0 rowsep0" align="center">11.4<a class="ref internalNav" href="#t4fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">1.5<a class="ref internalNav" href="#t4fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">2.5<a class="ref internalNav" href="#t4fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="left">10.4</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="char" char="±">69 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">78 ± 4</td><td class="colsep0 rowsep0" align="center">33.9 ± 5.4</td><td class="colsep0 rowsep0" align="center">7.2 ± 1.2</td><td class="colsep0 rowsep0" align="center">3.5 ± 0.3</td><td class="colsep0 rowsep0" align="left">7.71</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char="±">62 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">62 ± 3</td><td class="colsep0 rowsep0" align="center">27.4<a class="ref internalNav" href="#t4fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">1.6<a class="ref internalNav" href="#t4fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">1.0<a class="ref internalNav" href="#t4fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="left">19.1</td><td class="colsep0 rowsep0" align="char" char=".">0.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="char" char="±">75 ± 7</td><td class="colsep0 rowsep0" align="char" char="±">70 ± 4</td><td class="colsep0 rowsep0" align="center">22.6<a class="ref internalNav" href="#t4fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">3.8<a class="ref internalNav" href="#t4fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">2.9<a class="ref internalNav" href="#t4fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="left">67.6</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char="±">76 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">65 ± 1</td><td class="colsep0 rowsep0" align="center">17.6 ± 3.4</td><td class="colsep0 rowsep0" align="center">2.9 ± 1.2</td><td class="colsep0 rowsep0" align="center">2.9 ± 1.5</td><td class="colsep0 rowsep0" align="left">52.2</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="char" char="±">91 ± 8</td><td class="colsep0 rowsep0" align="char" char="±">79 ± 7</td><td class="colsep0 rowsep0" align="center">13.0 ± 1.8</td><td class="colsep0 rowsep0" align="center">3.7 ± 0.8</td><td class="colsep0 rowsep0" align="center">4.7 ± 0.8</td><td class="colsep0 rowsep0" align="left">14.3</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="char" char="±">80 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">90 ± 3</td><td class="colsep0 rowsep0" align="center">50.8 ± 9.8</td><td class="colsep0 rowsep0" align="center">3.9 ± 0.6</td><td class="colsep0 rowsep0" align="center">1.3 ± 0.1</td><td class="colsep0 rowsep0" align="left">31.6</td><td class="colsep0 rowsep0" align="char" char=".">0.59</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Percent remaining at 60 min.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Formulated as a solution in 15% DMA, 50% PEG, 35% D5W.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">Dose 2 mg/kg.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">Dose 10 mg/kg in SCID mice.</p></div><div class="footnote" id="t4fn5"><sup>e</sup><p class="last">SD not available with composite PK.</p></div><div class="footnote" id="t4fn6"><sup>f</sup><p class="last">mL/min/kg.</p></div><div class="footnote" id="t4fn7"><sup>g</sup><p class="last">L/kg.</p></div><div class="footnote" id="t4fn8"><sup>h</sup><p class="last">Hours.</p></div><div class="footnote" id="t4fn9"><sup>i</sup><p class="last">SD not available <i>n</i> = 2.</p></div><div class="footnote" id="t4fn10"><sup>j</sup><p class="last">Dose 5 mg/kg.</p></div></div></div><div class="NLM_p">Although the project was initiated on a phenotypic premise and TNBC Cal-51/Luminal BT-474 cell assays drove the SAR exploration, target identification was critical in supporting potential clinical advancement. In particular, a target biomarker would be required to guide dose and schedule during development. The pyrrolo[2,3-<i>d</i>]pyrimidine core along with the C-2 amine arranged a network of hydrogen bonds in a donor–acceptor–donor pattern resembling the hinge-binding motif of known kinase inhibitors. We therefore profiled project compounds in a commercial panel of >250 kinases.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> On the basis of the comparison of results for TNBC selective and nonselective compounds, a small set of candidate targets emerged. For example, when <b>23</b> was assessed in a panel of 255 kinases, only seven were inhibited by more than 80% at 3 μM (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01223/suppl_file/jm7b01223_si_001.pdf" class="ext-link">Table 1</a>). IC<sub>50</sub> values for the seven kinases are shown in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>, with only TTK and CLK2 having single-digit nanomolar potency.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. IC<sub>50</sub> (μM) of the Seven Kinases That Were >80% Inhibition at 3 μM of <b>23</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">TTK</th><th class="colsep0 rowsep0" align="center" char=".">CLK2</th><th class="colsep0 rowsep0" align="center" char=".">DYRK3</th><th class="colsep0 rowsep0" align="center" char=".">DYRK1A</th><th class="colsep0 rowsep0" align="center" char=".">PHKG</th><th class="colsep0 rowsep0" align="center" char=".">DYRK1B</th><th class="colsep0 rowsep0" align="center" char=".">CLK1</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>0.005</b></td><td class="colsep0 rowsep0" align="char" char="."><b>0.006</b></td><td class="colsep0 rowsep0" align="char" char=".">0.099</td><td class="colsep0 rowsep0" align="char" char=".">0.104</td><td class="colsep0 rowsep0" align="char" char=".">0.136</td><td class="colsep0 rowsep0" align="char" char=".">0.157</td><td class="colsep0 rowsep0" align="char" char=".">0.30</td></tr></tbody></table></div></div><div class="NLM_p">HCT-116 cell lysates were treated with compound <b>23</b> at 3 μM for 1 h and tested in the ActivX KiNative profiling assay. Only four kinases showed cellular binding of 75% or more including CLK2, CAMKK2, PIP4K22, and JNK (TTK not offered, full data in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01223/suppl_file/jm7b01223_si_001.pdf" class="ext-link">Table 2</a>). The IC<sub>50</sub> values for the four kinases were determined in the HCT-116 cell line (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). CLK2 was determined to be the most potent with an IC<sub>50</sub> value of 15 nM. From the seven kinases that were identified in the biochemical kinase screen, only one additional kinase (PHKG-1) was monitored in the HCT-116 KiNative kinase panel, and PhKG-1 only showed 26% binding in the 3 μM screen.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Kinase Binding in the HCT-116 Cell Line</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLK2</td><td class="colsep0 rowsep0" align="char" char=".">0.015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JNK1,2,3</td><td class="colsep0 rowsep0" align="char" char=".">0.68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAMKK2</td><td class="colsep0 rowsep0" align="char" char=".">1.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PIP4K2C</td><td class="colsep0 rowsep0" align="char" char=".">1.30</td></tr></tbody></table></div></div><div class="NLM_p">Inhibition of TTK and CLK2 phosphorylation substrates was monitored to confirm the cellular inhibitory mechanism of action. Cal-51 cells were treated with compound <b>23</b> for 1 h and analyzed by Western blot using antibodies against the autophosphorylation of TTK at T686 or phosphorylation of SR protein 75, a substrate of CLK2. Quantification of the Western blots enabled IC<sub>50</sub> determinations. The p-TTK and p-SRp75 potency of <b>23</b> was shown to be 0.057 and 0.549 μM, respectively (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>a). To assess the scope of the TNBC sensitivity versus Luminal BC resistance to compound <b>23</b>, we chose two additional cell lines in each category. As seen in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>b, the three TNBC lines are highly sensitive to compound <b>23</b> while the three Luminal BC lines are resistant.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Biochemical and cellular biomarker potency of compound <b>23</b>, confirming inhibition of TTK and CLK2 and phosphorylation of downstream substrates. (b) Compound <b>23</b> demonstrated preferential antiproliferative activities in TNBC lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The identification of the key targets responsible for TNBC cellular activity, namely TTK and CLK2, allowed us to initiate crystallography efforts to enable SBDD. We obtained a crystal structure of compound <b>23</b> with TTK at 2.99 Å resolution (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). A detailed view of <b>23</b> bound in the TTK binding pocket is shown in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>a. When compared to the apo structure of TTK, an induced fit of the glycine-rich loop (G-loop) is observed (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01223/suppl_file/jm7b01223_si_001.pdf" class="ext-link">Figure 1a,1b</a>). As anticipated, the pyrrolopyrimidine core of <b>23</b> forms three hydrogen bonds to the hinge region of the TTK ATP binding pocket. The pyrrole NH (N7) forms a hydrogen bond to backbone carbonyl of Glu603. The amino-pyrimidine moiety of the core forms two additional hydrogen bond interactions with the hinge residue Gly605.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Crystal structure of <b>23</b> bound in the TTK ATP pocket, and interactions with residues within 4.0 Å of the ligand are shown (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B4W">6B4W</a>). (b) TTK ATP binding pocket with the ordered portion of the activation loop shown in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The C5 methyl benzoxazole binds deep in the ATP binding pocket and forms favorable van der Waals interactions with the gatekeeper residue Met602, the side chain carbons of catalytic residue Lys553, and the side chain of activation loop residue Met671. In addition, N3 of the methyl benzoxazole forms a direct hydrogen bond with the side chain amine of Lys553. The C4 cyclopentyl substituent is enclosed in the ribose pocket by a portion of the activation loop, where residues Met671, Gln672, Pro673, and Asp674 are ordered in the crystal structure (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>b). This conformation of the activation loop has been observed in other crystal structures of TTK.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The ordered portion of the activation loop and the G-loop appear to interact though a network of hydrogen bonds (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01223/suppl_file/jm7b01223_si_001.pdf" class="ext-link">Figure 1a,1b</a> for additional views). This arrangement of the activation loop residues encapsulates the cyclopentyl ring in a hydrophobic pocket. The C2 aniline binds toward the “solvent” pocket. The <i>ortho</i>-methoxy substituent binds in a pocket formed by hinge residue Cys604 and G-loop residue Gln541. Cys604 is a small and fairly unique residue at the hinge important for obtaining kinase selectivity in this series.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The <i>para</i> amide substituent of the C-2 aniline is within 3.3 Å of Asp608 but does not appear to form specific hydrogen bonds. On the basis of modeling and docking studies, compound <b>23</b> binds similarly in the CLK2 binding pocket (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01223/suppl_file/jm7b01223_si_001.pdf" class="ext-link">Figure 2a</a>). The overall residue homology of CLK2 and TTK is low, however, there are similarities in the binding pocket that allows both kinases to accommodate compound <b>23</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01223/suppl_file/jm7b01223_si_001.pdf" class="ext-link">Figure 2b</a>).</div><div class="NLM_p">With numerous potent and selective compounds demonstrating good rat and mouse iv PK in hand, we set out to assess the time and exposure necessary to illicit an antiproliferative effect. Cal-51 cells were treated in cellular wash-out experiments with compound <b>23</b> for 6, 12, 24, 48, and 72 h followed by a wash out. Antiproliferative activity was measured at 3 days post washout. From the data represented in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>, at time points >12 h, a considerable left shift in the potency is observed. This in vitro data suggests that >12 h coverage by the compound is necessary to give maximal antiproliferative activity.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vitro wash-out data in Cal-51 cell line of compound <b>23</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>23</b> was chosen for in vivo efficacy assessment based on potency, selectivity, slow clearance, and long MRT in both rat and mouse species. We sought to investigate the optimal in vivo dosing schedule and finalize the target product profile including route of administration. On the basis of the washout data presented in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>, it is likely that daily dosing would be required. It is plausible that with the TTK mechanism, <24 h exposure could be sufficient to commit cells to apoptosis, although likely longer exposure might be necessary to capture all cycling cells in various phases of mitosis. To investigate this hypothesis, compound <b>23</b> was administered iv every 3 days (q3d) or every 7 days (q7d) in a Cal-51 mouse xenograft model (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Animals were treated for a minimum of 16 days and tumor growth compared to vehicle control and body weight loss (BWL) were measured on the day following the final day of dosing. Compound <b>23</b> demonstrated significant tumor growth inhibition (TGI) ((vehicle – treated/vehicle) × 100%) of 71% at both 10 and 20 mg/kg on a q3d dosing schedule (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>a). The BWL in the 20 mg/kg group was higher than in the 10 mg/kg group (17% vs 5%). In the q7d dosing paradigm, 20 mg/kg was well tolerated without appreciable BWL and compound <b>23</b> demonstrated 70% TGI (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>b). Both dosing schedules were better tolerated and more efficacious than Taxotere. Taxotere was administered at maximum tolerated dose (5 mg/kg, q4d). The BWL of Taxotere in this model was significant (20%) and required suspended dosing to allow for recovery. These data suggest that q7d dosing was sufficient to provide significant tumor volume reduction with improved tolerability over a more frequent dosing schedule, and thus an iv route of administration was acceptable. Compound <b>23</b> has improved efficacy and better tolerability in the Cal-51 xenograft than Taxotere, the current standard of care for TNBC.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cal-51 tumor xenograft studies with q3d (a) and q7d (b) dosing schedules of <b>23</b> (*<i>p</i> < 0.001, one way ANNOVA).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In addition to the data presented above, higher species PK, in vitro and in vivo toxicological assessments, and additional in vivo models were used to select compound <b>23</b> (CC-671) for IND enabling studies. Compound <b>23</b> has a favorable CEREP receptor profile and a hERG (human ether-a-go-go-related gene) ion channel IC<sub>50</sub> value of >33 μM. Full biological characterization and additional in vivo TNBC patient derived xenograft (PDX) data where compound <b>23</b> causes regression at well tolerated doses will be published in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85236" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85236" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have described the SAR and optimization of the 2,4,5-trisubstituted-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine series emanating from a TNBC phenotypic screen. Interrogation of the biology of these compounds identified two inhibitory targets, TTK and CLK2. This unique dual kinase profile of accelerated mitotic progression and mRNA splicing has been shown to be efficacious in TNBC cell lines in vitro and in xenograft models in vivo. Multiple compounds in this series were generated with the desired in vitro profile and good iv PK properties. This work ultimately led to the identification and nomination of compound <b>23</b> for IND-enabling studies. Compound <b>23</b> has excellent kinase selectivity, favorable iv pharmacokinetic properties in all species tested, superior in vivo efficacy and tolerability as compared to Taxotere, and an acceptable in vitro and in vivo toxicology profile. Additional biological characterization of compound <b>23</b> will be disclosed elsewhere.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Materials and Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40513" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40513" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Chemistry</h3><div class="NLM_p">All materials were obtained from commercial sources and used without further purification unless otherwise noted. Chromatography solvents were HPLC grade and used as purchased. All air-sensitive reactions were carried out under a positive pressure of an inert nitrogen atmosphere. <sup>1</sup>H NMR spectra were obtained on 300, 400, or 500 MHz spectrometers. Chemical shifts are relative to tetramethylsilane (TMS) as the internal standard or relative to a residual solvent peak. Chemical shifts (δ) are reported in ppm, and coupling constants (<i>J</i>) are given in Hz. Thin layer chromatography (TLC) analysis was performed on Whatman thin layer plates. LCMS analysis was performed on a PE Sciex ESI MS or Agilent 1100 MS. Semipreparative reverse phase HPLC was performed on a Shimadzu system equipped with a Phenomenex 15 μm C18 column (250 mm × 10 mm). Preparative reverse phase HPLC was performed on a Shimadzu system equipped with a Phenomenex 15 μm C18 column (250 mm × 50 mm). Compounds were analyzed for purity by one of two methods: (A) gradient (0–75% acetonitrile + 0.1% formic acid in water + 0.1% formic, over 7 min, followed by 75% acetonitrile + 0.1% formic acid for 2 min); flow Rate 1 mL/min, column Phenomenex Gemini-NX 5 μ C18 110A (50 mm × 4.60 mm); (B) gradient (0–75% acetonitrile + 0.1% formic acid in water + 0.1% formic, over 20 min, followed by 75% acetonitrile + 0.1% formic acid for 5 min); flow Rate 1 mL/min, column Phenomenex Gemini-NX 5 μ C18 110A (250 mm × 4.60 mm). The purity of final tested compounds was determined to be ≥95% by HPLC conducted on an Agilent 1100 system using a reverse phase C18 column and diode array detector (compounds <b>8</b>, <b>9</b>, <b>10</b>, <b>11</b>, <b>20</b>, <b>21</b>, and <b>44</b> are >90% pure). Elemental analysis was performed at Robertson Microlit Laboratories, Ledgewood, New Jersey. Reported yields are unoptimized. Compounds were named using ChemDraw Ultra.</div><div class="NLM_p last">Synthetic procedures for all intermediates <b>2</b>, <b>3a</b>–<b>3u</b>, <b>4a</b>–<b>4u</b>, <b>6a</b>–<b>6g</b>, and <b>7</b>–<b>44</b> SEM are included in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01223/suppl_file/jm7b01223_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General Procedure for the Synthesis of Compounds <b>1</b>, <b>7</b>–<b>23</b>, <b>25</b>–<b>29</b>, and <b>31</b>–<b>44</b></h3><div class="NLM_p">The appropriate SEM protected intermediate (1 equiv) was diluted with dichloromethane (0.2 M) and treated with trifluoroacetic acid (25–200 equiv). The solution was stirred at rt for 1–18 h. The mixture was concentrated under reduced pressure to afford an oil. The residue was treated with 2 M ammonia in methanol (50–500 equiv) for 3–18 h. The mixture was concentrated under reduced pressure. The residue was diluted with either acetonitrile, dioxane, or methanol (0.1 M), treated with a concentrated aqueous solution of ammonium hydroxide (50–500 equiv), and stirred for 2–24 h at temperatures of rt to 50 °C. The mixture was concentrated under reduced pressure and purified by reverse phase preparative HPLC. Fractions containing pure product were loaded onto a Phenomenex Strata-XC strong cation ion exchange column. The column was washed successively with water and methanol, and the product was eluted with 2 M ammonia in methanol. The combined product fractions were concentrated under reduced pressure to afford the title compound.</div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 4-((4-(Cyclopentyloxy)-5-(4-hydroxyphenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>1</b>)</h4><div class="NLM_p last">Yield 0.120 g, 0.253 mmol, 12% over 2 steps, HPLC purity >99%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.62 (br s, 1H), 9.27 (s, 1H), 8.65–8.63 (d, 1 H, <i>J</i> = 9 Hz), 8.30–3.28 (m, 1 H), 7.66 (s, 1H), 7.52–7.46 (m, 4 H), 7.12 (s, 1 H), 6.76–6.73 (d, 2 H, <i>J</i> = 9 Hz), 5.67–5.65 (br m., 1 H), 3.97 (s, 3 H), 2.80–2.79 (d, <i>J</i> = 4.4 Hz, 3 H), 1.99–1.94 (m, 2 H), 1.82–1.62 (m, 6 H). MS (ESI) <i>m</i>/<i>z</i> 474.2 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 4-((4-(Cyclopentyloxy)-5-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>7</b>)</h4><div class="NLM_p last">Yield 0.155 g, 0.339 mmol, 64%, HPLC purity >99%. <sup>1</sup>H NMR (499 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.78 (s, 1 H) 8.63 (d, <i>J</i> = 8.86 Hz, 1 H) 8.25–8.34 (m, 1 H) 7.63–7.75 (m, 3 H) 7.46–7.55 (m, 2 H) 7.29 (d, <i>J</i> = 2.46 Hz, 1 H) 7.18 (t, <i>J</i> = 8.86 Hz, 2 H) 5.58–5.70 (m, <i>J</i> = 5.78, 5.78, 2.71, 2.46 Hz, 1 H) 3.96 (s, 3 H) 2.79 (d, <i>J</i> = 4.43 Hz, 3 H) 1.90–2.03 (m, 2 H) 1.74–1.85 (m, 2 H) 1.56–1.73 (m, 4 H). MS (ESI) <i>m</i>/<i>z</i> 458.1 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 4-((4-(Cyclopentyloxy)-5-(3-hydroxyphenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>8</b>)</h4><div class="NLM_p last">Yield 0.014 g, 0.030 mmol, 9%, HPLC purity >93%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.69–11.75 (m, 1H), 9.17–9.25 (m, 1H), 8.59–8.68 (m, 1H), 8.27–8.33 (m, 1H), 7.66–7.71 (m, 1H), 7.47–7.56 (m, 2H), 7.20–7.24 (m, 1H), 7.05–7.16 (m, 3H), 6.62–6.67 (m, 1H), 5.62–5.69 (m, 1H), 3.91–4.07 (m, 3H), 2.74–2.84 (m, 3H), 1.92–2.02 (m, 2H), 1.55–1.87 (m, 6H). MS (ESI) <i>m</i>/<i>z</i> 474 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 4-((4-(Cyclopentyloxy)-5-(pyridin-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>9</b>)</h4><div class="NLM_p last">Yield 0.067 g, 0.15 mmol, 28%, HPLC purity >93%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.03–12.08 (m, 1H), 8.58–8.62 (m, 1H), 8.48–8.52 (m, 2H), 8.28–8.34 (m, 1H), 7.76–7.78 (m, 1H), 7.70–7.74 (m, 2H), 7.64 (d, <i>J</i> = 2.45 Hz, 1H), 7.49–7.54 (m, 2H), 5.68–5.74 (m, 1H), 3.96 (s, 3H), 2.79 (d, <i>J</i> = 4.65 Hz, 3H), 1.96–2.06 (m, 2H), 1.81–1.90 (m, 2H), 1.63–1.79 (m, 4H). MS (ESI) <i>m</i>/<i>z</i> 459 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 4-((4-(Cyclopentyloxy)-5-(pyridin-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>10</b>)</h4><div class="NLM_p last">Yield 0.033 g, 0.071 mmol, 19%, HPLC purity >93%. MS (ESI) <i>m</i>/<i>z</i> 459 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 4-((4-(Cyclopentyloxy)-5-(1<i>H</i>-pyrazol-3-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>11</b>)</h4><div class="NLM_p last">Yield 0.018 g, 0.040 mmol, 16%, HPLC purity >91%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.71–12.76 (m, 1H), 11.87–11.94 (m, 1H), 8.58–8.67 (m, 1H), 8.34–8.44 (m, 1H), 7.66–7.75 (m, 1H), 7.44–7.57 (m, 3H), 6.63–6.74 (m, 1H), 5.65–5.73 (m, 1H), 4.08–4.17 (m, 1H), 3.92–4.03 (m, 3H), 2.74–2.84 (m, 3H), 1.98–2.09 (m, 2H), 1.82–1.93 (m, 2H), 1.58–1.82 (m, 4H). MS (ESI) <i>m</i>/<i>z</i> 448 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 4-((4-(Cyclopentyloxy)-5-(1<i>H</i>-pyrazol-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>12</b>)</h4><div class="NLM_p last">Yield 0.012 g, 0.027 mmol, 8%, HPLC purity >97%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.67–12.77 (m, 1H), 11.53–11.65 (m, 1H), 8.61–8.69 (m, 1H), 8.28–8.37 (m, 1H), 7.94–8.02 (m, 1H), 7.83–7.91 (m, 1H), 7.64–7.69 (m, 1H), 7.49–7.58 (m, 2H), 7.25–7.33 (m, 1H), 5.64–5.76 (m, 1H), 3.97 (s, 3H), 2.77–2.85 (m, 3H), 2.00–2.14 (m, 2H), 1.84–1.94 (m, 2H), 1.64–1.81 (m, 4H). MS (ESI) <i>m</i>/<i>z</i> 448 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 4-((4-(Cyclopentyloxy)-5-(4-methoxyphenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>13</b>)</h4><div class="NLM_p last">Yield 0.033 g, 0.067 mmol, 17%, HPLC purity >95%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.66–11.70 (m, 1H), 8.61–8.67 (m, 1H), 8.27–8.33 (m, 1H), 7.66–7.70 (m, 1H), 7.57–7.63 (m, 2H), 7.48–7.53 (m, 2H), 7.18–7.22 (m, 1H), 6.88–6.95 (m, 2H), 5.63–5.69 (m, 1H), 3.96 (s, 3H), 3.77 (s, 3H), 2.76–2.84 (m, 3H), 1.92–2.03 (m, 2H), 1.76–1.86 (m, 2H), 1.61–1.76 (m, 4H). MS (ESI) <i>m</i>/<i>z</i> 488 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 4-((4-(Cyclopentyloxy)-5-(4-(hydroxymethyl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>14</b>)</h4><div class="NLM_p last">Yield 0.020 g, 0.041 mmol, 60%, HPLC purity >97%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.73–11.79 (m, 1H), 8.62–8.68 (m, 1H), 8.26–8.36 (m, 1H), 7.69–7.71 (m, 1H), 7.62–7.68 (m, 2H), 7.49–7.54 (m, 2H), 7.27–7.32 (m, 3H), 5.65–5.71 (m, 1H), 5.16 (t, <i>J</i> = 5.75 Hz, 1H), 4.52 (d, <i>J</i> = 5.87 Hz, 2H), 3.97 (s, 3H), 2.78–2.83 (m, 3H), 1.94–2.06 (m, 2H), 1.78–1.87 (m, 2H), 1.62–1.77 (m, 4H). MS (ESI) <i>m</i>/<i>z</i> 488.3 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 4-[4-Cyclopentyloxy-5-(3-hydroxymethyl-phenyl)-7-(2-trimethylsilanyl-ethoxymethyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-ylamino]-3-methoxy-<i>N</i>-methyl-benzamide (<b>15</b>)</h4><div class="NLM_p last">Yield 0.008 g, 0. 016 mmol, 5%, HPLC purity >95%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.70 (d, <i>J</i> = 8.4 Hz, 1H), 7.58 (s, 1H), 7.51 (d, <i>J</i> = 7.6 Hz, 1H), 7.41 (d, <i>J</i> = 7.6 Hz, 2H), 7.27 (t, <i>J</i> = 7.6 Hz, 1H), 7.20 (d, <i>J</i> = 7.6 Hz, 1H), 7.03 (s, 1H), 5.62 (s, 1H), 4.60 (s, 2H), 3.95 (s, 3H), 2.87 (s, 3H), 2.01–1.91 (m, 2H), 1.86–1.83 (m, 2H), 1.69–1.60 (m, 4H). MS (ESI) <i>m</i>/<i>z</i> 488.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4-((4-(Cyclopentyloxy)-5-(4-(methylcarbamoyl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>16</b>)</h4><div class="NLM_p last">Yield 0.335 g, 0.651 mmol, 56%, HPLC purity >99%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.91 (d, <i>J</i> = 1.95 Hz, 1 H), 8.63 (d, <i>J</i> = 8.98 Hz, 1 H), 8.43 (q, <i>J</i> = 4.43 Hz, 1 H), 8.29–8.35 (m, 1 H), 7.76–7.88 (m, 4 H), 7.74 (s, 1 H), 7.49–7.55 (m, 2 H), 7.46 (d, <i>J</i> = 2.34 Hz, 1 H), 5.64–5.75 (m, 1 H), 3.97 (s, 3 H), 2.74–2.85 (m, 6 H), 1.93–2.07 (m, 2 H), 1.78–1.90 (m, 2 H), 1.60–1.78 (m, 4 H). MS (ESI) <i>m</i>/<i>z</i> 515.0 [M + 1]<sup>+</sup>. Elemental Analysis calculated (%) for (C<sub>28</sub>H<sub>30</sub>N<sub>6</sub>O<sub>4</sub>·0.35H<sub>2</sub>O): C 64.52, H 5.94, N 16.12. Found C 64.21, H 5.85, N 15.90. KF = 1.26%.</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 4-(5-(4-(1<i>H</i>-Pyrazol-5-yl)phenyl)-4-(cyclopentyloxy)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-ylamino)-3-methoxy-<i>N</i>-methylbenzamide (<b>17</b>)</h4><div class="NLM_p last">Yield 0.046 g, 0.088 mmol, 12% over two steps, HPLC purity >96%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.65 (m, 1H), 8.35 (m, 1H), 7.80–7.72 (m, 6H), 7.53 (m, 2H), 7.37 (s, 1H), 6.73 (s, 1H), 5.70 (m, 1H), 3.97 (s, 3H), 2.80 (s, 3H), 2.00–1.64 (m, 8H). MS (ESI) <i>m</i>/<i>z</i> 524.2 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 4-(5-(4-(1<i>H</i>-Imidazol-2-yl)phenyl)-4-(cyclopentyloxy)-7<i>H</i>-pyrrolo[2,3-<i>d</i>] pyrimidin-2-ylamino)-3-methoxy-<i>N</i>-methylbenzamide (<b>18</b>)</h4><div class="NLM_p last">Yield 0.076 g, 0.15 mmol, 28%, HPLC purity >96%. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 8.79–8.78 (m, 1H), 7.89–7.80 (m, 4H), 7.51–7.48 (m, 2H), 7.22 (s, 1H), 5.75–5.73 (m, 1H), 4.03 (s, 3H), 2.94 (s, 3H), 2.04–1.72 (m, 8H). MS (ESI) <i>m</i>/<i>z</i> 524.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 4-((5-(4-(4<i>H</i>-1,2,4-Triazol-3-yl)phenyl)-4-(cyclopentyloxy)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>19</b>)</h4><div class="NLM_p last">Yield 0.049 g, 0.093 mmol, 27%, HPLC purity >97%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83–11.92 (m, 1H), 8.61–8.66 (m, 1H), 8.28–8.34 (m, 1H), 7.97–8.02 (m, 2H), 7.80–7.87 (m, 2H), 7.71–7.74 (m, 1H), 7.49–7.54 (m, 2H), 6.97–7.27 (m, 3H), 5.68–5.72 (m, 1H), 3.97 (s, 3H), 2.76–2.82 (m, 3H), 1.95–2.05 (m, 2H), 1.81–1.89 (m, 2H), 1.63–1.79 (m, 4H). MS (ESI) <i>m</i>/<i>z</i> 525.3 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 4-(5-(1<i>H</i>-Benzo[<i>d</i>]imidazol-6-yl)-4-(cyclopentyloxy)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-ylamino)-3-methoxy-<i>N</i>-methylbenzamide (<b>20</b>)</h4><div class="NLM_p last">Yield 0.014 g, 0.02 mmol, 5% over two steps, HPLC purity >94%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.70–8.68 (d, <i>J</i> = 8.8 Hz, 1H), 8.11 (br s, 1H), 7.79 (br s, 1H), 7.49 (br s, 2H), 7.41–7.38 (m, 2H), 7.00 (s, 1H), 5.61 (m, 1H), 3.93 (s, 3H), 2.83 (s, 3H), 1.91–1.51 (m, 8H). MS (ESI) <i>m</i>/<i>z</i> 498.2 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 4-[4-Cyclopentyloxy-5-(1<i>H</i>-indazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-ylamino]-3-methoxy-<i>N</i>-methylbenzamide (<b>21</b>)</h4><div class="NLM_p last">Yield 0.023 g, 0. 046 mmol, 21%, HPLC purity >90%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.21–12.86 (m, 1H), 12.04–11.65 (m, 1H), 8.82–8.55 (m, 1H), 8.47–8.23 (m, 1H), 8.14–8.01 (m, 1H), 7.72 (s, 3H), 7.51 (s, 4H), 5.82–5.62 (m, 1H), 3.97 (s, 3H), 2.80 (s, 3H), 2.07–1.90 (m, 2H), 1.88–1.73 (m, 2H), 1.63–1.52 (m, 5H). MS (ESI) <i>m</i>/<i>z</i> 498.2 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 4-((4-(Cyclopentyloxy)-5-(2-methylbenzo[<i>d</i>]oxazol-5-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>22</b>)</h4><div class="NLM_p last">Yield 0.045 g, 0.088 mmol, 26%, HPLC purity >97%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.78 (d, <i>J</i> = 8.9 Hz, 1H), 7.88 (s, 1H), 7.63 (d, <i>J</i> = 8.5 Hz, 1H), 7.56–7.41 (m, 3H), 7.11 (s, 1H), 5.71 (m, 1H), 4.03 (s, 3H), 2.93 (s, 3H), 2.66 (s, 3H), 2.09–1.84 (m, 4H), 1.80–1.58 (m, 4H). MS (ESI) <i>m</i>/<i>z</i> 513 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 4-((4-(Cyclopentyloxy)-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>23</b>)</h4><div class="NLM_p last">Yield 0.310 g, 0.60 mmol, 72%, HPLC purity >99%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.66 (d, <i>J</i> = 8.5 Hz, 1H), 8.31 (s, 1H), 7.93 (s, 1H), 7.79–7.29 (m, 6H), 5.69 (s, 1H), 3.97 (s, 3H), 2.80 (s, 3H), 2.61 (s, 3H), 2.16–1.43 (m, 8H). MS (ESI) <i>m</i>/<i>z</i> 513 [M + 1]<sup>+</sup>. Elemental Analysis calculated (%) for (C<sub>28</sub>H<sub>28</sub>N<sub>6</sub>O<sub>4</sub>): C 65.61, H 5.51, N 16.40. Found: C 65.79, H 5.48, N 16.37.</div></div><div id="sec5_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 4-((4-Cyclobutoxy-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>24</b>)</h4><div class="NLM_p last">Tetrabutylammonium fluoride (5.57 mL, 5.57 mmol) was added to a stirred solution of 4-((4-cyclobutoxy-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (0.350 g, 0.557 mmol) in tetrahydrofuran (20 mL). The resulting mixture was capped and stirred at 50 °C for 2 h. The solvent was removed on a rotary evaporator. The reaction mixture was purified using silica gel chromatography (0–25% methanol in dichloromethane) to afford the title compound (0.110 g, 0.221 mmol, 40% yield, HPLC purity >98%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.88 (d, <i>J</i> = 1.95 Hz, 1 H) 8.61 (d, <i>J</i> = 8.59 Hz, 1 H) 8.33 (d, <i>J</i> = 4.69 Hz, 1 H) 8.00 (s, 1 H) 7.66–7.75 (m, 2 H) 7.63 (d, 1 H) 7.49–7.56 (m, 2 H) 7.42 (d, <i>J</i> = 2.34 Hz, 1 H) 5.39 (t, <i>J</i> = 7.22 Hz, 1 H) 3.97 (s, 3 H) 2.80 (d, <i>J</i> = 4.69 Hz, 3 H) 2.63 (s, 3 H) 2.45–2.49 (m, 2 H) 2.06–2.20 (m, 2 H) 1.79–1.91 (m, 1 H) 1.74 (t, 1 H). MS (ESI) <i>m</i>/<i>z</i> 499.5 [M + l]<sup>+</sup>.</div></div><div id="sec5_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 4-(4-Cyclopropoxy-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-ylamino)-3-methoxy-<i>N</i>-methylbenzamide (<b>25</b>)</h4><div class="NLM_p last">Yield 1.3 g, 2.7 mmol, 68%, HPLC purity >98%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.90 (s, 1 H) 8.73 (d, <i>J</i> = 8.83 Hz, 1 H) 8.31 (d, <i>J</i> = 4.73 Hz, 1 H) 7.85 (s, 1 H) 7.77 (s, 1 H) 7.57–7.64 (m, 2 H) 7.50–7.55 (m, 2 H) 7.41 (s, 1 H) 4.50–4.58 (m, <i>J</i> = 6.19, 6.19, 3.07, 2.84 Hz, 1 H) 3.98 (s, 3 H) 2.80 (d, <i>J</i> = 4.41 Hz, 3 H) 2.63 (s, 3 H) 0.88 (d, <i>J</i> = 6.94 Hz, 2 H) 0.76–0.82 (m, 2 H). MS (ESI) <i>m</i>/<i>z</i> 485.2 [M + 1]<sup>+</sup>. Elemental Analysis calculated (%) for (C<sub>26</sub>H<sub>24</sub>N<sub>6</sub>O<sub>4</sub>): C 64.45, H 4.99, N 17.35. Found: C 64.28, H 4.72, N 17.25.</div></div><div id="sec5_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 4-(4-Isopropoxy-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-ylamino)-3-methoxy-<i>N</i>-methylbenzamide (<b>26</b>)</h4><div class="NLM_p last">Yield 0.459 g, 0.943 mmol, 86%, HPLC purity >99%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.77–11.95 (m, 1 H), 8.53–8.69 (m, 1 H), 8.27–8.37 (m, 1 H), 7.94–8.00 (m, 1 H), 7.70–7.75 (m, 1 H), 7.65–7.70 (m, 1 H), 7.57–7.64 (m, 1 H), 7.47–7.55 (m, 2 H), 7.34–7.43 (m, 1 H), 5.46–5.58 (m, 1 H), 3.97 (s, 3 H), 2.75–2.83 (m, 3 H), 2.62 (s, 3 H), 1.38 (d, <i>J</i> = 6.25 Hz, 6 H). MS (ESI) <i>m</i>/<i>z</i> 487.4 [M + 1]<sup>+</sup>. Elemental Analysis calculated (%) for (C<sub>26</sub>H<sub>26</sub>N<sub>6</sub>O<sub>4</sub>·0.19H<sub>2</sub>O): C 63.74, H 5.43, N 17.15. Found: C 64.07, H 5.30, N 17.14. KF = 0.70%.</div></div><div id="sec5_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 4-((4-(2-Hydroxyethoxy)-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>27</b>)</h4><div class="NLM_p last">Yield 0.057 g, 0.12 mmol, 11%, HPLC purity >98%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.54–8.69 (m, 1 H), 8.22–8.36 (m, 1 H), 7.93–8.04 (m, 1 H), 7.68–7.76 (m, 2 H), 7.55–7.61 (m, 1 H), 7.47–7.54 (m, 2 H), 7.36–7.44 (m, 1 H), 4.48–4.56 (m, 2 H), 3.92–4.00 (m, 3 H), 3.74–3.83 (m, 2 H), 2.77–2.83 (m, 3 H), 2.58–2.66 (m, 3 H). MS (ESI) <i>m</i>/<i>z</i> 488.9 [M + l]<sup>+</sup>.</div></div><div id="sec5_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 3-Methoxy-4-((4-(2-methoxyethoxy)-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-<i>N</i>-methylbenzamide (<b>28</b>)</h4><div class="NLM_p last">Yield 0.031 g, 0.062 mmol, 19%, HPLC purity >98%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.9 (s, 1H), 8.61 (d, <i>J</i> = 8.8 Hz, 1H), 8.30 (m, 1H), 8.03 (d, <i>J</i> = 1.6 Hz, 1H), 7.76 (s, 1H), 7.70 (dd, <i>J</i> = 8.3, 1.7 Hz, 1H), 7.59 (d, <i>J</i> = 8.3 Hz, 1H), 7.51 (m, 2H), 7.42 (d, <i>J</i> = 2.5 Hz, 1H), 4.60 (m, 2H), 3.97 (s, 3H), 3.72 (m, 2H), 3.33 (s, 3H), 2.80 (d, <i>J</i> = 4.5 Hz, 3H), 2.62 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 503 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 4-((4-Hydroxy-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>29</b>)</h4><div class="NLM_p last">Compound <b>6e</b> was treated under the standard SEM deprotection conditions. The title compound was isolated as a byproduct (0.017 g, 0.038 mmol, 16% yield, HPLC purity >95%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.66 (s, 1 H) 10.95 (br s, 1 H) 8.78 (s, 1 H) 8.34 (s, 1 H) 8.29 (s, 1 H) 8.22 (s, 1 H) 7.91 (d, 1 H) 7.55 (d, <i>J</i> = 8.20 Hz, 1 H) 7.49 (d, 1 H) 7.19 (s, 1 H) 7.10 (d, <i>J</i> = 8.20 Hz, 1 H) 3.94 (s, 3 H) 2.78 (d, <i>J</i> = 3.90 Hz, 3 H) 2.60 (s, 3 H). MS (ESI) <i>m</i>/<i>z</i> 445.5 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 3-Methoxy-<i>N</i>-methyl-4-((5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-4-(oxetan-3-yloxy)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)benzamide (<b>30</b>)</h4><div class="NLM_p last">Tetrabutylammonium fluoride (7.93 mL, 7.93 mmol) was added to a stirred solution of 3-methoxy-<i>N</i>-methyl-4-((5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-4-(oxetan-3-yloxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)benzamide (0.5 g, 0.793 mmol) in tetrahydrofuran (20 mL). The resulting mixture was capped and stirred at 50 °C for 2 h. The solvent was removed on a rotary evaporator. The reaction mixture was purified using silica gel chromatography (0–25% methanol in dichloromethane) to afford the title compound (0.190 g, 0.380 mmol, 48% yield, HPLC purity >99%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.94 (d, <i>J</i> = 1.89 Hz, 1 H) 8.48 (d, <i>J</i> = 8.20 Hz, 1 H) 8.33 (d, <i>J</i> = 4.41 Hz, 1 H) 8.02 (s, 1 H) 7.79 (s, 1 H) 7.70–7.75 (m, 1 H) 7.66 (d, 1 H) 7.54 (d, <i>J</i> = 8.51 Hz, 1 H) 7.52 (s, 1 H) 7.45 (d, <i>J</i> = 2.52 Hz, 1 H) 5.80 (q, 1 H) 4.96 (t, <i>J</i> = 6.94 Hz, 2 H) 4.62 (td, <i>J</i> = 7.41, 5.20 Hz, 2 H) 3.96 (s, 3 H) 2.81 (d, <i>J</i> = 4.41 Hz, 3 H) 2.64 (s, 3 H). MS (ESI) <i>m</i>/<i>z</i> 500.1 [M + l]<sup>+</sup>.</div></div><div id="sec5_2_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (<i>S</i>)-3-Methoxy-<i>N</i>-methyl-4-((5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-4-((tetrahydrofuran-3-yl)oxy)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)benzamide (<b>31</b>)</h4><div class="NLM_p last">Yield 0.130 g, 0.253 mmol, 96%, HPLC purity >98%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.90 (s, 1 H) 8.58 (d, <i>J</i> = 8.59 Hz, 1 H) 8.32 (d, <i>J</i> = 5.08 Hz, 1 H) 7.93 (s, 1 H) 7.78 (s, 1 H) 7.57–7.71 (m, 2 H) 7.46–7.56 (m, 2 H) 7.41 (d, <i>J</i> = 1.95 Hz, 1 H) 5.71–5.86 (m, 1 H) 4.00 (dd, <i>J</i> = 10.35, 4.88 Hz, 1 H) 3.96 (s, 3 H) 3.87 (s, 1 H) 3.75–3.86 (m, 3 H) 2.80 (d, <i>J</i> = 4.29 Hz, 3 H) 2.62 (s, 3 H) 2.29 (d, 1 H). MS (ESI) <i>m</i>/<i>z</i> 515.0 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 3-Methoxy-<i>N</i>-methyl-4-((5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-4-((tetrahydro-2<i>H</i>-pyran-4-yl)oxy)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)benzamide (<b>32</b>)</h4><div class="NLM_p last">Yield 0.148 g, 0.280 mmol, 14% over 2 steps, HPLC purity >96%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.96 (s, 1 H), 8.67 (d, <i>J</i> = 8.93 Hz, 1 H), 8.41 (br d, <i>J</i> = 4.52 Hz, 1 H), 8.06 (d, <i>J</i> = 1.10 Hz, 1 H), 7.85 (s, 1 H), 7.69–7.79 (m, 2 H), 7.58–7.64 (m, 2 H), 7.49 (d, <i>J</i> = 2.08 Hz, 1 H), 5.62 (tt, <i>J</i> = 7.90, 4.02 Hz, 1 H), 4.06 (s, 3 H), 3.80–3.93 (m, 2 H), 3.66 (ddd, <i>J</i> = 11.46, 8.22, 3.18 Hz, 2 H), 2.90 (d, <i>J</i> = 4.52 Hz, 3 H), 2.72 (s, 3 H), 2.20 (br dd, <i>J</i> = 8.86, 4.95 Hz, 2 H), 1.76–1.86 (m, 2 H). MS (ESI) <i>m</i>/<i>z</i> 529.2 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 4-((4-(((1<i>r</i>,4<i>r</i>)-4-Hydroxy-4-methylcyclohexyl)oxy)-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>33</b>)</h4><div class="NLM_p last">Compound <b>33</b> SEM was deprotected by the standard conditions and purified by prep HPLC (10–95% acetonitrile in water) to give the racemic product (280 mg, 0.50 mmol, 23% yield over two steps) as a yellow solid. This material was further purified by chiral HPLC (30% ethanol in hexane) to obtain the title compound (0.041 g, 0.07 mmol, 3% yield, HPLC purity >97%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.84 (s, 1H), 8.59 (d, <i>J</i> = 8.8 Hz, 1H), 8.32 (d, <i>J</i> = 4.8 Hz, 1H), 7.90 (s, 1H), 7.72 (s, 1H), 7.63–7.58 (m, 2H), 7.51 (d, <i>J</i> = 5.2 Hz, 2H), 7.34 (s, 1H), 5.56 (br s, 1H), 4.12 (s, 1H), 3.97 (s, 3H), 2.79 (d, <i>J</i> = 4.4 Hz, 3H), 2.61 (s, 3H), 2.01–1.94 (m, 2H), 1.71–1.68 (m, 2H), 1.48–1.42 (m, 2H), 1.37–1.34 (m, 2H), 1.01 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 557.2 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 4-((4-(((1<i>s</i>,4<i>s</i>)-4-Hydroxy-4-methylcyclohexyl)oxy)-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>-methylbenzamide (<b>34</b>)</h4><div class="NLM_p last">Compound <b>33</b> SEM was deprotected by the standard conditions and purified by prep HPLC (10–95% acetonitrile in water) to give the racemic product (280 mg, 0.50 mmol, 23% yield over two steps) as a yellow solid. This material was further purified by chiral HPLC (30% ethanol in hexane) to obtain the title compound (0.163 g, 0.29 mmol, 13% yield, HPLC purity >99%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 8.60 (d, <i>J</i> = 8.0 Hz, 1H), 8.31 (d, <i>J</i> = 4.8 Hz, 1H), 7.97 (s, 1H), 7.71–7.68 (m, 2H), 7.69 (d, <i>J</i> = 8.0 Hz, 1H), 7.50 (d, <i>J</i> = 9.2 Hz, 2H), 7.39 (d, <i>J</i> = 2.4 Hz, 1H), 5.25–5.20 (m, 1H), 4.19 (s, 1H), 3.97 (s, 3H), 2.80 (d, <i>J</i> = 4.4 Hz, 3H), 2.62 (s, 3H), 1.96–1.92 (m, 2H), 1.87–1.78 (m, 2H), 1.66–1.63 (m, 2H), 1.52–1.45 (m, 2H), 1.17 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 557.3 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 4-(Cyclopentyloxy)-<i>N</i>-(2-methoxyphenyl)-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-amine (<b>35</b>)</h4><div class="NLM_p last">Yield 0.058 g, 0.13 mmol, 34%, HPLC purity >95%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.05 (s, 1H), 8.60–8.58 (dd, <i>J</i> = 2.0 Hz, 1H), 7.82 (s, 1H), 7.59–7.59 (t, <i>J</i> = 1.6 Hz, 2H), 7.51 (s, 1H), 7.01–6.90 (m, 4H), 5.74–5.71 (m, 1H), 3.90 (s, 3H), 2.66 (s, 3H), 1.99–1.92 (m, 4H), 1.77–1.73 (m, 2H), 1.66–1.63 (d, <i>J</i> = 12 Hz, 2H). MS (ESI) <i>m</i>/<i>z</i> 456.2 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 4-((4-(Cyclopentyloxy)-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxy-<i>N</i>,<i>N</i>-dimethylbenzamide (<b>36</b>)</h4><div class="NLM_p last">Yield 0.073 g, 0.139 mmol, 87%, HPLC purity >96%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.74 (s, 1 H) 8.55 (d, <i>J</i> = 8.20 Hz, 1 H) 7.89 (s, 1 H) 7.48–7.71 (m, 3 H) 7.28 (s, 1 H) 6.84–7.13 (m, 2 H) 5.43–5.75 (m, 1 H) 3.89 (s, 3 H) 2.95 (s, 6 H) 2.58 (s, 3 H) 1.49–2.00 (m, 8 H). MS (ESI) <i>m</i>/<i>z</i> 527.2 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (4-((4-(Cyclopentyloxy)-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxyphenyl)(4-methylpiperazin-1-yl)methanone (<b>37</b>)</h4><div class="NLM_p last">Yield 0.250 g, 0.420 mmol, 78%, HPLC purity >97%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.59–1.76 (m, 4 H) 1.83 (br s, 2 H) 1.94–2.02 (m, 3 H) 2.22 (s, 3 H) 2.34 (br s, 4 H) 2.63 (s, 3 H) 3.54 (br s, 3 H) 3.95 (s, 3 H) 5.69 (br s, 1 H) 7.01–7.09 (m, 2 H) 7.35–7.40 (m, 1 H) 7.58–7.73 (m, 3 H) 7.94 (s, 1 H) 8.60 (d, <i>J</i> = 8.20 Hz, 1 H) 11.82 (s, 1 H). MS (ESI) <i>m</i>/<i>z</i> 582.0 [M + l]<sup>+</sup>.</div></div><div id="sec5_2_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (4-((4-(Cyclopentyloxy)-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-3-methoxyphenyl)(morpholino)methanone (<b>38</b>)</h4><div class="NLM_p last">Yield 0.110 g, 0.193 mmol, 68%, HPLC purity >98%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.74 (br s, 1 H) 8.58 (d, <i>J</i> = 8.20 Hz, 1 H) 7.89 (s, 1 H) 7.64 (s, 1 H) 7.50–7.62 (m, 2 H) 7.28 (s, 1 H) 6.95–7.09 (m, 2 H) 5.55–5.72 (m, 1 H) 3.90 (s, 3 H) 3.44–3.66 (m, 8 H) 2.58 (s, 3 H) 1.84–2.00 (m, 2 H) 1.71–1.81 (m, 2 H) 1.63–1.70 (m, 2 H) 1.57 (br s, 2 H). MS (ESI) <i>m</i>/<i>z</i> 569.3 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 4-((4-(Cyclopentyloxy)-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-2-yl)amino)-3-methoxy-<i>N</i>-(oxetan-3-yl)benzamide (<b>39</b>)</h4><div class="NLM_p last">Yield 0.127 g, 0.23 mmol, 45% over two steps, HPLC purity >97%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.88 (s, 1H), 8.69–8.67 (d, <i>J</i> = 8.0 Hz, 1H), 7.93 (s, 1H), 7.77 (s, 1H), 7.66–7.58 (m, 2H), 7.51–7.45 (m, 2H), 7.39 (s, 1H), 5.70–5.67 (m, 1H), 4.86–4.83 (m, 1H), 4.44–4.41 (m, 1H), 4.29–4.22 (m, 2H), 3.96 (s, 3H), 3.62–3.58 (m, 1H), 3.48–3.42 (m, 1H), 2.62 (s, 3H), 1.98–1.95 (m, 2H), 1.83–1.78 (m, 2H), 1.75–1.63 (m, 4H). MS (ESI) <i>m</i>/<i>z</i> 555.3 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 4-((4-(Cyclopentyloxy)-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-<i>N</i>-(2-hydroxyethyl)-3-methoxybenzamide (<b>40</b>)</h4><div class="NLM_p last">Yield 6 g, 11.0 mmol, 68%, HPLC purity >99%. <sup>1</sup>H NMR (400 MHz DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 8.61–8.63 (m, 1H), 8.34 (m, 1H), 7.91 (s, 1H), 7.71 (s, 1H), 7.52–7.64 (m, 4H), 7.37 (s, 1H), 5.67 (s, 1H), 4.74 (s, 1H), 3.95 (s, 3H), 3.49–3.51 (m, 2H), 3.32 (m, 2H), 2.60 (s, 3H), 1.95–1.96 (m, 2H), 1.82 (m, 2H), 1.64–1.67 (m, 4H). MS (ESI) <i>m</i>/<i>z</i> 543.2 [M + 1]<sup>+</sup>. Elemental Analysis calculated (%) for (C<sub>29</sub>H<sub>30</sub>N<sub>6</sub>O<sub>5</sub>·0.17H<sub>2</sub>O): C 63.83, H 5.60, N 15.40. Found: C 63.81, H 5.49, N 15.31. KF = 0.57%.</div></div><div id="sec5_2_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 4-((4-(Cyclopentyloxy)-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-<i>N</i>-(2-hydroxy-2-methylpropyl)-3-methoxybenzamide (<b>41</b>)</h4><div class="NLM_p last">Yield 0.061 g, 0.11 mmol, 21% over two steps, HPLC purity >97%. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 8.79 (d, <i>J</i> = 8.3 Hz, 1H), 7.88 (s, 1H), 7.73–7.60 (m, 1H), 7.54 (dd, <i>J</i> = 8.5, 3.3 Hz, 3H), 7.18 (s, 1H), 5.73 (s, 1H), 4.04 (s, 3H), 3.44 (s, 2H), 2.66 (s, 3H), 2.00–1.94 (m, 4H), 1.77–1.69 (m, 4H), 1.27 (s, 6H). MS (ESI) <i>m</i>/<i>z</i> 571.3 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 4-((4-(Cyclopentyloxy)-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-<i>N</i>-(1-hydroxy-2-methylpropan-2-yl)-3-methoxybenzamide (<b>42</b>)</h4><div class="NLM_p last">Yield 0.025 g, 0.044 mmol, 23%, HPLC purity >96%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (d, 1 H), 8.62 (d, 1 H), 7.93 (d, 1 H), 7.73 (s, 1 H), 7.68–7.57 (m, 2 H), 7.53–7.42 (m, 3 H), 7.39 (d, 1 H), 5.72–5.65 (m, 1 H), 5.00–4.93 (m, 1 H), 3.97 (s, 3 H), 3.53 (d, 2 H), 2.62 (s, 3 H), 2.04–1.92 (m, 2 H), 1.88–1.78 (m, 2 H), 1.67 (dd, 4 H), 1.33 (s, 6 H). MS (ESI) <i>m</i>/<i>z</i> 571.6 [M + l]<sup>+</sup>.</div></div><div id="sec5_2_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 4-((4-(Cyclopentyloxy)-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-<i>N</i>,3-dimethylbenzamide (<b>43</b>)</h4><div class="NLM_p last">Yield 0.045 g, 0.091 mmol, 13% over 2 steps, HPLC purity >98%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.33 (d, <i>J</i> = 8.59 Hz, 1 H), 7.85 (s, 1 H), 7.57–7.69 (m, 3 H), 7.46–7.52 (m, 1 H), 7.06 (s, 1 H), 5.64 (br s, 1 H), 2.89 (s, 3 H), 2.63 (s, 3 H), 2.38 (s, 3 H), 1.54–1.99 (m, 8 H). MS (ESI) <i>m</i>/<i>z</i> 497.0 [M + 1]<sup>+</sup>.</div></div><div id="sec5_2_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 3-Chloro-4-((4-(cyclopentyloxy)-5-(2-methylbenzo[<i>d</i>]oxazol-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-<i>N</i>-methylbenzamide (<b>44</b>)</h4><div class="NLM_p last">Yield 0.051 g, 0.099 mmol, 64%, HPLC purity >94%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.87 (s, 1 H), 8.43–8.50 (m, 2 H), 8.15 (s, 1 H), 7.97 (d, <i>J</i> = 1.95 Hz, 1 H), 7.94 (d, <i>J</i> = 1.17 Hz, 1 H), 7.83 (dd, <i>J</i> = 8.59, 1.95 Hz, 1 H), 7.64–7.67 (m, 1 H), 7.58–7.62 (m, 1 H), 7.41 (d, <i>J</i> = 2.34 Hz, 1 H), 5.66 (tt, <i>J</i> = 5.52, 2.69 Hz, 1 H), 2.79 (d, <i>J</i> = 4.30 Hz, 3 H), 2.62 (s, 3 H), 1.90–2.00 (m, 2 H), 1.77–1.86 (m, 2 H), 1.58–1.74 (m, 4 H). MS (ESI) <i>m</i>/<i>z</i> 517.6 [M + 1]<sup>+</sup>.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Cellular Proliferation Assays</h3><div class="NLM_p last">Cal-51 was purchased from DSMZ. MDA-MB-231, MDA-MB-468, BT-474, MDA-MB-361, and ZR-75-30 cells were purchased from the American Tissue Culture Collection. All cell lines were maintained in growth media as recommended by the vendors. The growth inhibitory effect was determined using the CellTiter-Glo luminescent cell viability assay. The cells were incubated with compound for 3 days. At the end of the assay period, CellTiter-Glo reagent was added to each well and the luminescence was measured on the Envision Multilabel (PerkinElmer) plate reader. The percent inhibition at each compound concentration was determined by normalizing data to the DMSO control values for each set of triplicate wells. All data were analyzed using XLfit from IDBS. The formula used for determining IC<sub>50</sub> in XLfit was model number 205, which utilizes a four-parameter logistic model or sigmoidal dose–response model to calculate IC<sub>50</sub> values. Full experimental details have been previously described.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> In Vitro Kinase Selectivity Profiling</h3><div class="NLM_p last">The kinase selectivity profile of compound <b>23</b> was assessed using the Invitrogen panel of 255 kinases using one of the following Invitrogen protocols: Z′-Lyte protocol, ADAPTA, or the Lantha Binding Assay. The screen was conducted with the concentration of compound <b>23</b> held constant at 3 μM. The TTK binding affinity was measured at Invitrogen using the LanthaScreen Eu kinase binding assays. The LanthaScreen Eu kinase binding assays are based on the binding and displacement of a proprietary, Alexa Fluor 647-labeled, ATP-competitive kinase inhibitor scaffold (kinase tracer).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> ActivX Cellular Kinase Profiling</h3><div class="NLM_p last">The HCT-116 cell line (CRL-1619) was acquired from American Type Culture Collection (ATCC) and cultured in RPMI-1640 media with 10% fetal bovine serum. Upon confluence, compound was added to form a 1000× DMSO stock solution so that the final compound concentration was 3 μM. For control cells (no compound), an equivalent volume of DMSO was added. After 1 h, cells were washed once with ice-cold 1× phosphate buffered saline (PBS), scrapped, and collected by centrifugation. The cell pellets were stored at −80 °C until ready for processing. The samples were analyzed using the KiNativ approach (ActivX, San Diego). The KiNativ (ActivX, San Diego) approach allows for selective enrichment of native kinases based on covalent modification of the active site with ATP and adenosinediphosphate (ADP) acylphosphate probes. Quantitation of enriched kinases is achieved through liquid chromatography (LC)-mass spectrometry (MS)/mass spectrometry. Procedure describe in Patricelli et al.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Immunoblot Analyses</h3><div class="NLM_p last">Cells were lysed in RIPA buffer (Thermos Scientific, catalogue no. 89900). The protein concentration of the lysates was determined by the Bio-Rad protein assay (Bio-Rad, catalogue no. 500-0001). Then 30 μg of protein from each lysate were loaded onto NuPAGE Novex 4–12% Bis-Tris gels (Invitrogen catalogue no. EA0375) and run in MES SDS running buffer. Protein was then transferred and blotted with primary antibodies. Primary antibodys used were as follows: Phospho-TTK T686 (custom-made rabbit monoclonal antibody), Phospho-SR (mouse 1H4G7) (Invitrogen catalogue no. 339400). Goat antirabbit AlexaFluor680 (Invitrogen catalogue no. A21076) and goat antimouse IRDye800 (Rockland Immunochemicals catalogue 610-132-121) were then used to detect the protein bands. The membranes were then scanned using the Odyssey infrared imaging system (LI-COR Biosciences).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Wash-out Studies</h3><div class="NLM_p last">Cal-51 cells were plated at a density of 3000 cells per well in a 96-well plate (Costar catalogue no. 33595) in 100 μL of growth media. The following day, compound dilutions were prepared with a final DMSO concentration of 0.2% in each well. All concentrations were assessed in triplicate within each 96-well assay plate. The cells were incubated with compound in 5% CO<sub>2</sub> at 37 °C for 6, 12, 24, 48, and 72 h. At the end of each time point, wells were washed three times with fresh cell culture medium. The cells were cultured in 100 μL growth medium for up to 72 h post compound treatment. At the end of the assay, 100 μL of CellTiter-Glo reagent was added to each well. The luminescence was measured on the Envision Multilabel (2104 PerkinElmer) plate reader.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Crystallization</h3><div class="NLM_p">The TTK kinase domain with a thrombin-cleavable, N-terminal 6XHis tag was expressed in E. coli strain BL21(DE3) (Life Technologies). Cells were grown in LB media, and induced at 20 °C for 4 h. Initial capture was performed via nickel affinity chromatography using nickel-NTA resin. The 6XHis tag was subsequently cleaved by addition of thrombin, and the protein passed back over nickel-NTA resin. Cleaved TTK was further purified by S-75 size exclusion chromatography (GE Healthcare), and concentrated to 11 mg/mL. TTK was crystallized by sitting drop vapor diffusion at 4 °C in the presence of 1 mM of compound <b>23</b>. The TTK:<b>23</b> complex was mixed 1:1 with, and subsequently equilibrated against, a solution of 100 mM sodium cacodylate pH 7, 200 mM potassium thiocyanate, 15% PEG 4K. Crystals were cryo-protected by addition of 20% ethylene gycol, and flash cooled under liquid nitrogen.</div><div class="NLM_p last">Diffraction data was collected at the Canadian Light Source, beamline CMCF-08ID. Data were indexed, integrated and scaled using HKL2000.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The structure was solved using molecular replacement using PHASER.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Manual model building was performed using COOT, with subsequently rounds of refinement using CCP4.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a> Coordinates and structure factors have been deposited in the Protein Data Bank with the accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B4W">6B4W</a>.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Computational Methods and Modeling</h3><div class="NLM_p last">The Schrodinger Small-Molecule Drug Discovery Suite was used for all crystal structure and small molecule-protein visualization and analysis, including SiteMap generation (Maestro, Schrödinger Release 2017-1; MS Jaguar, Schrödinger, LLC, New York, NY, 2017; SiteMap (version 4201).<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> CLK2 crystal structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3NR9">3NR9</a>) was obtained from <a href="http://www.rcsb.org" class="extLink">http://www.rcsb.org</a>. Docking experiments were conducted with Glide as implemented in Schrodinger Small-molecule Suite (Schrödinger Release 2017-1, Glide; Schrödinger, LLC, New York, NY, 2017). Alignments and sequence comparisons were done with Clustal Omega Program ((<a href="http://www.ebi.ac.uk/Tools/msa/clustalw2/" class="extLink">http://www.ebi.ac.uk/Tools/msa/clustalw2/</a>) and with the Schrodinger multiple sequence alignment tool PrimeX (Schrödinger Release 2017-1: PrimeX; Schrödinger, LLC, New York, NY, 2017). Some portions of the modeling studies are included in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01223/suppl_file/jm7b01223_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> In Vivo Studies</h3><div class="NLM_p last">All animal studies were performed under protocols approved by Institutional Animal Care and Use Committees. Female SCID mice were inoculated subcutaneously with 5 × 10<sup>6</sup> Cal-51 cells. Mice with tumors of approximately 125 mm<sup>3</sup> were randomized and treated intravenously at various doses and schedules of compound <b>23</b> (<i>n</i> = 8–10/group). Tumors were measured twice a week for the duration of the study. The long and short axes of each tumor were measured using a digital caliper in millimeters and the tumor volumes were calculated using the formula: width 2 x_ length/2. The tumor volumes were expressed in cubic millimeters (mm<sup>3</sup>).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01223">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43522" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43522" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01223" class="ext-link">10.1021/acs.jmedchem.7b01223</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">In vitro and cellular kinase selectivity data for compound <b>23</b>, additional TTK crystal structure views, docked structure of <b>23</b> in CLK2, experimental procedures for intermediates (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01223/suppl_file/jm7b01223_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01223/suppl_file/jm7b01223_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01223/suppl_file/jm7b01223_si_001.pdf">jm7b01223_si_001.pdf (1.26 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01223/suppl_file/jm7b01223_si_002.csv">jm7b01223_si_002.csv (3.81 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01223" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06131" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06131" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer R. Riggs</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9012-1428" title="Orcid link">http://orcid.org/0000-0001-9012-1428</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#caa0b8a3adadb98aa9afa6adafa4afe4a9a5a7"><span class="__cf_email__" data-cfemail="6d071f040a0a1e2d0e08010a080308430e0200">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Nagy</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jan Elsner</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Erdman</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dan Cashion</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dale Robinson</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roy Harris</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dehua Huang</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lida Tehrani</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gordafaried Deyanat-Yazdi</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rama Krishna Narla</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaohui Peng</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tam Tran</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leo Barnes</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Terra Miller</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Katz</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yang Tang</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ming Chen</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mehran F. Moghaddam</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sogole Bahmanyar</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barbra Pagarigan</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Silvia Delker</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laurie LeBrun</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip P. Chamberlain</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6407-7344" title="Orcid link">http://orcid.org/0000-0002-6407-7344</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Calabrese</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stacie S. Canan</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katerina Leftheris</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dan Zhu</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John F. Boylan</span> - <span class="hlFld-Affiliation affiliation">Celgene Corporation, 10300 Campus Pointe Drive, Suite
100, San Diego, California 92121, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e3858-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i65">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54505" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54505" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the Celgene San Diego DMPK department for analysis, the Celgene San Diego CLMD and analytical groups for project support, and Deborah Mortensen for helpful discussions and editorial comments. Crystal structure determination described in this paper was performed using beamline 08ID-1 at the Canadian Light Source, which is supported by the Canada Foundation for Innovation, Natural Sciences and Engineering Research Council of Canada, the University of Saskatchewan, the Government of Saskatchewan, Western Economic Diversification Canada, the National Research Council Canada, and the Canadian Institutes of Health Research.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i66" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i66"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i67" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i67"> Abbreviations Used</h2><tr><td class="NLM_term">Mps1</td><td class="NLM_def"><p class="first last">monopolar spindle 1</p></td></tr><tr><td class="NLM_term">CLK2</td><td class="NLM_def"><p class="first last">CDC2-like kinase</p></td></tr><tr><td class="NLM_term">DYRK1A, 1B, 3</td><td class="NLM_def"><p class="first last">dual specificity tyrosine-phosphorylation-regulated kinase 1A, 1B, 3</p></td></tr><tr><td class="NLM_term">PHKG1</td><td class="NLM_def"><p class="first last">phosphorylase kinase catalytic subunit gamma 1</p></td></tr><tr><td class="NLM_term">CAMKK2</td><td class="NLM_def"><p class="first last">calcium/calmodulin dependent protein kinase kinase 2</p></td></tr><tr><td class="NLM_term">PIP4K22</td><td class="NLM_def"><p class="first last">phosphatidylinositol 5-phosphate 4-kinase</p></td></tr><tr><td class="NLM_term">JNK</td><td class="NLM_def"><p class="first last">c-Jun N-terminal kinase</p></td></tr><tr><td class="NLM_term">SAC</td><td class="NLM_def"><p class="first last">spindle assembly checkpoint</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple negative breast cancer</p></td></tr><tr><td class="NLM_term">SR proteins</td><td class="NLM_def"><p class="first last">serine- and arginine-rich proteins</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">BWL</td><td class="NLM_def"><p class="first last">body weight loss</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i68">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11554" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11554" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 36 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Swinney, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, J.</span><span> </span><span class="NLM_article-title">How were new medicines discovered?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span><span class="refDoi"> DOI: 10.1038/nrd3480</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1038%2Fnrd3480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=21701501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlCmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=507-519&author=D.+C.+Swinneyauthor=J.+Anthony&title=How+were+new+medicines+discovered%3F&doi=10.1038%2Fnrd3480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">How were new medicines discovered?</span></div><div class="casAuthors">Swinney, David C.; Anthony, Jason</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">507-519</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Preclin. strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biol.-based approaches.  To investigate whether some strategies have been more successful than others in the discovery of new drugs, we analyzed the discovery strategies and the mol. mechanism of action (MMOA) for new mol. entities and new biologics that were approved by the US Food and Drug Administration between 1999 and 2008.  Out of the 259 agents that were approved, 75 were first-in-class drugs with new MMOAs, and out of these, 50 (67%) were small mols. and 25 (33%) were biologics.  The results also show that the contribution of phenotypic screening to the discovery of first-in-class small-mol. drugs exceeded that of target-based approaches - with 28 and 17 of these drugs coming from the two approaches, resp. - in an era in which the major focus was on target-based approaches.  We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE8Ah1iNz76bVg90H21EOLACvtfcHk0lh6Jr18MFO0rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlCmsbs%253D&md5=7503620f8fbadb0a829f6ea2029936a2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd3480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3480%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26aulast%3DAnthony%26aufirst%3DJ.%26atitle%3DHow%2520were%2520new%2520medicines%2520discovered%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D507%26epage%3D519%26doi%3D10.1038%2Fnrd3480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Eder, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sedrani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span> </span><span class="NLM_article-title">The discovery of first-in-class drugs: origins and evolution</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">587</span><span class="refDoi"> DOI: 10.1038/nrd4336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1038%2Fnrd4336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=25033734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=577-587&author=J.+Ederauthor=R.+Sedraniauthor=C.+Wiesmann&title=The+discovery+of+first-in-class+drugs%3A+origins+and+evolution&doi=10.1038%2Fnrd4336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of first-in-class drugs: origins and evolution</span></div><div class="casAuthors">Eder, Jorg; Sedrani, Richard; Wiesmann, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">577-587</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Anal. of the origins of new drugs approved by the US Food and Drug Administration (FDA) from 1999 to 2008 suggested that phenotypic screening strategies had been more productive than target-based approaches in the discovery of first-in-class small-mol. drugs.  However, given the relatively recent introduction of target-based approaches in the context of the long time frames of drug development, their full impact might not yet have become apparent.  Here, we present an anal. of the origins of all 113 first-in-class drugs approved by the FDA from 1999 to 2013, which shows that the majority (78) were discovered through target-based approaches (45 small-mol. drugs and 33 biologics).  In addn., of 33 drugs identified in the absence of a target hypothesis, 25 were found through a chemocentric approach in which compds. with known pharmacol. served as the starting point, with only eight coming from what we define here as phenotypic screening: testing a large no. of compds. in a target-agnostic assay that monitors phenotypic changes.  We also discuss the implications for drug discovery strategies, including viewing phenotypic screening as a novel discipline rather than as a neoclassical approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqthEelveRWN7Vg90H21EOLACvtfcHk0liYEpOVeI-iyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7I&md5=b2061d96a71893a329b5b654acec5420</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd4336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4336%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DJ.%26aulast%3DSedrani%26aufirst%3DR.%26aulast%3DWiesmann%26aufirst%3DC.%26atitle%3DThe%2520discovery%2520of%2520first-in-class%2520drugs%253A%2520origins%2520and%2520evolution%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D577%26epage%3D587%26doi%3D10.1038%2Fnrd4336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Moffat, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, D.</span><span> </span><span class="NLM_article-title">Phenotypic screening in cancer drug discovery - past, present and future</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">588</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span><span class="refDoi"> DOI: 10.1038/nrd4366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1038%2Fnrd4366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=25033736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=588-602&author=J.+G.+Moffatauthor=J.+Rudolphauthor=D.+Bailey&title=Phenotypic+screening+in+cancer+drug+discovery+-+past%2C+present+and+future&doi=10.1038%2Fnrd4366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic screening in cancer drug discovery - past, present and future</span></div><div class="casAuthors">Moffat, John G.; Rudolph, Joachim; Bailey, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">588-602</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches.  Given that oncol. is currently the most active therapeutic area, and also one in which target-focused approaches have been particularly prominent in the past two decades, we investigated the contribution of phenotypic assays to oncol. drug discovery by analyzing the origins of all new small-mol. cancer drugs approved by the US Food and Drug Administration (FDA) over the past 15 years and those currently in clin. development.  Although the majority of these drugs originated from target-based discovery, we identified a significant no. whose discovery depended on phenotypic screening approaches.  We postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes.  However, tech. and biol. advances that enable such mechanistically informed phenotypic models have the potential to empower phenotypic drug discovery in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTWtoTIgWqvbVg90H21EOLACvtfcHk0liYEpOVeI-iyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7L&md5=0e8efed90e5bc4b47f959b83a6ab5b96</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd4366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4366%26sid%3Dliteratum%253Aachs%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DD.%26atitle%3DPhenotypic%2520screening%2520in%2520cancer%2520drug%2520discovery%2520-%2520past%252C%2520present%2520and%2520future%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D588%26epage%3D602%26doi%3D10.1038%2Fnrd4366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Lehmann, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanders, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarthy, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shyr, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietenpol, J. A.</span><span> </span><span class="NLM_article-title">Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">2750</span><span class="NLM_x">–</span> <span class="NLM_lpage">2767</span><span class="refDoi"> DOI: 10.1172/JCI45014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1172%2FJCI45014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=21633166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVKgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=2750-2767&author=B.+D.+Lehmannauthor=J.+A.+Bauerauthor=X.+Chenauthor=M.+E.+Sandersauthor=A.+B.+Chakravarthyauthor=Y.+Shyrauthor=J.+A.+Pietenpol&title=Identification+of+human+triple-negative+breast+cancer+subtypes+and+preclinical+models+for+selection+of+targeted+therapies&doi=10.1172%2FJCI45014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</span></div><div class="casAuthors">Lehmann, Brian D.; Bauer, Joshua A.; Chen, Xi; Sanders, Melinda E.; Chakravarthy, A. Bapsi; Shyr, Yu; Pietenpol, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2750-2767</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a highly diverse group of cancers, and subtyping is necessary to better identify mol.-based therapies.  In this study, we analyzed gene expression (GE) profiles from 21 breast cancer data sets and identified 587 TNBC cases.  Cluster anal. identified 6 TNBC subtypes displaying unique GE and ontologies, including 2 basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR) subtype.  Further, GE anal. allowed us to identify TNBC cell line models representative of these subtypes.  Predicted "driver" signaling pathways were pharmacol. targeted in these cell line models as proof of concept that anal. of distinct GE signatures can inform therapy selection.  BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines preferentially responded to cisplatin.  M and MSL subtypes were enriched in GE for epithelial-mesenchymal transition, and growth factor pathways and cell models responded to NVP-BEZ235 (a PI3K/mTOR inhibitor) and dasatinib (an abl/src inhibitor).  The LAR subtype includes patients with decreased relapse-free survival and was characterized by androgen receptor (AR) signaling.  LAR cell lines were uniquely sensitive to bicalutamide (an AR antagonist).  These data may be useful in biomarker selection, drug discovery, and clin. trial design that will enable alignment of TNBC patients to appropriate targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbhoQQUFogW7Vg90H21EOLACvtfcHk0liYEpOVeI-iyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVKgu78%253D&md5=c3681c79e0b972f16f6d5a5ecdc99fec</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1172%2FJCI45014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI45014%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DBauer%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSanders%26aufirst%3DM.%2BE.%26aulast%3DChakravarthy%26aufirst%3DA.%2BB.%26aulast%3DShyr%26aufirst%3DY.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DIdentification%2520of%2520human%2520triple-negative%2520breast%2520cancer%2520subtypes%2520and%2520preclinical%2520models%2520for%2520selection%2520of%2520targeted%2520therapies%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D2750%26epage%3D2767%26doi%3D10.1172%2FJCI45014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Calabrese, A. C.; Jeffy, B.; Robinson, D.; Zhu, D.; Huang, D.; Elsner, J.; Boylan, J.; Tehrani, L.; Nagy, M. A.; Raheja, R. K.; Erdman, P.; Narla, R. K.; Harris, R. L.; Tran, T. M.; Riggs, J.; Ning, Y.; Xu, S.</span><span> </span><span class="NLM_article-title">Substituted Pyrrolopyrimidine Compounds, Compositions Thereof, and Methods of Treatment Therewith</span>. U.S. Patent 9,346,812, May 24,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=A.+C.+Calabrese&author=B.+Jeffy&author=D.+Robinson&author=D.+Zhu&author=D.+Huang&author=J.+Elsner&author=J.+Boylan&author=L.+Tehrani&author=M.+A.+Nagy&author=R.+K.+Raheja&author=P.+Erdman&author=R.+K.+Narla&author=R.+L.+Harris&author=T.+M.+Tran&author=J.+Riggs&author=Y.+Ning&author=S.+Xu&title=Substituted+Pyrrolopyrimidine+Compounds%2C+Compositions+Thereof%2C+and+Methods+of+Treatment+Therewith"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCalabrese%26aufirst%3DA.%2BC.%26atitle%3DSubstituted%2520Pyrrolopyrimidine%2520Compounds%252C%2520Compositions%2520Thereof%252C%2520and%2520Methods%2520of%2520Treatment%2520Therewith%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Zhu, D.; Boylan, J.; Xu, S.; Riggs, J.; Shi, T.; Wurmser, A.; Mikolon, D.; Deyanat-Yazdi, G.</span><span> </span><span class="NLM_article-title">Methods of Treating a Cancer Using Substituted Pyrrolopyrimidine Compounds, Compositions Therof</span>. U.S. Patent 9,623,028, April 18,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=D.+Zhu&author=J.+Boylan&author=S.+Xu&author=J.+Riggs&author=T.+Shi&author=A.+Wurmser&author=D.+Mikolon&author=G.+Deyanat-Yazdi&title=Methods+of+Treating+a+Cancer+Using+Substituted+Pyrrolopyrimidine+Compounds%2C+Compositions+Therof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DD.%26atitle%3DMethods%2520of%2520Treating%2520a%2520Cancer%2520Using%2520Substituted%2520Pyrrolopyrimidine%2520Compounds%252C%2520Compositions%2520Therof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Hiruma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacristan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachis, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuijt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubbink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Castelmur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrakis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kops, G. J.</span><span> </span><span class="NLM_article-title">Cell division cycle. Competition between MPS1 and microtubules at kinetochores regulates spindle checkpoint signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">1264</span><span class="NLM_x">–</span> <span class="NLM_lpage">1267</span><span class="refDoi"> DOI: 10.1126/science.aaa4055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1126%2Fscience.aaa4055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=1264-1267&author=Y.+Hirumaauthor=C.+Sacristanauthor=S.+T.+Pachisauthor=A.+Adamopoulosauthor=T.+Kuijtauthor=M.+Ubbinkauthor=E.+von+Castelmurauthor=A.+Perrakisauthor=G.+J.+Kops&title=Cell+division+cycle.+Competition+between+MPS1+and+microtubules+at+kinetochores+regulates+spindle+checkpoint+signaling&doi=10.1126%2Fscience.aaa4055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaa4055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaa4055%26sid%3Dliteratum%253Aachs%26aulast%3DHiruma%26aufirst%3DY.%26aulast%3DSacristan%26aufirst%3DC.%26aulast%3DPachis%26aufirst%3DS.%2BT.%26aulast%3DAdamopoulos%26aufirst%3DA.%26aulast%3DKuijt%26aufirst%3DT.%26aulast%3DUbbink%26aufirst%3DM.%26aulast%3Dvon%2BCastelmur%26aufirst%3DE.%26aulast%3DPerrakis%26aufirst%3DA.%26aulast%3DKops%26aufirst%3DG.%2BJ.%26atitle%3DCell%2520division%2520cycle.%2520Competition%2520between%2520MPS1%2520and%2520microtubules%2520at%2520kinetochores%2520regulates%2520spindle%2520checkpoint%2520signaling%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D1264%26epage%3D1267%26doi%3D10.1126%2Fscience.aaa4055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Janssen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kops, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medema, R. H.</span><span> </span><span class="NLM_article-title">Targeting the mitotic checkpoint to kill tumor cells</span> <span class="citation_source-journal">Horm. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1007/s12672-010-0059-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1007%2Fs12672-010-0059-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=21475725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnot1Wkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=113-116&author=A.+Janssenauthor=G.+J.+Kopsauthor=R.+H.+Medema&title=Targeting+the+mitotic+checkpoint+to+kill+tumor+cells&doi=10.1007%2Fs12672-010-0059-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the mitotic checkpoint to kill tumor cells</span></div><div class="casAuthors">Janssen Aniek; Kops Geert J; Medema Rene H</div><div class="citationInfo"><span class="NLM_cas:title">Hormones & cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">One of the most common hallmarks of cancer cells is aneuploidy or an abnormal number of chromosomes.  This abnormal chromosome content is a consequence of chromosome missegregation during mitosis, a defect that is seen more frequently in tumor cell divisions as in normal cell divisions.  In fact, a large fraction of human tumors display a chromosome instable phenotype, meaning that they very frequently missegregate chromosomes.  This can cause variegated aneuploidy within the tumor tissue.  It has been argued that this hallmark of cancer could be exploited in anti-cancer therapies.  Here we test this hypothesis by inactivation of the mitotic checkpoint through RNAi-mediated depletion of an essential checkpoint component, Mps1.  The mitotic checkpoint delays segregation of chromosomes during mitosis until all chromosomes are properly attached to the mitotic spindle.  Its inactivation will therefore lead to increased segregation errors.  Indeed, we show that this can lead to increased cell death in tumor cells.  We demonstrate that increased cell death is associated with a dramatic increase in segregation errors.  This suggests that inhibition of the mitotic checkpoint might represent a useful anti-cancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTx5ZlxKChceNts4TFFB11gfW6udTcc2eaGaBTbMPDcpLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnot1Wkug%253D%253D&md5=7ea1be16c9e26670ce447b0caca260c3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs12672-010-0059-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12672-010-0059-x%26sid%3Dliteratum%253Aachs%26aulast%3DJanssen%26aufirst%3DA.%26aulast%3DKops%26aufirst%3DG.%2BJ.%26aulast%3DMedema%26aufirst%3DR.%2BH.%26atitle%3DTargeting%2520the%2520mitotic%2520checkpoint%2520to%2520kill%2520tumor%2520cells%26jtitle%3DHorm.%2520Cancer%26date%3D2011%26volume%3D2%26spage%3D113%26epage%3D116%26doi%3D10.1007%2Fs12672-010-0059-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Colombo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldarelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mennecozzi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giorgini, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sola, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappella, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrera, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depaolini, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cucchi, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colotta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J.</span><span> </span><span class="NLM_article-title">Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">10255</span><span class="NLM_x">–</span> <span class="NLM_lpage">10264</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1158%2F0008-5472.CAN-10-2101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=21159646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGrt7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=10255-10264&author=R.+Colomboauthor=M.+Caldarelliauthor=M.+Mennecozziauthor=M.+L.+Giorginiauthor=F.+Solaauthor=P.+Cappellaauthor=C.+Perreraauthor=S.+R.+Depaoliniauthor=L.+Rusconiauthor=U.+Cucchiauthor=N.+Avanziauthor=J.+A.+Bertrandauthor=R.+T.+Bossiauthor=E.+Pesentiauthor=A.+Galvaniauthor=A.+Isacchiauthor=F.+Colottaauthor=D.+Donatiauthor=J.+Moll&title=Targeting+the+mitotic+checkpoint+for+cancer+therapy+with+NMS-P715%2C+an+inhibitor+of+MPS1+kinase&doi=10.1158%2F0008-5472.CAN-10-2101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase</span></div><div class="casAuthors">Colombo, Riccardo; Caldarelli, Marina; Mennecozzi, Milena; Giorgini, Maria Laura; Sola, Francesco; Cappella, Paolo; Perrera, Claudia; Depaolini, Stefania Re; Rusconi, Luisa; Cucchi, Ulisse; Avanzi, Nilla; Bertrand, Jay Aaron; Bossi, Roberto Tiberio; Pesenti, Enrico; Galvani, Arturo; Isacchi, Antonella; Colotta, Francesco; Donati, Daniele; Moll, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10255-10264</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">MPS1 kinase is a key regulator of the spindle assembly checkpoint (SAC), a mitotic mechanism specifically required for proper chromosomal alignment and segregation.  It has been found aberrantly overexpressed in a wide range of human tumors and is necessary for tumoral cell proliferation.  Here the authors report the identification and characterization of NMS-P715, a selective and orally bioavailable MPS1 small-mol. inhibitor, which selectively reduces cancer cell proliferation, leaving normal cells almost unaffected.  NMS-P715 accelerates mitosis and affects kinetochore components localization causing massive aneuploidy and cell death in a variety of tumoral cell lines and inhibits tumor growth in preclin. cancer models.  Inhibiting the SAC could represent a promising new approach to selectively target cancer cells.  Cancer Res; 70(24); 10255-64.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJeGyiQf0_uLVg90H21EOLACvtfcHk0lhF331K7knbqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGrt7bK&md5=6478b34886d1d2f2a364d142bbd388fe</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2101%26sid%3Dliteratum%253Aachs%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DCaldarelli%26aufirst%3DM.%26aulast%3DMennecozzi%26aufirst%3DM.%26aulast%3DGiorgini%26aufirst%3DM.%2BL.%26aulast%3DSola%26aufirst%3DF.%26aulast%3DCappella%26aufirst%3DP.%26aulast%3DPerrera%26aufirst%3DC.%26aulast%3DDepaolini%26aufirst%3DS.%2BR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DCucchi%26aufirst%3DU.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DColotta%26aufirst%3DF.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DMoll%26aufirst%3DJ.%26atitle%3DTargeting%2520the%2520mitotic%2520checkpoint%2520for%2520cancer%2520therapy%2520with%2520NMS-P715%252C%2520an%2520inhibitor%2520of%2520MPS1%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D10255%26epage%3D10264%26doi%3D10.1158%2F0008-5472.CAN-10-2101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Maire, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldeyron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tesson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent-Salomon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gravier, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marty-Prouvost, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Koning, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigaill, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumont, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentien, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barillot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roman-Roman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruzalegui, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubois, T.</span><span> </span><span class="NLM_article-title">TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e63712</span><span class="refDoi"> DOI: 10.1371/journal.pone.0063712</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1371%2Fjournal.pone.0063712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=23700430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslamtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e63712&author=V.+Maireauthor=C.+Baldeyronauthor=M.+Richardsonauthor=B.+Tessonauthor=A.+Vincent-Salomonauthor=E.+Gravierauthor=B.+Marty-Prouvostauthor=L.+De+Koningauthor=G.+Rigaillauthor=A.+Dumontauthor=D.+Gentienauthor=E.+Barillotauthor=S.+Roman-Romanauthor=S.+Depilauthor=F.+Cruzaleguiauthor=A.+Pierreauthor=G.+C.+Tuckerauthor=T.+Dubois&title=TTK%2FhMPS1+is+an+attractive+therapeutic+target+for+triple-negative+breast+cancer&doi=10.1371%2Fjournal.pone.0063712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer</span></div><div class="casAuthors">Maire, Virginie; Baldeyron, Celine; Richardson, Marion; Tesson, Bruno; Vincent-Salomon, Anne; Gravier, Eleonore; Marty-Prouvost, Berengere; De Koning, Leanne; Rigaill, Guillem; Dumont, Aurelie; Gentien, David; Barillot, Emmanuel; Roman-Roman, Sergio; Depil, Stephane; Cruzalegui, Francisco; Pierre, Alain; Tucker, Gordon C.; Dubois, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e63712</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) represents a subgroup of breast cancers (BC) assocd. with the most aggressive clin. behavior.  No targeted therapy is currently available for the treatment of patients with TNBC.  In order to discover potential therapeutic targets, we searched for protein kinases that are overexpressed in human TNBC biopsies and whose silencing in TNBC cell lines causes cell death.  A cohort including human BC biopsies obtained at Institut Curie as well as normal tissues has been analyzed at a gene-expression level.  The data revealed that the human protein kinase monopolar spindle 1 (hMPS1), also known as TTK and involved in mitotic checkpoint, is specifically overexpressed in TNBC, compared to the other BC subgroups and healthy tissues.  We confirmed by immunohistochem. and reverse phase protein array that TNBC expressed higher levels of TTK protein compared to the other BC subgroups.  We then detd. the biol. effects of TTK depletion by RNA interference, through analyses of tumorigenic capacity and cell viability in different human TNBC cell lines.  We found that RNAi-mediated depletion of TTK in various TNBC cell lines severely compromised their viability and their ability to form colonies in an anchorage-independent manner.  Moreover, we obsd. that TTK silencing led to an increase in H2AX phosphorylation, activation of caspases 3/7, sub-G1 cell population accumulation and high annexin V staining, as well as to a decrease in G1 phase cell population and an increased aneuploidy.  Altogether, these data indicate that TTK depletion in TNBC cells induces apoptosis.  These results point out TTK as a protein kinase overexpressed in TNBC that may represent an attractive therapeutic target specifically for this poor prognosis assocd. subgroup of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCemS4PKt5pLVg90H21EOLACvtfcHk0lhZDW37v_tJuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslamtrs%253D&md5=21e30c2ca30b75839c07e13cdd19d897</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0063712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0063712%26sid%3Dliteratum%253Aachs%26aulast%3DMaire%26aufirst%3DV.%26aulast%3DBaldeyron%26aufirst%3DC.%26aulast%3DRichardson%26aufirst%3DM.%26aulast%3DTesson%26aufirst%3DB.%26aulast%3DVincent-Salomon%26aufirst%3DA.%26aulast%3DGravier%26aufirst%3DE.%26aulast%3DMarty-Prouvost%26aufirst%3DB.%26aulast%3DDe%2BKoning%26aufirst%3DL.%26aulast%3DRigaill%26aufirst%3DG.%26aulast%3DDumont%26aufirst%3DA.%26aulast%3DGentien%26aufirst%3DD.%26aulast%3DBarillot%26aufirst%3DE.%26aulast%3DRoman-Roman%26aufirst%3DS.%26aulast%3DDepil%26aufirst%3DS.%26aulast%3DCruzalegui%26aufirst%3DF.%26aulast%3DPierre%26aufirst%3DA.%26aulast%3DTucker%26aufirst%3DG.%2BC.%26aulast%3DDubois%26aufirst%3DT.%26atitle%3DTTK%252FhMPS1%2520is%2520an%2520attractive%2520therapeutic%2520target%2520for%2520triple-negative%2520breast%2520cancer%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De63712%26doi%3D10.1371%2Fjournal.pone.0063712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Huang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shieh, S. Y.</span><span> </span><span class="NLM_article-title">TTK/hMps1 mediates the p53-dependent postmitotic checkpoint by phosphorylating p53 at Thr18</span> <span class="citation_source-journal">Mol. Cell. Bio.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2935</span><span class="NLM_x">–</span> <span class="NLM_lpage">2944</span><span class="refDoi"> DOI: 10.1128/MCB.01837-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1128%2FMCB.01837-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=19332559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmvVCqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=2935-2944&author=Y.+F.+Huangauthor=M.+D.+Changauthor=S.+Y.+Shieh&title=TTK%2FhMps1+mediates+the+p53-dependent+postmitotic+checkpoint+by+phosphorylating+p53+at+Thr18&doi=10.1128%2FMCB.01837-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">TTK/hMps1 mediates the p53-dependent postmitotic checkpoint by phosphorylating p53 at Thr18</span></div><div class="casAuthors">Huang, Yi-Fu; Chang, Margaret Dah-Tsyr; Shieh, Sheau-Yann</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2935-2944</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Upon prolonged arrest in mitosis, cells undergo adaptation and exit mitosis without cell division.  These tetraploid cells are either eliminated by apoptosis or arrested in the subsequent G1 phase in a spindle checkpoint- and p53-dependent manner.  P53 has long been known to be activated by spindle poisons, such as nocodazole and Taxol, although the underlying mechanism remains elusive.  Here we present evidence that stabilization and activation of p53 by spindle disruption requires the spindle checkpoint kinase TTK/hMps1.  TTK/hMps1 phosphorylates the N-terminal domain of p53 at Thr18, and this phosphorylation disrupts the interaction with MDM2 and abrogates MDM2-mediated p53 ubiquitination.  Phosphorylation at Thr18 enhances p53-dependent activation of not only p21 but also Lats2, two mediators of the postmitotic checkpoint.  Furthermore, a phospho-mimicking substitution at Thr18 (T18D) is more competent than the phospho-deficient mutant (T18A) in rescuing the tetraploid checkpoint defect of p53-depleted cells.  Our findings therefore provide a mechanism connecting the spindle checkpoint with p53 in the maintenance of genome stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOjZaulBvOZrVg90H21EOLACvtfcHk0lhZDW37v_tJuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmvVCqsLw%253D&md5=608e4070bd4f5c6cf0d7f2767cdf49a9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FMCB.01837-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01837-08%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%2BF.%26aulast%3DChang%26aufirst%3DM.%2BD.%26aulast%3DShieh%26aufirst%3DS.%2BY.%26atitle%3DTTK%252FhMps1%2520mediates%2520the%2520p53-dependent%2520postmitotic%2520checkpoint%2520by%2520phosphorylating%2520p53%2520at%2520Thr18%26jtitle%3DMol.%2520Cell.%2520Bio.%26date%3D2009%26volume%3D29%26spage%3D2935%26epage%3D2944%26doi%3D10.1128%2FMCB.01837-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Yu, Z. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shieh, S. Y.</span><span> </span><span class="NLM_article-title">Requirement for human Mps1/TTK in oxidative DNA damage repair and cell survival through MDM2 phosphorylation</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1133</span><span class="NLM_x">–</span> <span class="NLM_lpage">1150</span><span class="refDoi"> DOI: 10.1093/nar/gkv1173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1093%2Fnar%2Fgkv1173" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=1133-1150&author=Z.+C.+Yuauthor=Y.+F.+Huangauthor=S.+Y.+Shieh&title=Requirement+for+human+Mps1%2FTTK+in+oxidative+DNA+damage+repair+and+cell+survival+through+MDM2+phosphorylation&doi=10.1093%2Fnar%2Fgkv1173"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkv1173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkv1173%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DZ.%2BC.%26aulast%3DHuang%26aufirst%3DY.%2BF.%26aulast%3DShieh%26aufirst%3DS.%2BY.%26atitle%3DRequirement%2520for%2520human%2520Mps1%252FTTK%2520in%2520oxidative%2520DNA%2520damage%2520repair%2520and%2520cell%2520survival%2520through%2520MDM2%2520phosphorylation%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2016%26volume%3D44%26spage%3D1133%26epage%3D1150%26doi%3D10.1093%2Fnar%2Fgkv1173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Laufer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brokx, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beletskaya, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotnikova, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awrey, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiarash, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madeira, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, H. W.</span><span> </span><span class="NLM_article-title">Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of tyrosine threonine kinase, TTK</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3562</span><span class="NLM_x">–</span> <span class="NLM_lpage">3566</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1016%2Fj.bmcl.2016.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=27335255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKgtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3562-3566&author=R.+Lauferauthor=S.+W.+Liauthor=Y.+Liuauthor=G.+Ngauthor=Y.+Langauthor=M.+Feherauthor=R.+Brokxauthor=I.+Beletskayaauthor=R.+Hodgsonauthor=G.+Maoauthor=O.+Plotnikovaauthor=D.+E.+Awreyauthor=J.+M.+Masonauthor=X.+Weiauthor=D.+C.+Linauthor=Y.+Cheauthor=R.+Kiarashauthor=B.+Madeiraauthor=G.+C.+Fletcherauthor=T.+W.+Makauthor=M.+R.+Brayauthor=H.+W.+Pauls&title=Discovery+of+4-%284-aminopyrazolo%5B1%2C5-a%5D%5B1%2C3%2C5%5Dtriazin-8-yl%29benzamides+as+novel%2C+highly+potent+and+selective%2C+orally+bioavailable+inhibitors+of+tyrosine+threonine+kinase%2C+TTK&doi=10.1016%2Fj.bmcl.2016.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK</span></div><div class="casAuthors">Laufer, Radoslaw; Li, Sze-Wan; Liu, Yong; Ng, Grace; Lang, Yunhui; Feher, Miklos; Brokx, Richard; Beletskaya, Irina; Hodgson, Richard; Mao, Guodong; Plotnikova, Olga; Awrey, Donald E.; Mason, Jacqueline M.; Wei, Xin; Lin, Dan Chi-Chia; Che, Yi; Kiarash, Reza; Madeira, Brian; Fletcher, Graham C.; Mak, Tak W.; Bray, Mark R.; Pauls, Henry W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3562-3566</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">TTK/Mps1 is a key kinase controlling progression of cell division via participation in the mitotic spindle assembly checkpoint and is overexpressed in a no. of human cancers.  Herein the authors report the discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as a potent, novel class of TTK inhibitors.  The series was identified by bioisosteric replacement of the related imidazopyrazine and imidazopyridazine scaffolds.  Optimization led to the identification of compds. with excellent potency (Ki = 0.8 nM) and exceptional kinase selectivity.  The SAR indicates a strong dependence of activity on the presence of the N-cyclopropyl-2-methylbenzamide moiety delineating the geometry for 11/2 type kinase inhibitor.  Mol. modeling indicates the extensive and optimal contacts, mediated through H-bonds and hydrophobic interactions, are responsible for the selectivity and potency of the inhibitors.  The compds. demonstrate a strong anti-proliferative activity in a panel of human cancer cell lines (HCT116 GIC50 <15 nM) and good rodent pharmacokinetics (oral %F 97%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTb2Z2xtkAWLVg90H21EOLACvtfcHk0lhZDW37v_tJuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKgtLnL&md5=d107d562ed4407d05bfbba57abcd6b98</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DNg%26aufirst%3DG.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DBrokx%26aufirst%3DR.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DMao%26aufirst%3DG.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DD.%2BC.%26aulast%3DChe%26aufirst%3DY.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DMadeira%26aufirst%3DB.%26aulast%3DFletcher%26aufirst%3DG.%2BC.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DBray%26aufirst%3DM.%2BR.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DDiscovery%2520of%25204-%25284-aminopyrazolo%255B1%252C5-a%255D%255B1%252C3%252C5%255Dtriazin-8-yl%2529benzamides%2520as%2520novel%252C%2520highly%2520potent%2520and%2520selective%252C%2520orally%2520bioavailable%2520inhibitors%2520of%2520tyrosine%2520threonine%2520kinase%252C%2520TTK%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3562%26epage%3D3566%26doi%3D10.1016%2Fj.bmcl.2016.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Laufer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awrey, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beletskaya, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotnikova, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiarash, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris-Brandts, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ban, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadeem, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirgadze, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, H. W.</span><span> </span><span class="NLM_article-title">Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4968</span><span class="NLM_x">–</span> <span class="NLM_lpage">4997</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.06.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1016%2Fj.bmc.2014.06.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=25043312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyjt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=4968-4997&author=R.+Lauferauthor=G.+Ngauthor=Y.+Liuauthor=N.+K.+Patelauthor=L.+G.+Edwardsauthor=Y.+Langauthor=S.+W.+Liauthor=M.+Feherauthor=D.+E.+Awreyauthor=G.+Leungauthor=I.+Beletskayaauthor=O.+Plotnikovaauthor=J.+M.+Masonauthor=R.+Hodgsonauthor=X.+Weiauthor=G.+Maoauthor=X.+Luoauthor=P.+Huangauthor=E.+Greenauthor=R.+Kiarashauthor=D.+C.+Linauthor=M.+Harris-Brandtsauthor=F.+Banauthor=V.+Nadeemauthor=T.+W.+Makauthor=G.+J.+Panauthor=W.+Qiuauthor=N.+Y.+Chirgadzeauthor=H.+W.+Pauls&title=Discovery+of+inhibitors+of+the+mitotic+kinase+TTK+based+on+N-%283-%283-sulfamoylphenyl%29-1H-indazol-5-yl%29-acetamides+and+carboxamides&doi=10.1016%2Fj.bmc.2014.06.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamides and carboxamides</span></div><div class="casAuthors">Laufer, Radoslaw; Ng, Grace; Liu, Yong; Patel, Narendra Kumar B.; Edwards, Louise G.; Lang, Yunhui; Li, Sze-Wan; Feher, Miklos; Awrey, Don E.; Leung, Genie; Beletskaya, Irina; Plotnikova, Olga; Mason, Jacqueline M.; Hodgson, Richard; Wei, Xin; Mao, Guodong; Luo, Xunyi; Huang, Ping; Green, Erin; Kiarash, Reza; Lin, Dan Chi-Chia; Harris-Brandts, Marees; Ban, Fuqiang; Nadeem, Vincent; Mak, Tak W.; Pan, Guohua J.; Qiu, Wei; Chirgadze, Nickolay Y.; Pauls, Henry W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4968-4997</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">TTK kinase was identified by inhouse siRNA screen and pursued as a tractable, novel target for cancer treatment.  A screening campaign and systematic optimization, supported by computer modeling led to an indazole core with key sulfamoylphenyl and acetamido moieties at positions 3 and 5, resp., establishing a novel chem. class culminating in identification of I (CFI-400936).  This potent inhibitor of TTK (IC50 = 3.6 nM) demonstrated good activity in cell based assay and selectivity against a panel of human kinases.  A complex TTK x-ray crystal structure and results of a xenograft study with TTK inhibitors from this class are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYMVdifCP5IrVg90H21EOLACvtfcHk0lixoB-jUHuVCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyjt7fK&md5=71dac8de6f21ee67d1c18fd4e521a4f9</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.06.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.06.027%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DNg%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPatel%26aufirst%3DN.%2BK.%26aulast%3DEdwards%26aufirst%3DL.%2BG.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DLeung%26aufirst%3DG.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DMao%26aufirst%3DG.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DGreen%26aufirst%3DE.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DD.%2BC.%26aulast%3DHarris-Brandts%26aufirst%3DM.%26aulast%3DBan%26aufirst%3DF.%26aulast%3DNadeem%26aufirst%3DV.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DPan%26aufirst%3DG.%2BJ.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DChirgadze%26aufirst%3DN.%2BY.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DDiscovery%2520of%2520inhibitors%2520of%2520the%2520mitotic%2520kinase%2520TTK%2520based%2520on%2520N-%25283-%25283-sulfamoylphenyl%2529-1H-indazol-5-yl%2529-acetamides%2520and%2520carboxamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D4968%26epage%3D4997%26doi%3D10.1016%2Fj.bmc.2014.06.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampson, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ban, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awrey, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beletskaya, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotnikova, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirgadze, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiarash, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madeira, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, H. W.</span><span> </span><span class="NLM_article-title">The discovery of orally bioavailable tyrosine threonine kinase (TTK) inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as anticancer agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3366</span><span class="NLM_x">–</span> <span class="NLM_lpage">3392</span><span class="refDoi"> DOI: 10.1021/jm501740a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501740a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3366-3392&author=Y.+Liuauthor=Y.+Langauthor=N.+K.+Patelauthor=G.+Ngauthor=R.+Lauferauthor=S.+W.+Liauthor=L.+Edwardsauthor=B.+Forrestauthor=P.+B.+Sampsonauthor=M.+Feherauthor=F.+Banauthor=D.+E.+Awreyauthor=I.+Beletskayaauthor=G.+Maoauthor=R.+Hodgsonauthor=O.+Plotnikovaauthor=W.+Qiuauthor=N.+Y.+Chirgadzeauthor=J.+M.+Masonauthor=X.+Weiauthor=D.+C.+Linauthor=Y.+Cheauthor=R.+Kiarashauthor=B.+Madeiraauthor=G.+C.+Fletcherauthor=T.+W.+Makauthor=M.+R.+Brayauthor=H.+W.+Pauls&title=The+discovery+of+orally+bioavailable+tyrosine+threonine+kinase+%28TTK%29+inhibitors%3A+3-%284-%28heterocyclyl%29phenyl%29-1H-indazole-5-carboxamides+as+anticancer+agents&doi=10.1021%2Fjm501740a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm501740a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501740a%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DPatel%26aufirst%3DN.%2BK.%26aulast%3DNg%26aufirst%3DG.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DEdwards%26aufirst%3DL.%26aulast%3DForrest%26aufirst%3DB.%26aulast%3DSampson%26aufirst%3DP.%2BB.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DBan%26aufirst%3DF.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DMao%26aufirst%3DG.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DChirgadze%26aufirst%3DN.%2BY.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DD.%2BC.%26aulast%3DChe%26aufirst%3DY.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DMadeira%26aufirst%3DB.%26aulast%3DFletcher%26aufirst%3DG.%2BC.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DBray%26aufirst%3DM.%2BR.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DThe%2520discovery%2520of%2520orally%2520bioavailable%2520tyrosine%2520threonine%2520kinase%2520%2528TTK%2529%2520inhibitors%253A%25203-%25284-%2528heterocyclyl%2529phenyl%2529-1H-indazole-5-carboxamides%2520as%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3366%26epage%3D3392%26doi%3D10.1021%2Fjm501740a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampson, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brokx, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beletskaya, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotnikova, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awrey, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirgadze, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiarash, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, H. W.</span><span> </span><span class="NLM_article-title">Discovery of pyrazolo[1,5-a]pyrimidine TTK inhibitors: CFI-402257 is a potent, selective, bioavailable anticancer agent</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">675</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00485</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00485" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC28Xntl2isLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=671-675&author=Y.+Liuauthor=R.+Lauferauthor=N.+K.+Patelauthor=G.+Ngauthor=P.+B.+Sampsonauthor=S.+W.+Liauthor=Y.+Langauthor=M.+Feherauthor=R.+Brokxauthor=I.+Beletskayaauthor=R.+Hodgsonauthor=O.+Plotnikovaauthor=D.+E.+Awreyauthor=W.+Qiuauthor=N.+Y.+Chirgadzeauthor=J.+M.+Masonauthor=X.+Weiauthor=D.+C.+Linauthor=Y.+Cheauthor=R.+Kiarashauthor=G.+C.+Fletcherauthor=T.+W.+Makauthor=M.+R.+Brayauthor=H.+W.+Pauls&title=Discovery+of+pyrazolo%5B1%2C5-a%5Dpyrimidine+TTK+inhibitors%3A+CFI-402257+is+a+potent%2C+selective%2C+bioavailable+anticancer+agent&doi=10.1021%2Facsmedchemlett.5b00485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent</span></div><div class="casAuthors">Liu, Yong; Laufer, Radoslaw; Patel, Narendra Kumar; Ng, Grace; Sampson, Peter B.; Li, Sze-Wan; Lang, Yunhui; Feher, Miklos; Brokx, Richard; Beletskaya, Irina; Hodgson, Richard; Plotnikova, Olga; Awrey, Donald E.; Qiu, Wei; Chirgadze, Nickolay Y.; Mason, Jacqueline M.; Wei, Xin; Lin, Dan Chi-Chia; Che, Yi; Kiarash, Reza; Fletcher, Graham C.; Mak, Tak W.; Bray, Mark R.; Pauls, Henry W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">671-675</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This work describes a scaffold hopping exercise that begins with known imidazo[1,2-a]pyrazines, briefly explores pyrazolo[1,5-a][1,3,5]triazines, and ultimately yields pyrazolo[1,5-a]pyrimidines as a novel class of potent TTK inhibitors.  An X-ray structure of a representative compd. is consistent with 11/2 type inhibition and provides structural insight to aid subsequent optimization of in vitro activity and physicochem. and pharmacokinetic properties.  Incorporation of polar moieties in the hydrophobic and solvent accessible regions modulates physicochem. properties while maintaining potency.  Compds. with enhanced oral exposure were identified for xenograft studies.  The work culminates in the identification of a potent (TTK Ki = 0.1 nM), highly selective, orally bioavailable anticancer agent (CFI-402257) for IND enabling studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8YPAge-MdqLVg90H21EOLACvtfcHk0li5i1ewx6W0BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xntl2isLo%253D&md5=3eb4e1971e0c0a73e6eee657ac9d6fe0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00485%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DN.%2BK.%26aulast%3DNg%26aufirst%3DG.%26aulast%3DSampson%26aufirst%3DP.%2BB.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DBrokx%26aufirst%3DR.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DChirgadze%26aufirst%3DN.%2BY.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DD.%2BC.%26aulast%3DChe%26aufirst%3DY.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DFletcher%26aufirst%3DG.%2BC.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DBray%26aufirst%3DM.%2BR.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DDiscovery%2520of%2520pyrazolo%255B1%252C5-a%255Dpyrimidine%2520TTK%2520inhibitors%253A%2520CFI-402257%2520is%2520a%2520potent%252C%2520selective%252C%2520bioavailable%2520anticancer%2520agent%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D671%26epage%3D675%26doi%3D10.1021%2Facsmedchemlett.5b00485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Mason, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiarash, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brokx, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beletskaya, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span> </span><span class="NLM_article-title">Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">3127</span><span class="NLM_x">–</span> <span class="NLM_lpage">3132</span><span class="refDoi"> DOI: 10.1073/pnas.1700234114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1073%2Fpnas.1700234114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=28270606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvVyjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=3127-3132&author=J.+M.+Masonauthor=X.+Weiauthor=G.+C.+Fletcherauthor=R.+Kiarashauthor=R.+Brokxauthor=R.+Hodgsonauthor=I.+Beletskayaauthor=M.+R.+Brayauthor=T.+W.+Mak&title=Functional+characterization+of+CFI-402257%2C+a+potent+and+selective+Mps1%2FTTK+kinase+inhibitor%2C+for+the+treatment+of+cancer&doi=10.1073%2Fpnas.1700234114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer</span></div><div class="casAuthors">Mason, Jacqueline M.; Wei, Xin; Fletcher, Graham C.; Kiarash, Reza; Brokx, Richard; Hodgson, Richard; Beletskaya, Irina; Bray, Mark R.; Mak, Tak W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3127-3132</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Loss of cell-cycle control is a hallmark of human cancer.  Cell-cycle checkpoints are essential for maintaining genome integrity and balanced growth and division.  They are specifically deregulated in cancer cells and contain regulators that represent potential therapeutic targets.  Monopolar spindle 1 (Mps1; also known as TTK protein kinase) is a core component of the spindle assembly checkpoint (SAC), a genome-surveillance mechanism that is important for cell survival, and has emerged as a candidate target for anticancer therapy.  Here, the authors report the cellular and antitumor effects of CFI-402257, a potent (Mps1 Ki = 0.09±0.02 nM; cellular Mps1 EC50 = 6.5±0.5 nM), highly selective, and orally active small-mol. inhibitor of Mps1 that was identified through a drug-discovery program.  Human cancer cells treated with CFI-402257 exhibit effects consistent with Mps1 kinase inhibition, specifically SAC inactivation, leading to chromosome missegregation, aneuploidy, and ultimately cell death.  Oral administration of CFI-402257 in monotherapy or in combination with an anti-programmed cell death 1 (PD-1) antibody in mouse models of human cancer results in inhibition of tumor growth at doses that are well-tolerated.  The authors' findings provide a rationale for the clin. evaluation of CFI-402257 in patients with solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFQJ3eg_c-qLVg90H21EOLACvtfcHk0li5i1ewx6W0BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvVyjsL8%253D&md5=bb9742c8d07314e7d3c322bef71ef0ff</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1700234114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1700234114%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DFletcher%26aufirst%3DG.%2BC.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DBrokx%26aufirst%3DR.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DBray%26aufirst%3DM.%2BR.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DFunctional%2520characterization%2520of%2520CFI-402257%252C%2520a%2520potent%2520and%2520selective%2520Mps1%252FTTK%2520kinase%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D3127%26epage%3D3132%26doi%3D10.1073%2Fpnas.1700234114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Faisal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, G. W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurden, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xavier, C. P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderhub, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innocenti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwood, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Haven Brandon, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Fee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">vanMontfort, R. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardopoulos, S.</span><span> </span><span class="NLM_article-title">Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">1166</span><span class="NLM_x">–</span> <span class="NLM_lpage">1176</span><span class="refDoi"> DOI: 10.1038/bjc.2017.75</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1038%2Fbjc.2017.75" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=28334731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVKht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2017&pages=1166-1176&author=A.+Faisalauthor=G.+W.+Y.+Makauthor=M.+D.+Gurdenauthor=C.+P.+R.+Xavierauthor=S.+J.+Anderhubauthor=P.+Innocentiauthor=I.+M.+Westwoodauthor=S.+Naudauthor=A.+Hayesauthor=G.+Boxauthor=M.+R.+Valentiauthor=A.+K.+De+Haven+Brandonauthor=L.+O%E2%80%99Feeauthor=J.+Schmittauthor=H.+L.+Woodwardauthor=R.+Burkeauthor=R.+L.+M.+vanMontfortauthor=J.+Blaggauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=S.+Hoelderauthor=S.+Linardopoulos&title=Characterisation+of+CCT271850%2C+a+selective%2C+oral+and+potent+MPS1+inhibitor%2C+used+to+directly+measure+in+vivo+MPS1+inhibition+vs+therapeutic+efficacy&doi=10.1038%2Fbjc.2017.75"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy</span></div><div class="casAuthors">Faisal, Amir; Mak, Grace W. Y.; Gurden, Mark D.; Xavier, Cristina P. R.; Anderhub, Simon J.; Innocenti, Paolo; Westwood, Isaac M.; Naud, Sebastien; Hayes, Angela; Box, Gary; Valenti, Melanie R.; De Haven Brandon, Alexis K.; O'Fee, Lisa; Schmitt, Jessica; Woodward, Hannah L.; Burke, Rosemary; van Montfort, Rob L. M.; Blagg, Julian; Raynaud, Florence I.; Eccles, Suzanne A.; Hoelder, Swen; Linardopoulos, Spiros</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1166-1176</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: The main role of the cell cycle is to enable error-free DNA replication, chromosome segregation and cytokinesis.  One of the best characterized checkpoint pathways is the spindle assembly checkpoint, which prevents anaphase onset until the appropriate attachment and tension across kinetochores is achieved.  MPS1 kinase activity is essential for the activation of the spindle assembly checkpoint and has been shown to be deregulated in human tumors with chromosomal instability and aneuploidy.  Therefore, MPS1 inhibition represents an attractive strategy to target cancers.  Methods: To evaluate CCT271850 cellular potency, two specific antibodies that recognize the activation sites of MPS1 were used and its antiproliferative activity was detd. in 91 human cancer cell lines.  DLD1 cells with induced GFP-MPS1 and HCT116 cells were used in in vivo studies to directly measure MPS1 inhibition and efficacy of CCT271850 treatment.  Results: CCT271850 selectively and potently inhibits MPS1 kinase activity in biochem. and cellular assays and in in vivo models.  Mechanistically, tumor cells treated with CCT271850 acquire aberrant nos. of chromosomes and the majority of cells divide their chromosomes without proper alignment because of abrogation of the mitotic checkpoint, leading to cell death.  We demonstrated a moderate level of efficacy of CCT271850 as a single agent in a human colorectal carcinoma xenograft model.  Conclusions: CCT271850 is a potent, selective and orally bioavailable MPS1 kinase inhibitor.  On the basis of in vivo pharmacodynamic vs efficacy relationships, we predict that more than 80% inhibition of MPS1 activity for at least 24 h is required to achieve tumor stasis or regression by CCT271850.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodu8v7zdjvabVg90H21EOLACvtfcHk0lhfhtD5P4rkcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVKht74%253D&md5=656368a488e47677a8cb455de962371e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2017.75&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2017.75%26sid%3Dliteratum%253Aachs%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DMak%26aufirst%3DG.%2BW.%2BY.%26aulast%3DGurden%26aufirst%3DM.%2BD.%26aulast%3DXavier%26aufirst%3DC.%2BP.%2BR.%26aulast%3DAnderhub%26aufirst%3DS.%2BJ.%26aulast%3DInnocenti%26aufirst%3DP.%26aulast%3DWestwood%26aufirst%3DI.%2BM.%26aulast%3DNaud%26aufirst%3DS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DValenti%26aufirst%3DM.%2BR.%26aulast%3DDe%2BHaven%2BBrandon%26aufirst%3DA.%2BK.%26aulast%3DO%25E2%2580%2599Fee%26aufirst%3DL.%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DWoodward%26aufirst%3DH.%2BL.%26aulast%3DBurke%26aufirst%3DR.%26aulast%3DvanMontfort%26aufirst%3DR.%2BL.%2BM.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DHoelder%26aufirst%3DS.%26aulast%3DLinardopoulos%26aufirst%3DS.%26atitle%3DCharacterisation%2520of%2520CCT271850%252C%2520a%2520selective%252C%2520oral%2520and%2520potent%2520MPS1%2520inhibitor%252C%2520used%2520to%2520directly%2520measure%2520in%2520vivo%2520MPS1%2520inhibition%2520vs%2520therapeutic%2520efficacy%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2017%26volume%3D116%26spage%3D1166%26epage%3D1176%26doi%3D10.1038%2Fbjc.2017.75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Innocenti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solanki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwood, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faisal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Fee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saville, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matijssen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardopoulos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span> </span><span class="NLM_article-title">Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (MPS1) using a structure-based hybridization approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3671</span><span class="NLM_x">–</span> <span class="NLM_lpage">3688</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01811</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01811" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsF2qsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3671-3688&author=P.+Innocentiauthor=H.+L.+Woodwardauthor=S.+Solankiauthor=S.+Naudauthor=I.+M.+Westwoodauthor=N.+Croninauthor=A.+Hayesauthor=J.+Robertsauthor=A.+T.+Henleyauthor=R.+Bakerauthor=A.+Faisalauthor=G.+W.+Makauthor=G.+Boxauthor=M.+Valentiauthor=A.+De+Haven+Brandonauthor=L.+O%E2%80%99Feeauthor=H.+Savilleauthor=J.+Schmittauthor=B.+Matijssenauthor=R.+Burkeauthor=R.+L.+van+Montfortauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=S.+Linardopoulosauthor=J.+Blaggauthor=S.+Hoelder&title=Rapid+discovery+of+pyrido%5B3%2C4-d%5Dpyrimidine+inhibitors+of+monopolar+spindle+kinase+1+%28MPS1%29+using+a+structure-based+hybridization+approach&doi=10.1021%2Facs.jmedchem.5b01811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach</span></div><div class="casAuthors">Innocenti, Paolo; Woodward, Hannah L.; Solanki, Savade; Naud, Sebastien; Westwood, Isaac M.; Cronin, Nora; Hayes, Angela; Roberts, Jennie; Henley, Alan T.; Baker, Ross; Faisal, Amir; Mak, Grace Wing-Yan; Box, Gary; Valenti, Melanie; De Haven Brandon, Alexis; O'Fee, Lisa; Saville, Harry; Schmitt, Jessica; Matijssen, Berry; Burke, Rosemary; van Montfort, Rob L. M.; Raynaud, Florence I.; Eccles, Suzanne A.; Linardopoulos, Spiros; Blagg, Julian; Hoelder, Swen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3671-3688</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monopolar spindle 1 (MPS1) plays a central role in the transition of cells from metaphase to anaphase and is one of the main components of the spindle assembly checkpoint.  Chromosomally unstable cancer cells rely heavily on MPS1 to cope with the stress arising from abnormal nos. of chromosomes and centrosomes and are thus more sensitive to MPS1 inhibition than normal cells.  We report the discovery and optimization of a series of new pyrido[3,4-d]pyrimidine based inhibitors via a structure-based hybridization approach from our previously reported inhibitor CCT251455 and a modestly potent screening hit.  Compds. in this novel series display excellent potency and selectivity for MPS1, which translates into biomarker modulation in an in vivo human tumor xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr42v6loNvM1bVg90H21EOLACvtfcHk0lhfhtD5P4rkcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsF2qsro%253D&md5=dd858ed11744e0b036061baf5e2c181a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01811%26sid%3Dliteratum%253Aachs%26aulast%3DInnocenti%26aufirst%3DP.%26aulast%3DWoodward%26aufirst%3DH.%2BL.%26aulast%3DSolanki%26aufirst%3DS.%26aulast%3DNaud%26aufirst%3DS.%26aulast%3DWestwood%26aufirst%3DI.%2BM.%26aulast%3DCronin%26aufirst%3DN.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DJ.%26aulast%3DHenley%26aufirst%3DA.%2BT.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DMak%26aufirst%3DG.%2BW.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DDe%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Fee%26aufirst%3DL.%26aulast%3DSaville%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DMatijssen%26aufirst%3DB.%26aulast%3DBurke%26aufirst%3DR.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DLinardopoulos%26aufirst%3DS.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DRapid%2520discovery%2520of%2520pyrido%255B3%252C4-d%255Dpyrimidine%2520inhibitors%2520of%2520monopolar%2520spindle%2520kinase%25201%2520%2528MPS1%2529%2520using%2520a%2520structure-based%2520hybridization%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3671%26epage%3D3688%26doi%3D10.1021%2Facs.jmedchem.5b01811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Kusakabe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ide, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daigo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashizume, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nozu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagashira, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashino, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanazawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishioka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baba, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span> </span><span class="NLM_article-title">Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1760</span><span class="NLM_x">–</span> <span class="NLM_lpage">1775</span><span class="refDoi"> DOI: 10.1021/jm501599u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501599u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2it7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1760-1775&author=K.+Kusakabeauthor=N.+Ideauthor=Y.+Daigoauthor=T.+Itohauthor=T.+Yamamotoauthor=H.+Hashizumeauthor=K.+Nozuauthor=H.+Yoshidaauthor=G.+Tadanoauthor=S.+Tagashiraauthor=K.+Higashinoauthor=Y.+Okanoauthor=Y.+Satoauthor=M.+Inoueauthor=M.+Iguchiauthor=T.+Kanazawaauthor=Y.+Ishiokaauthor=K.+Dohiauthor=Y.+Kidoauthor=S.+Sakamotoauthor=S.+Andoauthor=M.+Maedaauthor=M.+Higakiauthor=Y.+Babaauthor=Y.+Nakamura&title=Discovery+of+imidazo%5B1%2C2-b%5Dpyridazine+derivatives%3A+selective+and+orally+available+Mps1+%28TTK%29+kinase+inhibitors+exhibiting+remarkable+antiproliferative+activity&doi=10.1021%2Fjm501599u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Imidazo[1,2-b]pyridazine Derivatives: Selective and Orally Available Mps1 (TTK) Kinase Inhibitors Exhibiting Remarkable Antiproliferative Activity</span></div><div class="casAuthors">Kusakabe, Ken-ichi; Ide, Nobuyuki; Daigo, Yataro; Itoh, Takeshi; Yamamoto, Takahiko; Hashizume, Hiroshi; Nozu, Kohei; Yoshida, Hiroshi; Tadano, Genta; Tagashira, Sachie; Higashino, Kenichi; Okano, Yousuke; Sato, Yuji; Inoue, Makiko; Iguchi, Motofumi; Kanazawa, Takayuki; Ishioka, Yukichi; Dohi, Keiji; Kido, Yasuto; Sakamoto, Shingo; Ando, Shigeru; Maeda, Masahiro; Higaki, Masayo; Baba, Yoshiyasu; Nakamura, Yusuke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1760-1775</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monopolar spindle 1 (Mps1) is an attractive oncol. target due to its high expression level in cancer cells as well as the correlation of its expression levels with histol. grades of cancers.  An imidazo[1,2-a]pyrazine 10a was identified during an HTS campaign.  Although 10a exhibited good biochem. activity, its moderate cellular as well as antiproliferative activities needed to be improved.  The cocrystal structure of an analog of 10a guided our lead optimization to introduce substituents at the 6-position of the scaffold, giving the 6-aryl substituted 21b which had improved cellular activity but no oral bioavailability in rat.  Property-based optimization at the 6-position and a scaffold change led to the discovery of the imidazo[1,2-b]pyridazine-based 27f, an extremely potent (cellular Mps1 IC50 = 0.70 nM, A549 IC50 = 6.0 nM), selective Mps1 inhibitor over 192 kinases, which could be orally administered and was active in vivo.  This 27f demonstrated remarkable antiproliferative activity in the nanomolar range against various tissue cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8D9nRl5vWabVg90H21EOLACvtfcHk0lhfhtD5P4rkcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2it7g%253D&md5=bee62a50247a363dc3e35fcdeac6a64f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm501599u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501599u%26sid%3Dliteratum%253Aachs%26aulast%3DKusakabe%26aufirst%3DK.%26aulast%3DIde%26aufirst%3DN.%26aulast%3DDaigo%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DNozu%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DTadano%26aufirst%3DG.%26aulast%3DTagashira%26aufirst%3DS.%26aulast%3DHigashino%26aufirst%3DK.%26aulast%3DOkano%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DIguchi%26aufirst%3DM.%26aulast%3DKanazawa%26aufirst%3DT.%26aulast%3DIshioka%26aufirst%3DY.%26aulast%3DDohi%26aufirst%3DK.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DSakamoto%26aufirst%3DS.%26aulast%3DAndo%26aufirst%3DS.%26aulast%3DMaeda%26aufirst%3DM.%26aulast%3DHigaki%26aufirst%3DM.%26aulast%3DBaba%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520imidazo%255B1%252C2-b%255Dpyridazine%2520derivatives%253A%2520selective%2520and%2520orally%2520available%2520Mps1%2520%2528TTK%2529%2520kinase%2520inhibitors%2520exhibiting%2520remarkable%2520antiproliferative%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1760%26epage%3D1775%26doi%3D10.1021%2Fjm501599u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Uitdehaag, J. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Man, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willemsen-Seegers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinsen, M. B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libouban, M. A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterrenburg, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Wit, J. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vetter, J. R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Roos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buijsman, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaman, G. J. R.</span><span> </span><span class="NLM_article-title">Target residence time-guided optimization on TTK kinase results in inhibitors with potent anti-proliferative activity</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">429</span><span class="NLM_x">, </span> <span class="NLM_fpage">2211</span><span class="NLM_x">–</span> <span class="NLM_lpage">2230</span><span class="refDoi"> DOI: 10.1016/j.jmb.2017.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1016%2Fj.jmb.2017.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=28539250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1Wiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=429&publication_year=2017&pages=2211-2230&author=J.+C.+M.+Uitdehaagauthor=J.+de+Manauthor=N.+Willemsen-Seegersauthor=M.+B.+W.+Prinsenauthor=M.+A.+A.+Liboubanauthor=J.+G.+Sterrenburgauthor=J.+J.+P.+de+Witauthor=J.+R.+F.+de+Vetterauthor=J.+de+Roosauthor=R.+C.+Buijsmanauthor=G.+J.+R.+Zaman&title=Target+residence+time-guided+optimization+on+TTK+kinase+results+in+inhibitors+with+potent+anti-proliferative+activity&doi=10.1016%2Fj.jmb.2017.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity</span></div><div class="casAuthors">Uitdehaag, Joost C. M.; de Man, Jos; Willemsen-Seegers, Nicole; Prinsen, Martine B. W.; Libouban, Marion A. A.; Sterrenburg, Jan Gerard; de Wit, Joeri J. P.; de Vetter, Judith R. F.; de Roos, Jeroen A. D. M.; Buijsman, Rogier C.; Zaman, Guido J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">429</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2211-2230</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The protein kinase threonine tyrosine kinase (TTK; also known as Mps1) is a crit. component of the spindle assembly checkpoint and a promising drug target for the treatment of aggressive cancers, such as triple neg. breast cancer.  While the first TTK inhibitors have entered clin. trials, little is known about how the inhibition of TTK with small-mol. compds. affects cellular activity.  The authors studied the selective TTK inhibitor NTRC 0066-0, which was developed in the authors' own lab., together with 11 TTK inhibitors developed by other companies, including Mps-BAY2b, BAY 1161909, BAY 1217389 (Bayer), TC-Mps1-12 (Shionogi), and MPI-0479605 (Myrexis).  Parallel testing shows that the cellular activity of these TTK inhibitors correlates with their binding affinity to TTK and, more strongly, with target residence time.  TTK inhibitors are therefore an example where target residence time dets. activity in in vitro cellular assays.  X-ray structures and thermal stability expts. reveal that the most potent compds. induce a shift of the glycine-rich loop as a result of binding to the catalytic lysine at position 553.  This "lysine trap" disrupts the catalytic machinery.  Based on these insights, the authors developed TTK inhibitors, based on a (5,6-dihydro)pyrimido[4,5-e]indolizine scaffold, with longer target residence times, which further exploit an allosteric pocket surrounding Lys 553.  Their binding mode is new for kinase inhibitors and can be classified as hybrid Type I/Type III.  These inhibitors have very potent anti-proliferative activity that rivals classic cytotoxic therapy.  The authors' findings will open up new avenues for more applications for TTK inhibitors in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT_6mZVMoVTrVg90H21EOLACvtfcHk0lj9oA8O4-1A8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1Wiuro%253D&md5=c02b149e673dec7b0212b37a4c7b0831</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2017.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2017.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DUitdehaag%26aufirst%3DJ.%2BC.%2BM.%26aulast%3Dde%2BMan%26aufirst%3DJ.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DPrinsen%26aufirst%3DM.%2BB.%2BW.%26aulast%3DLibouban%26aufirst%3DM.%2BA.%2BA.%26aulast%3DSterrenburg%26aufirst%3DJ.%2BG.%26aulast%3Dde%2BWit%26aufirst%3DJ.%2BJ.%2BP.%26aulast%3Dde%2BVetter%26aufirst%3DJ.%2BR.%2BF.%26aulast%3Dde%2BRoos%26aufirst%3DJ.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%2BR.%26atitle%3DTarget%2520residence%2520time-guided%2520optimization%2520on%2520TTK%2520kinase%2520results%2520in%2520inhibitors%2520with%2520potent%2520anti-proliferative%2520activity%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2017%26volume%3D429%26spage%3D2211%26epage%3D2230%26doi%3D10.1016%2Fj.jmb.2017.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Jemaa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galluzzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kepp, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senovilla, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brands, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boemer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koppitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lienau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prechtl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siemeister, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wengner, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mumberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziegelbauer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrieu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castedo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitale, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroemer, G.</span><span> </span><span class="NLM_article-title">Characterization of novel MPS1 inhibitors with preclinical anticancer activity</span> <span class="citation_source-journal">Cell Death Differ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1532</span><span class="NLM_x">–</span> <span class="NLM_lpage">1545</span><span class="refDoi"> DOI: 10.1038/cdd.2013.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1038%2Fcdd.2013.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=23933817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2gurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1532-1545&author=M.+Jemaaauthor=L.+Galluzziauthor=O.+Keppauthor=L.+Senovillaauthor=M.+Brandsauthor=U.+Boemerauthor=M.+Koppitzauthor=P.+Lienauauthor=S.+Prechtlauthor=V.+Schulzeauthor=G.+Siemeisterauthor=A.+M.+Wengnerauthor=D.+Mumbergauthor=K.+Ziegelbauerauthor=A.+Abrieuauthor=M.+Castedoauthor=I.+Vitaleauthor=G.+Kroemer&title=Characterization+of+novel+MPS1+inhibitors+with+preclinical+anticancer+activity&doi=10.1038%2Fcdd.2013.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of novel MPS1 inhibitors with preclinical anticancer activity</span></div><div class="casAuthors">Jemaa, M.; Galluzzi, L.; Kepp, O.; Senovilla, L.; Brands, M.; Boemer, U.; Koppitz, M.; Lienau, P.; Prechtl, S.; Schulze, V.; Siemeister, G.; Wengner, A. M.; Mumberg, D.; Ziegelbauer, K.; Abrieu, A.; Castedo, M.; Vitale, I.; Kroemer, G.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1532-1545</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Monopolar spindle 1 (MPS1), a mitotic kinase that is overexpressed in several human cancers, contributes to the alignment of chromosomes to the metaphase plate as well as to the execution of the spindle assembly checkpoint (SAC).  Here, we report the identification and functional characterization of three novel inhibitors of MPS1 of two independent structural classes, N-(4-{2-[(2-cyanophenyl)amino][1,2,4]triazolo[1,5-a]pyridin-6-yl}phenyl)-2-phenylacetamide (Mps-BAY1) (a triazolopyridine), N-cyclopropyl-4-{8-[(2-methylpropyl)amino]-6-(quinolin-5-yl)imidazo[1,2-a]pyrazin-3-yl}benzamide (Mps-BAY2a) and N-cyclopropyl-4-{8-(isobutylamino)imidazo[1,2-a]pyrazin-3-yl}benzamide (Mps-BAY2b) (two imidazopyrazines).  By selectively inactivating MPS1, these small inhibitors can arrest the proliferation of cancer cells, causing their polyploidization and/or their demise.  Cancer cells treated with Mps-BAY1 or Mps-BAY2a manifested multiple signs of mitotic perturbation including inefficient chromosomal congression during metaphase, unscheduled SAC inactivation and severe anaphase defects.  Videomicroscopic cell fate profiling of histone 2B-green fluorescent protein-expressing cells revealed the capacity of MPS1 inhibitors to subvert the correct timing of mitosis as they induce a premature anaphase entry in the context of misaligned metaphase plates.  Hence, in the presence of MPS1 inhibitors, cells either divided in a bipolar (but often asym.) manner or entered one or more rounds of abortive mitoses, generating gross aneuploidy and polyploidy, resp.  In both cases, cells ultimately succumbed to the mitotic catastrophe-induced activation of the mitochondrial pathway of apoptosis.  Of note, low doses of MPS1 inhibitors and paclitaxel (a microtubular poison) synergized at increasing the frequency of chromosome misalignments and missegregations in the context of SAC inactivation.  This resulted in massive polyploidization followed by the activation of mitotic catastrophe.  A synergistic interaction between paclitaxel and MPS1 inhibitors could also be demonstrated in vivo, as the combination of these agents efficiently reduced the growth of tumor xenografts and exerted superior antineoplastic effects compared with either compd. employed alone.  Altogether, these results suggest that MPS1 inhibitors may exert robust anticancer activity, either as standalone therapeutic interventions or combined with microtubule-targeting chems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHoriIGxHO_rVg90H21EOLACvtfcHk0lj9oA8O4-1A8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2gurjI&md5=867fb902b15b6df0f7049b069bd47a4c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2013.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2013.105%26sid%3Dliteratum%253Aachs%26aulast%3DJemaa%26aufirst%3DM.%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DKepp%26aufirst%3DO.%26aulast%3DSenovilla%26aufirst%3DL.%26aulast%3DBrands%26aufirst%3DM.%26aulast%3DBoemer%26aufirst%3DU.%26aulast%3DKoppitz%26aufirst%3DM.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DPrechtl%26aufirst%3DS.%26aulast%3DSchulze%26aufirst%3DV.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DAbrieu%26aufirst%3DA.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DCharacterization%2520of%2520novel%2520MPS1%2520inhibitors%2520with%2520preclinical%2520anticancer%2520activity%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2013%26volume%3D20%26spage%3D1532%26epage%3D1545%26doi%3D10.1038%2Fcdd.2013.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Wengner, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siemeister, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koppitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosemund, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoeckigt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuhaus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lienau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prechtl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raschke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frisk, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Ahsen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michels, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreft, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Nussbaum, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brands, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mumberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziegelbauer, K.</span><span> </span><span class="NLM_article-title">Novel Mps1 kinase inhibitors with potent antitumor activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">583</span><span class="NLM_x">–</span> <span class="NLM_lpage">592</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1158%2F1535-7163.MCT-15-0500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=26832791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVSqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=583-592&author=A.+M.+Wengnerauthor=G.+Siemeisterauthor=M.+Koppitzauthor=V.+Schulzeauthor=D.+Kosemundauthor=U.+Klarauthor=D.+Stoeckigtauthor=R.+Neuhausauthor=P.+Lienauauthor=B.+Baderauthor=S.+Prechtlauthor=M.+Raschkeauthor=A.+L.+Friskauthor=O.+von+Ahsenauthor=M.+Michelsauthor=B.+Kreftauthor=F.+von+Nussbaumauthor=M.+Brandsauthor=D.+Mumbergauthor=K.+Ziegelbauer&title=Novel+Mps1+kinase+inhibitors+with+potent+antitumor+activity&doi=10.1158%2F1535-7163.MCT-15-0500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity</span></div><div class="casAuthors">Wengner, Antje M.; Siemeister, Gerhard; Koppitz, Marcus; Schulze, Volker; Kosemund, Dirk; Klar, Ulrich; Stoeckigt, Detlef; Neuhaus, Roland; Lienau, Philip; Bader, Benjamin; Prechtl, Stefan; Raschke, Marian; Frisk, Anna-Lena; von Ahsen, Oliver; Michels, Martin; Kreft, Bertolt; von Nussbaum, Franz; Brands, Michael; Mumberg, Dominik; Ziegelbauer, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">583-592</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Monopolar spindle 1 (Mps1) has been shown to function as the key kinase that activates the spindle assembly checkpoint (SAC) to secure proper distribution of chromosomes to daughter cells.  Here, we report the structure and functional characterization of two novel selective Mps1 inhibitors, BAY 1161909 and BAY 1217389, derived from structurally distinct chem. classes.  BAY 1161909 and BAY 1217389 inhibited Mps1 kinase activity with IC50 values below 10 nmol/L while showing an excellent selectivity profile.  In cellular mechanistic assays, both Mps1 inhibitors abrogated nocodazole-induced SAC activity and induced premature exit from mitosis ("mitotic breakthrough"), resulting in multinuclearity and tumor cell death.  Both compds. efficiently inhibited tumor cell proliferation in vitro (IC50 nmol/L range).  In vivo, BAY 1161909 and BAY 1217389 achieved moderate efficacy in monotherapy in tumor xenograft studies.  However, in line with its unique mode of action, when combined with paclitaxel, low doses of Mps1 inhibitor reduced paclitaxel-induced mitotic arrest by the weakening of SAC activity.  As a result, combination therapy strongly improved efficacy over paclitaxel or Mps1 inhibitor monotreatment at the resp. MTDs in a broad range of xenograft models, including those showing acquired or intrinsic paclitaxel resistance.  Both Mps1 inhibitors showed good tolerability without adding toxicity to paclitaxel monotherapy.  These preclin. findings validate the innovative concept of SAC abrogation for cancer therapy and justify clin. proof-of-concept studies evaluating the Mps1 inhibitors BAY 1161909 and BAY 1217389 in combination with antimitotic cancer drugs to enhance their efficacy and potentially overcome resistance.  Mol Cancer Ther; 15(4); 583-92. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGZQmIvWHFcLVg90H21EOLACvtfcHk0lgxeHc1wAglWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVSqt7g%253D&md5=f2b5cf0daf178088479be4be2aefa6b7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0500%26sid%3Dliteratum%253Aachs%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DKoppitz%26aufirst%3DM.%26aulast%3DSchulze%26aufirst%3DV.%26aulast%3DKosemund%26aufirst%3DD.%26aulast%3DKlar%26aufirst%3DU.%26aulast%3DStoeckigt%26aufirst%3DD.%26aulast%3DNeuhaus%26aufirst%3DR.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DBader%26aufirst%3DB.%26aulast%3DPrechtl%26aufirst%3DS.%26aulast%3DRaschke%26aufirst%3DM.%26aulast%3DFrisk%26aufirst%3DA.%2BL.%26aulast%3Dvon%2BAhsen%26aufirst%3DO.%26aulast%3DMichels%26aufirst%3DM.%26aulast%3DKreft%26aufirst%3DB.%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DBrands%26aufirst%3DM.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26atitle%3DNovel%2520Mps1%2520kinase%2520inhibitors%2520with%2520potent%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D583%26epage%3D592%26doi%3D10.1158%2F1535-7163.MCT-15-0500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Yomoda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muraki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kataoka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosoya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagiwara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span> </span><span class="NLM_article-title">Combination of Clk family kinase and SRp75 modulates alternative splicing of adenovirus E1A</span> <span class="citation_source-journal">Genes Cells</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">233</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span><span class="refDoi"> DOI: 10.1111/j.1365-2443.2008.01163.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1111%2Fj.1365-2443.2008.01163.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=18298798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVensrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=233-244&author=J.+Yomodaauthor=M.+Murakiauthor=N.+Kataokaauthor=T.+Hosoyaauthor=M.+Suzukiauthor=M.+Hagiwaraauthor=H.+Kimura&title=Combination+of+Clk+family+kinase+and+SRp75+modulates+alternative+splicing+of+adenovirus+E1A&doi=10.1111%2Fj.1365-2443.2008.01163.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of Clk family kinase and SRp75 modulates alternative splicing of adenovirus E1A</span></div><div class="casAuthors">Yomoda, Jun-ichiro; Muraki, Michiko; Kataoka, Naoyuki; Hosoya, Takamitsu; Suzuki, Masaaki; Hagiwara, Masatoshi; Kimura, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Genes to Cells</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">233-244</span>CODEN:
                <span class="NLM_cas:coden">GECEFL</span>;
        ISSN:<span class="NLM_cas:issn">1356-9597</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Inc.</span>)
        </div><div class="casAbstract">SR proteins are non-snRNP splicing factors harboring a domain rich in Arg-Ser repeats, which are extensively phosphorylated by several kinases.  We performed a comparative study of different SR kinases, including SRPK, Clk, PRP4 and DYRK, and found that only Clks efficiently altered 5' splice site selection of Adenovirus E1A.  The phosphorylation state of SR proteins was examd. using a phospho-SR specific antibody mAb1H4 and a 75 kDa protein was most evidently hyperphosphorylated by Clks.  Administration of TG003, a specific inhibitor for the Clk family members, specifically and rapidly induced dephosphorylation of 75 kDa SR protein.  Imaging with mRFP-SRp75 in living cells revealed that its nuclear distribution was rapidly altered upon inhibition of the Clk activity by TG003.  Co-transfection expts. demonstrated that HA-tagged SRp75 was hyperphosphorylated by Clk family members, but not by other SR kinases.  These results indicate that Clks specifically hyperphosphorylate SRp75.  Furthermore, SRp75 over-expression promoted the selection of 12S 5' splice site in E1A pre-mRNA, which is stimulated by co-expression of Clks.  These results suggest that the specific combination of SR protein and SR kinase plays a distinct role in alternative splicing through dynamic balance of phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuPpVncHxTVLVg90H21EOLACvtfcHk0lgxeHc1wAglWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVensrY%253D&md5=cbf3231037575ed191494dd01cc4c1be</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2443.2008.01163.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2443.2008.01163.x%26sid%3Dliteratum%253Aachs%26aulast%3DYomoda%26aufirst%3DJ.%26aulast%3DMuraki%26aufirst%3DM.%26aulast%3DKataoka%26aufirst%3DN.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DHagiwara%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DH.%26atitle%3DCombination%2520of%2520Clk%2520family%2520kinase%2520and%2520SRp75%2520modulates%2520alternative%2520splicing%2520of%2520adenovirus%2520E1A%26jtitle%3DGenes%2520Cells%26date%3D2008%26volume%3D13%26spage%3D233%26epage%3D244%26doi%3D10.1111%2Fj.1365-2443.2008.01163.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Aubol, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plocinik, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagopian, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGlone, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandyopadhyay, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, X. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. A.</span><span> </span><span class="NLM_article-title">Partitioning RS domain phosphorylation in an SR protein through the CLK and SRPK protein kinases</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">425</span><span class="NLM_x">, </span> <span class="NLM_fpage">2894</span><span class="NLM_x">–</span> <span class="NLM_lpage">2909</span><span class="refDoi"> DOI: 10.1016/j.jmb.2013.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1016%2Fj.jmb.2013.05.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=425&publication_year=2013&pages=2894-2909&author=B.+E.+Aubolauthor=R.+M.+Plocinikauthor=J.+C.+Hagopianauthor=C.+T.+Maauthor=M.+L.+McGloneauthor=R.+Bandyopadhyayauthor=X.+D.+Fuauthor=J.+A.+Adams&title=Partitioning+RS+domain+phosphorylation+in+an+SR+protein+through+the+CLK+and+SRPK+protein+kinases&doi=10.1016%2Fj.jmb.2013.05.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2013.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2013.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DAubol%26aufirst%3DB.%2BE.%26aulast%3DPlocinik%26aufirst%3DR.%2BM.%26aulast%3DHagopian%26aufirst%3DJ.%2BC.%26aulast%3DMa%26aufirst%3DC.%2BT.%26aulast%3DMcGlone%26aufirst%3DM.%2BL.%26aulast%3DBandyopadhyay%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DX.%2BD.%26aulast%3DAdams%26aufirst%3DJ.%2BA.%26atitle%3DPartitioning%2520RS%2520domain%2520phosphorylation%2520in%2520an%2520SR%2520protein%2520through%2520the%2520CLK%2520and%2520SRPK%2520protein%2520kinases%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2013%26volume%3D425%26spage%3D2894%26epage%3D2909%26doi%3D10.1016%2Fj.jmb.2013.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Yoshida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carver, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weremowicz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mei, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polyak, K.</span><span> </span><span class="NLM_article-title">CLK2 Is an oncogenic kinase and splicing regulator in breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1516</span><span class="NLM_x">–</span> <span class="NLM_lpage">1526</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-2443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1158%2F0008-5472.CAN-14-2443" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1516-1526&author=T.+Yoshidaauthor=J.+H.+Kimauthor=K.+Carverauthor=Y.+Suauthor=S.+Weremowiczauthor=L.+Mulveyauthor=S.+Yamamotoauthor=C.+Brennanauthor=S.+Meiauthor=H.+Longauthor=J.+Yaoauthor=K.+Polyak&title=CLK2+Is+an+oncogenic+kinase+and+splicing+regulator+in+breast+cancer&doi=10.1158%2F0008-5472.CAN-14-2443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-2443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-2443%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DCarver%26aufirst%3DK.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DWeremowicz%26aufirst%3DS.%26aulast%3DMulvey%26aufirst%3DL.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DC.%26aulast%3DMei%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DPolyak%26aufirst%3DK.%26atitle%3DCLK2%2520Is%2520an%2520oncogenic%2520kinase%2520and%2520splicing%2520regulator%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D1516%26epage%3D1526%26doi%3D10.1158%2F0008-5472.CAN-14-2443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Araki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dairiki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashita, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwatani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, O.</span><span> </span><span class="NLM_article-title">Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0116929</span><span class="refDoi"> DOI: 10.1371/journal.pone.0116929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1371%2Fjournal.pone.0116929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=25581376" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0116929&author=S.+Arakiauthor=R.+Dairikiauthor=Y.+Nakayamaauthor=A.+Muraiauthor=R.+Miyashitaauthor=M.+Iwataniauthor=T.+Nomuraauthor=O.+Nakanishi&title=Inhibitors+of+CLK+protein+kinases+suppress+cell+growth+and+induce+apoptosis+by+modulating+pre-mRNA+splicing&doi=10.1371%2Fjournal.pone.0116929"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0116929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0116929%26sid%3Dliteratum%253Aachs%26aulast%3DAraki%26aufirst%3DS.%26aulast%3DDairiki%26aufirst%3DR.%26aulast%3DNakayama%26aufirst%3DY.%26aulast%3DMurai%26aufirst%3DA.%26aulast%3DMiyashita%26aufirst%3DR.%26aulast%3DIwatani%26aufirst%3DM.%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DNakanishi%26aufirst%3DO.%26atitle%3DInhibitors%2520of%2520CLK%2520protein%2520kinases%2520suppress%2520cell%2520growth%2520and%2520induce%2520apoptosis%2520by%2520modulating%2520pre-mRNA%2520splicing%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0116929%26doi%3D10.1371%2Fjournal.pone.0116929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><div class="note"><p class="first last">SelectScreen Kinase Profiling Services: Thermo Fisher Scientific, M., WI, USA.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=SelectScreen+Kinase+Profiling+Services%3A+Thermo+Fisher+Scientific%2C+M.%2C+WI%2C+USA."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Naud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwood, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faisal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldrake, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bavetsias, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atrash, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAndrew, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matijssen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardopoulos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span> </span><span class="NLM_article-title">Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">10045</span><span class="NLM_x">–</span> <span class="NLM_lpage">10065</span><span class="refDoi"> DOI: 10.1021/jm401395s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401395s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVShsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=10045-10065&author=S.+Naudauthor=I.+M.+Westwoodauthor=A.+Faisalauthor=P.+Sheldrakeauthor=V.+Bavetsiasauthor=B.+Atrashauthor=K.+M.+Cheungauthor=M.+Liuauthor=A.+Hayesauthor=J.+Schmittauthor=A.+Woodauthor=V.+Choiauthor=K.+Boxallauthor=G.+Makauthor=M.+Gurdenauthor=M.+Valentiauthor=A.+de+Haven+Brandonauthor=A.+Henleyauthor=R.+Bakerauthor=C.+McAndrewauthor=B.+Matijssenauthor=R.+Burkeauthor=S.+Hoelderauthor=S.+A.+Ecclesauthor=F.+I.+Raynaudauthor=S.+Linardopoulosauthor=R.+L.+van+Montfortauthor=J.+Blagg&title=Structure-based+design+of+orally+bioavailable+1H-pyrrolo%5B3%2C2-c%5Dpyridine+inhibitors+of+mitotic+kinase+monopolar+spindle+1+%28MPS1%29&doi=10.1021%2Fjm401395s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Orally Bioavailable 1H-Pyrrolo[3,2-c]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1)</span></div><div class="casAuthors">Naud, Sebastien; Westwood, Isaac M.; Faisal, Amir; Sheldrake, Peter; Bavetsias, Vassilios; Atrash, Butrus; Cheung, Kwai-Ming J.; Liu, Manjuan; Hayes, Angela; Schmitt, Jessica; Wood, Amy; Choi, Vanessa; Boxall, Kathy; Mak, Grace; Gurden, Mark; Valenti, Melanie; de Haven Brandon, Alexis; Henley, Alan; Baker, Ross; McAndrew, Craig; Matijssen, Berry; Burke, Rosemary; Hoelder, Swen; Eccles, Suzanne A.; Raynaud, Florence I.; Linardopoulos, Spiros; van Montfort, Rob L. M.; Blagg, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10045-10065</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The protein kinase MPS1 is a crucial component of the spindle assembly checkpoint signal and is aberrantly overexpressed in many human cancers.  MPS1 is one of the top 25 genes overexpressed in tumors with chromosomal instability and aneuploidy.  PTEN-deficient breast tumor cells are particularly dependent upon MPS1 for their survival, making it a target of significant interest in oncol.  The authors report the discovery and optimization of potent and selective MPS1 inhibitors based on the 1H-pyrrolo-[3,2-c]-pyridine scaffold, guided by structure-based design and cellular characterization of MPS1 inhibition, leading to CCT251455.  This potent and selective chem. tool stabilizes an inactive conformation of MPS1 with the activation loop ordered in a manner incompatible with ATP and substrate-peptide binding; it displays a favorable oral pharmacokinetic profile, shows dose-dependent inhibition of MPS1 in an HCT116 human tumor xenograft model, and is an attractive tool compd. to elucidate further the therapeutic potential of MPS1 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVRsRcyzCEBLVg90H21EOLACvtfcHk0ljG3oybDy-iMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVShsLzO&md5=6564efe14dec83774e94c355be756845</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm401395s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401395s%26sid%3Dliteratum%253Aachs%26aulast%3DNaud%26aufirst%3DS.%26aulast%3DWestwood%26aufirst%3DI.%2BM.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DSheldrake%26aufirst%3DP.%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DAtrash%26aufirst%3DB.%26aulast%3DCheung%26aufirst%3DK.%2BM.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DChoi%26aufirst%3DV.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DMak%26aufirst%3DG.%26aulast%3DGurden%26aufirst%3DM.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DMcAndrew%26aufirst%3DC.%26aulast%3DMatijssen%26aufirst%3DB.%26aulast%3DBurke%26aufirst%3DR.%26aulast%3DHoelder%26aufirst%3DS.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DLinardopoulos%26aufirst%3DS.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DBlagg%26aufirst%3DJ.%26atitle%3DStructure-based%2520design%2520of%2520orally%2520bioavailable%25201H-pyrrolo%255B3%252C2-c%255Dpyridine%2520inhibitors%2520of%2520mitotic%2520kinase%2520monopolar%2520spindle%25201%2520%2528MPS1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D10045%26epage%3D10065%26doi%3D10.1021%2Fjm401395s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0ljG3oybDy-iMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storoni, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span> </span><span class="NLM_article-title">Phaser crystallographic software</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span><span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0ljG3oybDy-iMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohkamp, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Features and development of Coot</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lgAETZMhpmoQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skubak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebedev, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pannu, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholls, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span> </span><span class="NLM_article-title">REFMAC5 for the refinement of macromolecular crystal structures</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span><span class="refDoi"> DOI: 10.1107/S0907444911001314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1107%2FS0907444911001314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=21460454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=355-367&author=G.+N.+Murshudovauthor=P.+Skubakauthor=A.+A.+Lebedevauthor=N.+S.+Pannuauthor=R.+A.+Steinerauthor=R.+A.+Nichollsauthor=M.+D.+Winnauthor=F.+Longauthor=A.+A.+Vagin&title=REFMAC5+for+the+refinement+of+macromolecular+crystal+structures&doi=10.1107%2FS0907444911001314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">REFMAC5 for the refinement of macromolecular crystal structures</span></div><div class="casAuthors">Murshudov, Garib N.; Skubak, Pavol; Lebedev, Andrey A.; Pannu, Navraj S.; Steiner, Roberto A.; Nicholls, Robert A.; Winn, Martyn D.; Long, Fei; Vagin, Alexei A.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">355-367</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">This paper describes various components of the macromol. crystallog. refinement program REFMAC5, which is distributed as part of the CCP4 suite.  REFMAC5 utilizes different likelihood functions depending on the diffraction data employed (amplitudes or intensities), the presence of twinning and the availability of SAD/SIRAS exptl. diffraction data.  To ensure chem. and structural integrity of the refined model, REFMAC5 offers several classes of restraints and choices of model parameterization.  Reliable models at resolns. at least as low as 4 Å can be achieved thanks to low-resoln. refinement tools such as secondary-structure restraints, restraints to known homologous structures, automatic global and local NCS restraints, 'jelly-body' restraints and the use of novel long-range restraints on at. displacement parameters (ADPs) based on the Kullback-Leibler divergence.  REFMAC5 addnl. offers TLS parameterization and, when high-resoln. data are available, fast refinement of anisotropic ADPs.  Refinement in the presence of twinning is performed in a fully automated fashion.  REFMAC5 is a flexible and highly optimized refinement package that is ideally suited for refinement across the entire resoln. spectrum encountered in macromol. crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Jq-i2qIq5rVg90H21EOLACvtfcHk0lgAETZMhpmoQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqtbk%253D&md5=f8f3202d246908500057ad7c71015b7b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1107%2FS0907444911001314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444911001314%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DSkubak%26aufirst%3DP.%26aulast%3DLebedev%26aufirst%3DA.%2BA.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DSteiner%26aufirst%3DR.%2BA.%26aulast%3DNicholls%26aufirst%3DR.%2BA.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DLong%26aufirst%3DF.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26atitle%3DREFMAC5%2520for%2520the%2520refinement%2520of%2520macromolecular%2520crystal%2520structures%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D355%26epage%3D367%26doi%3D10.1107%2FS0907444911001314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Halgren, T. A.</span><span> </span><span class="NLM_article-title">Identifying and characterizing binding sites and assessing druggability</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">389</span><span class="refDoi"> DOI: 10.1021/ci800324m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800324m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1OhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=377-389&author=T.+A.+Halgren&title=Identifying+and+characterizing+binding+sites+and+assessing+druggability&doi=10.1021%2Fci800324m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying and Characterizing Binding Sites and Assessing Druggability</span></div><div class="casAuthors">Halgren, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">377-389</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification and characterization of binding sites is key in the process of structure-based drug design.  In some cases there may not be any information about the binding site for a target of interest.  In other cases, a putative binding site has been identified by computational or exptl. means, but the druggability of the target is not known.  Even when a site for a given target is known, it may be desirable to find addnl. sites whose targeting could produce a desired biol. response.  A new program, called SiteMap, is presented for identifying and analyzing binding sites and for predicting target druggability.  In a large-scale validation, SiteMap correctly identifies the known binding site as the top-ranked site in 86% of the cases, with best results (>98%) coming for sites that bind ligands with subnanomolar affinity.  In addn., a modified version of the score employed for binding-site identification allows SiteMap to accurately classify the druggability of proteins as measured by their ability to bind passively absorbed small mols. tightly.  In characterizing binding sites, SiteMap provides quant. and graphical information that can help guide efforts to critically assess virtual hits in a lead-discovery application or to modify ligand structure to enhance potency or improve phys. properties in a lead-optimization context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfAt0-gvcXDLVg90H21EOLACvtfcHk0lgAETZMhpmoQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1OhsA%253D%253D&md5=f03c7b27e30ae03d10e4127ed1f1ed3c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fci800324m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800324m%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26atitle%3DIdentifying%2520and%2520characterizing%2520binding%2520sites%2520and%2520assessing%2520druggability%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D377%26epage%3D389%26doi%3D10.1021%2Fci800324m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="ref35_1"><span><span class="NLM_contrib-group">Halgren, T. A.</span><span> </span><span class="NLM_article-title">New method for fast and accurate binding-site identification and analysis</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00483.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/ref35_1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1111%2Fj.1747-0285.2007.00483.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/ref35_1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=17381729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/ref35_1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkt1OnsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2007&pages=146-148&author=T.+A.+Halgren&title=New+method+for+fast+and+accurate+binding-site+identification+and+analysis&doi=10.1111%2Fj.1747-0285.2007.00483.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_ref35_1R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">New method for fast and accurate binding-site identification and analysis</span></div><div class="casAuthors">Halgren, Tom</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-148</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Structure-based drug design seeks to exploit the structure of protein-ligand or protein-protein binding sites, but the site is not always known at the outset.  Even when the site is known, the researcher may wish to identify alternative prospective binding sites that may result in different biol. effects or new class of compds.  It is also vital in lead optimization to clearly understand the degree to which known binders or docking hits satisfy or violate complementarity to the receptor.  SiteMap is a new technique for identifying potential binding sites and for predicting their druggability in lead-discovery applications and for characterizing binding sites and critically assessing prospective ligands in lead-optimization applications.  In large-scale validation tests, SiteMap correctly identifies the known binding site in > 96% of the cases, with best results (> 98%) coming for sites that bind ligands tightly.  It also accurately distinguishes between sites that bind ligands and sites that don't.  In binding-site anal., SiteMap provides a wealth of quant. and graphical information that can help guide efforts to modify ligand structure to enhance potency or improve phys. properties.  These attributes allow SiteMap to nicely complement techniques such as docking and computational lead optimization in structure-base drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr245hmZWXilrVg90H21EOLACvtfcHk0lgQ2Ic7k-VdkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkt1OnsLg%253D&md5=c233276ba9580393b282f255781f9ce6</span></div><a href="/servlet/linkout?suffix=ref35_1&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00483.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00483.x%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26atitle%3DNew%2520method%2520for%2520fast%2520and%2520accurate%2520binding-site%2520identification%2520and%2520analysis%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D69%26spage%3D146%26epage%3D148%26doi%3D10.1111%2Fj.1747-0285.2007.00483.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Patricelli, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomanbhoy, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagannathan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okerberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herring, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozarich, J. W.</span><span> </span><span class="NLM_article-title">In situ kinase profiling reveals functionally relevant properties of native kinases</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">699</span><span class="NLM_x">–</span> <span class="NLM_lpage">710</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2011.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1016%2Fj.chembiol.2011.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=21700206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVejtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=699-710&author=M.+P.+Patricelliauthor=T.+K.+Nomanbhoyauthor=J.+Wuauthor=H.+Brownauthor=D.+Zhouauthor=J.+Zhangauthor=S.+Jagannathanauthor=A.+Abanauthor=E.+Okerbergauthor=C.+Herringauthor=B.+Nordinauthor=H.+Weissigauthor=Q.+Yangauthor=J.+D.+Leeauthor=N.+S.+Grayauthor=J.+W.+Kozarich&title=In+situ+kinase+profiling+reveals+functionally+relevant+properties+of+native+kinases&doi=10.1016%2Fj.chembiol.2011.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases</span></div><div class="casAuthors">Patricelli, Matthew P.; Nomanbhoy, Tyzoon K.; Wu, Jiangyue; Brown, Heidi; Zhou, David; Zhang, Jianming; Jagannathan, Subadhra; Aban, Arwin; Okerberg, Eric; Herring, Chris; Nordin, Brian; Weissig, Helge; Yang, Qingkai; Lee, Jiing-Dwan; Gray, Nathanael S.; Kozarich, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">699-710</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Protein kinases are intensely studied mediators of cellular signaling, yet important questions remain regarding their regulation and in vivo properties.  Here, we use a probe-based chemoprotemics platform to profile several well studied kinase inhibitors against >200 kinases in native cell proteomes and reveal biol. targets for some of these inhibitors.  Several striking differences were identified between native and recombinant kinase inhibitory profiles, in particular, for the Raf kinases.  The native kinase binding profiles presented here closely mirror the cellular activity of these inhibitors, even when the inhibition profiles differ dramatically from recombinant assay results.  Addnl., Raf activation events could be detected on live cell treatment with inhibitors.  These studies highlight the complexities of protein kinase behavior in the cellular context and demonstrate that profiling with only recombinant/purified enzymes can be misleading.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopb21npuaC_rVg90H21EOLACvtfcHk0lgQ2Ic7k-VdkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVejtbo%253D&md5=dda091b895850c95131f80c3aba9e8c7</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DJagannathan%26aufirst%3DS.%26aulast%3DAban%26aufirst%3DA.%26aulast%3DOkerberg%26aufirst%3DE.%26aulast%3DHerring%26aufirst%3DC.%26aulast%3DNordin%26aufirst%3DB.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BD.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKozarich%26aufirst%3DJ.%2BW.%26atitle%3DIn%2520situ%2520kinase%2520profiling%2520reveals%2520functionally%2520relevant%2520properties%2520of%2520native%2520kinases%26jtitle%3DChem.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D699%26epage%3D710%26doi%3D10.1016%2Fj.chembiol.2011.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['ref35_1'],'ref36':['cit36']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 21 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Younho Lee, Hyunkyung Kim, Haelee Kim, Ha Yeon Cho, Jun-Goo Jee, Kyung-Ah Seo, Jung Beom Son, Eunhwa Ko, Hwan Geun Choi, Nam Doo Kim, <span class="NLM_string-name hlFld-ContribAuthor">Ikyon Kim</span>. </span><span class="cited-content_cbyCitation_article-title">X-ray Crystal Structure-Guided Design and Optimization of 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile Scaffold as a Potent and Orally Active Monopolar Spindle 1 Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (10)
                                     , 6985-6995. <a href="https://doi.org/10.1021/acs.jmedchem.1c00542" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00542</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00542%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DX-ray%252BCrystal%252BStructure-Guided%252BDesign%252Band%252BOptimization%252Bof%252B7H-Pyrrolo%25255B2%25252C3-d%25255Dpyrimidine-5-carbonitrile%252BScaffold%252Bas%252Ba%252BPotent%252Band%252BOrally%252BActive%252BMonopolar%252BSpindle%252B1%252BInhibitor%26aulast%3DLee%26aufirst%3DYounho%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D25032021%26date%3D04052021%26volume%3D64%26issue%3D10%26spage%3D6985%26epage%3D6995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jennifer R. Riggs, Jan Elsner, Dan Cashion, Dale Robinson, Lida Tehrani, Mark Nagy, Kimberly E. Fultz, Rama Krishna Narla, Xiaohui Peng, Tam Tran, Ashutosh Kulkarni, Sogole Bahmanyar, Kevin Condroski, Barbra Pagarigan, Gustavo Fenalti, Laurie LeBrun, Katerina Leftheris, Dan Zhu, <span class="NLM_string-name hlFld-ContribAuthor">John F. Boylan</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (9)
                                     , 4401-4410. <a href="https://doi.org/10.1021/acs.jmedchem.8b01869" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01869</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01869%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BOptimization%252BLeading%252Bto%252Ban%252BOrally%252BActive%252BTTK%252BProtein%252BKinase%252BInhibitor%252Bwith%252BRobust%252BSingle%252BAgent%252BEfficacy%26aulast%3DRiggs%26aufirst%3DJennifer%2BR.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D28112018%26date%3D30042019%26date%3D18042019%26volume%3D62%26issue%3D9%26spage%3D4401%26epage%3D4410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nazarii Sabat, Lenka Poštová Slavětínská, Blanka Klepetářová, <span class="NLM_string-name hlFld-ContribAuthor">Michal Hocek</span>. </span><span class="cited-content_cbyCitation_article-title">C–H Imidation of 7-Deazapurines. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (4)
                                     , 4674-4678. <a href="https://doi.org/10.1021/acsomega.8b00520" title="DOI URL">https://doi.org/10.1021/acsomega.8b00520</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b00520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b00520%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DC%2525E2%252580%252593H%252BImidation%252Bof%252B7-Deazapurines%26aulast%3DSabat%26aufirst%3DNazarii%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D19032018%26date%3D20042018%26volume%3D3%26issue%3D4%26spage%3D4674%26epage%3D4678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mattias F.  Lindberg</span>, <span class="hlFld-ContribAuthor ">Laurent  Meijer</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (11)
                                     , 6047. <a href="https://doi.org/10.3390/ijms22116047" title="DOI URL">https://doi.org/10.3390/ijms22116047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22116047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22116047%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DDual-Specificity%25252C%252BTyrosine%252BPhosphorylation-Regulated%252BKinases%252B%252528DYRKs%252529%252Band%252Bcdc2-Like%252BKinases%252B%252528CLKs%252529%252Bin%252BHuman%252BDisease%25252C%252Ban%252BOverview%26aulast%3DLindberg%26aufirst%3DMattias%2BF.%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D11%26spage%3D6047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maxime  Blijlevens</span>, <span class="hlFld-ContribAuthor ">Jing  Li</span>, <span class="hlFld-ContribAuthor ">Victor W.  van Beusechem</span>. </span><span class="cited-content_cbyCitation_article-title">Biology of the mRNA Splicing Machinery and Its Dysregulation in Cancer Providing Therapeutic Opportunities. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (10)
                                     , 5110. <a href="https://doi.org/10.3390/ijms22105110" title="DOI URL">https://doi.org/10.3390/ijms22105110</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22105110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22105110%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DBiology%252Bof%252Bthe%252BmRNA%252BSplicing%252BMachinery%252Band%252BIts%252BDysregulation%252Bin%252BCancer%252BProviding%252BTherapeutic%252BOpportunities%26aulast%3DBlijlevens%26aufirst%3DMaxime%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D10%26spage%3D5110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dabbugoddu  Brahmaiah</span>, <span class="hlFld-ContribAuthor ">Anagani  Kanaka Durga Bhavani</span>, <span class="hlFld-ContribAuthor ">Pasula  Aparna</span>, <span class="hlFld-ContribAuthor ">Nangunoori  Sampath Kumar</span>, <span class="hlFld-ContribAuthor ">Hélène  Solhi</span>, <span class="hlFld-ContribAuthor ">Rémy  Le Guevel</span>, <span class="hlFld-ContribAuthor ">Blandine  Baratte</span>, <span class="hlFld-ContribAuthor ">Sandrine  Ruchaud</span>, <span class="hlFld-ContribAuthor ">Stéphane  Bach</span>, <span class="hlFld-ContribAuthor ">Surender  Singh Jadav</span>, <span class="hlFld-ContribAuthor ">Chada  Raji Reddy</span>, <span class="hlFld-ContribAuthor ">Thierry  Roisnel</span>, <span class="hlFld-ContribAuthor ">Paul  Mosset</span>, <span class="hlFld-ContribAuthor ">Nicolas  Levoin</span>, <span class="hlFld-ContribAuthor ">René  Grée</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>31 </em>, 115962. <a href="https://doi.org/10.1016/j.bmc.2020.115962" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115962</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115962%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BDB18%25252C%252Ba%252Bpotent%252Binhibitor%252Bof%252BCLK%252Bkinases%252Bwith%252Ba%252Bhigh%252Bselectivity%252Bagainst%252BDYRK1A%252Bkinase%26aulast%3DBrahmaiah%26aufirst%3DDabbugoddu%26date%3D2021%26volume%3D31%26spage%3D115962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minhao  Huang</span>, <span class="hlFld-ContribAuthor ">Yongjun  Huang</span>, <span class="hlFld-ContribAuthor ">Jing  Guo</span>, <span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Yu  Chang</span>, <span class="hlFld-ContribAuthor ">Xiaolu  Wang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Yanhui  Huang</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113023. <a href="https://doi.org/10.1016/j.ejmech.2020.113023" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113023%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrido%25255B2%25252C%252B3-d%25255Dpyrimidin-7%2525288H%252529-ones%252Bas%252Bnew%252Bselective%252Borally%252Bbioavailable%252BThreonine%252BTyrosine%252BKinase%252B%252528TTK%252529%252Binhibitors%26aulast%3DHuang%26aufirst%3DMinhao%26date%3D2021%26volume%3D211%26spage%3D113023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vishal  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Tim  Seo</span>, <span class="hlFld-ContribAuthor ">Alyssa L.  O'Green</span>, <span class="hlFld-ContribAuthor ">Maureen  Ibanez</span>, <span class="hlFld-ContribAuthor ">Brian  Hofilena</span>, <span class="hlFld-ContribAuthor ">Sunil  KC</span>, <span class="hlFld-ContribAuthor ">Joshua  Stewart</span>, <span class="hlFld-ContribAuthor ">Luis  Dellamary</span>, <span class="hlFld-ContribAuthor ">Kevin  Chiu</span>, <span class="hlFld-ContribAuthor ">Abdullah  Ghias</span>, <span class="hlFld-ContribAuthor ">Charlene  Barroga</span>, <span class="hlFld-ContribAuthor ">Sarah  Kennedy</span>, <span class="hlFld-ContribAuthor ">Jeyanesh  Tambiah</span>, <span class="hlFld-ContribAuthor ">John  Hood</span>, <span class="hlFld-ContribAuthor ">Yusuf  Yazici</span>. </span><span class="cited-content_cbyCitation_article-title">SM04755, a small‐molecule inhibitor of the Wnt pathway, as a potential topical treatment for tendinopathy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Orthopaedic Research</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.1002/jor.24898" title="DOI URL">https://doi.org/10.1002/jor.24898</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jor.24898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjor.24898%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Orthopaedic%2520Research%26atitle%3DSM04755%25252C%252Ba%252Bsmall%2525E2%252580%252590molecule%252Binhibitor%252Bof%252Bthe%252BWnt%252Bpathway%25252C%252Bas%252Ba%252Bpotential%252Btopical%252Btreatment%252Bfor%252Btendinopathy%26aulast%3DDeshmukh%26aufirst%3DVishal%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinjia  Yan</span>, <span class="hlFld-ContribAuthor ">Jing  Wen</span>, <span class="hlFld-ContribAuthor ">Lin  Zhou</span>, <span class="hlFld-ContribAuthor ">Lei  Fan</span>, <span class="hlFld-ContribAuthor ">Xiaobo  Wang</span>, <span class="hlFld-ContribAuthor ">Zhi  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Current Scenario of 1,3-oxazole Derivatives for Anticancer Activity. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (21)
                                     , 1916-1937. <a href="https://doi.org/10.2174/1568026620666200624161151" title="DOI URL">https://doi.org/10.2174/1568026620666200624161151</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026620666200624161151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026620666200624161151%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252BScenario%252Bof%252B1%25252C3-oxazole%252BDerivatives%252Bfor%252BAnticancer%252BActivity%26aulast%3DYan%26aufirst%3DXinjia%26date%3D2020%26volume%3D20%26issue%3D21%26spage%3D1916%26epage%3D1937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhuo‐Xun  Wu</span>, <span class="hlFld-ContribAuthor ">Yuqi  Yang</span>, <span class="hlFld-ContribAuthor ">Guangsuo  Wang</span>, <span class="hlFld-ContribAuthor ">Jing‐Quan  Wang</span>, <span class="hlFld-ContribAuthor ">Qiu‐Xu  Teng</span>, <span class="hlFld-ContribAuthor ">Lingling  Sun</span>, <span class="hlFld-ContribAuthor ">Zi‐Ning  Lei</span>, <span class="hlFld-ContribAuthor ">Lizhu  Lin</span>, <span class="hlFld-ContribAuthor ">Zhe‐Sheng  Chen</span>, <span class="hlFld-ContribAuthor ">Chang  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Dual TTK/CLK2 inhibitor, CC‐671, selectively antagonizes ABCG2‐mediated multidrug resistance in lung cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Cancer Science</span><span> <strong>2020,</strong> <em>111 </em>
                                    (8)
                                     , 2872-2882. <a href="https://doi.org/10.1111/cas.14505" title="DOI URL">https://doi.org/10.1111/cas.14505</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cas.14505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcas.14505%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Science%26atitle%3DDual%252BTTK%25252FCLK2%252Binhibitor%25252C%252BCC%2525E2%252580%252590671%25252C%252Bselectively%252Bantagonizes%252BABCG2%2525E2%252580%252590mediated%252Bmultidrug%252Bresistance%252Bin%252Blung%252Bcancer%252Bcells%26aulast%3DWu%26aufirst%3DZhuo%25E2%2580%2590Xun%26date%3D2020%26date%3D2020%26volume%3D111%26issue%3D8%26spage%3D2872%26epage%3D2882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Betty Y.  Tam</span>, <span class="hlFld-ContribAuthor ">Kevin  Chiu</span>, <span class="hlFld-ContribAuthor ">Heekyung  Chung</span>, <span class="hlFld-ContribAuthor ">Carine  Bossard</span>, <span class="hlFld-ContribAuthor ">John Duc  Nguyen</span>, <span class="hlFld-ContribAuthor ">Emily  Creger</span>, <span class="hlFld-ContribAuthor ">Brian W.  Eastman</span>, <span class="hlFld-ContribAuthor ">Chi Ching  Mak</span>, <span class="hlFld-ContribAuthor ">Maureen  Ibanez</span>, <span class="hlFld-ContribAuthor ">Abdullah  Ghias</span>, <span class="hlFld-ContribAuthor ">Joseph  Cahiwat</span>, <span class="hlFld-ContribAuthor ">Long  Do</span>, <span class="hlFld-ContribAuthor ">Shawn  Cho</span>, <span class="hlFld-ContribAuthor ">Jackie  Nguyen</span>, <span class="hlFld-ContribAuthor ">Vishal  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Josh  Stewart</span>, <span class="hlFld-ContribAuthor ">Chiao-Wen  Chen</span>, <span class="hlFld-ContribAuthor ">Charlene  Barroga</span>, <span class="hlFld-ContribAuthor ">Luis  Dellamary</span>, <span class="hlFld-ContribAuthor ">Sunil K.  KC</span>, <span class="hlFld-ContribAuthor ">Timothy J.  Phalen</span>, <span class="hlFld-ContribAuthor ">John  Hood</span>, <span class="hlFld-ContribAuthor ">Steven  Cha</span>, <span class="hlFld-ContribAuthor ">Yusuf  Yazici</span>. </span><span class="cited-content_cbyCitation_article-title">The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2020,</strong> <em>473 </em>, 186-197. <a href="https://doi.org/10.1016/j.canlet.2019.09.009" title="DOI URL">https://doi.org/10.1016/j.canlet.2019.09.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2019.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2019.09.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DThe%252BCLK%252Binhibitor%252BSM08502%252Binduces%252Banti-tumor%252Bactivity%252Band%252Breduces%252BWnt%252Bpathway%252Bgene%252Bexpression%252Bin%252Bgastrointestinal%252Bcancer%252Bmodels%26aulast%3DTam%26aufirst%3DBetty%2BY.%26date%3D2020%26volume%3D473%26spage%3D186%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dejuan  Sun</span>, <span class="hlFld-ContribAuthor ">Yuqian  Zhao</span>, <span class="hlFld-ContribAuthor ">Shouyue  Zhang</span>, <span class="hlFld-ContribAuthor ">Lan  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo  Liu</span>, <span class="hlFld-ContribAuthor ">Liang  Ouyang</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-target kinase drug design: Current strategies and future directions in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>188 </em>, 112025. <a href="https://doi.org/10.1016/j.ejmech.2019.112025" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.112025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.112025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.112025%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual-target%252Bkinase%252Bdrug%252Bdesign%25253A%252BCurrent%252Bstrategies%252Band%252Bfuture%252Bdirections%252Bin%252Bcancer%252Btherapy%26aulast%3DSun%26aufirst%3DDejuan%26date%3D2020%26volume%3D188%26spage%3D112025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheng  Wang</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Yao  Li</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Zhi  Huang</span>, <span class="hlFld-ContribAuthor ">Zhongxiang  Qin</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>, <span class="hlFld-ContribAuthor ">Yan  Fan</span>. </span><span class="cited-content_cbyCitation_article-title">Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>95 </em>, 103547. <a href="https://doi.org/10.1016/j.bioorg.2019.103547" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103547</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103547%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%252Band%252Boptimization%252Bof%252Borally%252Bspleen%252Btyrosine%252Bkinase%252B%252528SYK%252529%252Binhibitors%252Bfor%252Btreatment%252Bof%252Bsolid%252Btumor%26aulast%3DWang%26aufirst%3DCheng%26date%3D2020%26volume%3D95%26spage%3D103547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yue  Li</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Zhou</span>, <span class="hlFld-ContribAuthor ">Jiali  Liu</span>, <span class="hlFld-ContribAuthor ">Yang  Yin</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Yuan</span>, <span class="hlFld-ContribAuthor ">Ruihua  Yang</span>, <span class="hlFld-ContribAuthor ">Qi  Wang</span>, <span class="hlFld-ContribAuthor ">Jing  Ji</span>, <span class="hlFld-ContribAuthor ">Qian  He</span>. </span><span class="cited-content_cbyCitation_article-title">Differentially expressed genes and key molecules of
              BRCA1/2
              -mutant breast cancer: evidence from bioinformatics analyses. </span><span class="cited-content_cbyCitation_journal-name">PeerJ</span><span> <strong>2020,</strong> <em>8 </em>, e8403. <a href="https://doi.org/10.7717/peerj.8403" title="DOI URL">https://doi.org/10.7717/peerj.8403</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7717/peerj.8403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7717%2Fpeerj.8403%26sid%3Dliteratum%253Aachs%26jtitle%3DPeerJ%26atitle%3DDifferentially%252Bexpressed%252Bgenes%252Band%252Bkey%252Bmolecules%252Bof%252BBRCA1%25252F2%252B-mutant%252Bbreast%252Bcancer%25253A%252Bevidence%252Bfrom%252Bbioinformatics%252Banalyses%26aulast%3DLi%26aufirst%3DYue%26date%3D2020%26date%3D2020%26volume%3D8%26spage%3De8403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">V.  Deshmukh</span>, <span class="hlFld-ContribAuthor ">A.L.  O'Green</span>, <span class="hlFld-ContribAuthor ">C.  Bossard</span>, <span class="hlFld-ContribAuthor ">T.  Seo</span>, <span class="hlFld-ContribAuthor ">L.  Lamangan</span>, <span class="hlFld-ContribAuthor ">M.  Ibanez</span>, <span class="hlFld-ContribAuthor ">A.  Ghias</span>, <span class="hlFld-ContribAuthor ">C.  Lai</span>, <span class="hlFld-ContribAuthor ">L.  Do</span>, <span class="hlFld-ContribAuthor ">S.  Cho</span>, <span class="hlFld-ContribAuthor ">J.  Cahiwat</span>, <span class="hlFld-ContribAuthor ">K.  Chiu</span>, <span class="hlFld-ContribAuthor ">M.  Pedraza</span>, <span class="hlFld-ContribAuthor ">S.  Anderson</span>, <span class="hlFld-ContribAuthor ">R.  Harris</span>, <span class="hlFld-ContribAuthor ">L.  Dellamary</span>, <span class="hlFld-ContribAuthor ">S.  KC</span>, <span class="hlFld-ContribAuthor ">C.  Barroga</span>, <span class="hlFld-ContribAuthor ">B.  Melchior</span>, <span class="hlFld-ContribAuthor ">B.  Tam</span>, <span class="hlFld-ContribAuthor ">S.  Kennedy</span>, <span class="hlFld-ContribAuthor ">J.  Tambiah</span>, <span class="hlFld-ContribAuthor ">J.  Hood</span>, <span class="hlFld-ContribAuthor ">Y.  Yazici</span>. </span><span class="cited-content_cbyCitation_article-title">Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. </span><span class="cited-content_cbyCitation_journal-name">Osteoarthritis and Cartilage</span><span> <strong>2019,</strong> <em>27 </em>
                                    (9)
                                     , 1347-1360. <a href="https://doi.org/10.1016/j.joca.2019.05.006" title="DOI URL">https://doi.org/10.1016/j.joca.2019.05.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.joca.2019.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.joca.2019.05.006%26sid%3Dliteratum%253Aachs%26jtitle%3DOsteoarthritis%2520and%2520Cartilage%26atitle%3DModulation%252Bof%252Bthe%252BWnt%252Bpathway%252Bthrough%252Binhibition%252Bof%252BCLK2%252Band%252BDYRK1A%252Bby%252Blorecivivint%252Bas%252Ba%252Bnovel%25252C%252Bpotentially%252Bdisease-modifying%252Bapproach%252Bfor%252Bknee%252Bosteoarthritis%252Btreatment%26aulast%3DDeshmukh%26aufirst%3DV.%26date%3D2019%26volume%3D27%26issue%3D9%26spage%3D1347%26epage%3D1360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shutao  Wang</span>, <span class="hlFld-ContribAuthor ">Muxin  Zhang</span>, <span class="hlFld-ContribAuthor ">Di  Liang</span>, <span class="hlFld-ContribAuthor ">Wei  Sun</span>, <span class="hlFld-ContribAuthor ">Chaozai  Zhang</span>, <span class="hlFld-ContribAuthor ">Mengnan  Jiang</span>, <span class="hlFld-ContribAuthor ">Junli  Liu</span>, <span class="hlFld-ContribAuthor ">Jiaguo  Li</span>, <span class="hlFld-ContribAuthor ">Chenchen  Li</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Yang</span>, <span class="hlFld-ContribAuthor ">Xiaoping  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>175 </em>, 247-268. <a href="https://doi.org/10.1016/j.ejmech.2019.04.047" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.04.047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.04.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.04.047%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMolecular%252Bdesign%252Band%252Banticancer%252Bactivities%252Bof%252Bsmall-molecule%252Bmonopolar%252Bspindle%252B1%252Binhibitors%25253A%252BA%252BMedicinal%252Bchemistry%252Bperspective%26aulast%3DWang%26aufirst%3DShutao%26date%3D2019%26volume%3D175%26spage%3D247%26epage%3D268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weizhi  Ge</span>, <span class="hlFld-ContribAuthor ">Xin  Hao</span>, <span class="hlFld-ContribAuthor ">Fangzhi  Han</span>, <span class="hlFld-ContribAuthor ">Zhongquan  Liu</span>, <span class="hlFld-ContribAuthor ">Tianpeng  Wang</span>, <span class="hlFld-ContribAuthor ">Mengmeng  Wang</span>, <span class="hlFld-ContribAuthor ">Ning  Chen</span>, <span class="hlFld-ContribAuthor ">Yahui  Ding</span>, <span class="hlFld-ContribAuthor ">Yue  Chen</span>, <span class="hlFld-ContribAuthor ">Quan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and structure-activity relationship studies of parthenolide derivatives as potential anti-triple negative breast cancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>166 </em>, 445-469. <a href="https://doi.org/10.1016/j.ejmech.2019.01.058" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.01.058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.01.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.01.058%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bstructure-activity%252Brelationship%252Bstudies%252Bof%252Bparthenolide%252Bderivatives%252Bas%252Bpotential%252Banti-triple%252Bnegative%252Bbreast%252Bcancer%252Bagents%26aulast%3DGe%26aufirst%3DWeizhi%26date%3D2019%26volume%3D166%26spage%3D445%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yujie  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuxin  Zhang</span>, <span class="hlFld-ContribAuthor ">Li  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Expression of cancer–testis antigens in esophageal cancer and their progress in immunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cancer Research and Clinical Oncology</span><span> <strong>2019,</strong> <em>145 </em>
                                    (2)
                                     , 281-291. <a href="https://doi.org/10.1007/s00432-019-02840-3" title="DOI URL">https://doi.org/10.1007/s00432-019-02840-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00432-019-02840-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00432-019-02840-3%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cancer%2520Research%2520and%2520Clinical%2520Oncology%26atitle%3DExpression%252Bof%252Bcancer%2525E2%252580%252593testis%252Bantigens%252Bin%252Besophageal%252Bcancer%252Band%252Btheir%252Bprogress%252Bin%252Bimmunotherapy%26aulast%3DZhang%26aufirst%3DYujie%26date%3D2019%26date%3D2019%26volume%3D145%26issue%3D2%26spage%3D281%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicolas  Boutard</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Sabiniarz</span>, <span class="hlFld-ContribAuthor ">Klaudia  Czerwińska</span>, <span class="hlFld-ContribAuthor ">Małgorzata  Jarosz</span>, <span class="hlFld-ContribAuthor ">Anna  Cierpich</span>, <span class="hlFld-ContribAuthor ">Ewa  Kolasińska</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Wiklik</span>, <span class="hlFld-ContribAuthor ">Karolina  Gluza</span>, <span class="hlFld-ContribAuthor ">Claude  Commandeur</span>, <span class="hlFld-ContribAuthor ">Anna  Buda</span>, <span class="hlFld-ContribAuthor ">Agata  Stasiowska</span>, <span class="hlFld-ContribAuthor ">Aneta  Bobowska</span>, <span class="hlFld-ContribAuthor ">Mariusz  Galek</span>, <span class="hlFld-ContribAuthor ">Charles-Henry  Fabritius</span>, <span class="hlFld-ContribAuthor ">Marta  Bugaj</span>, <span class="hlFld-ContribAuthor ">Edyta  Palacz</span>, <span class="hlFld-ContribAuthor ">Andrzej  Mazan</span>, <span class="hlFld-ContribAuthor ">Adrian  Zarębski</span>, <span class="hlFld-ContribAuthor ">Karolina  Krawczyńska</span>, <span class="hlFld-ContribAuthor ">Małgorzata  Żurawska</span>, <span class="hlFld-ContribAuthor ">Przemysław  Zawadzki</span>, <span class="hlFld-ContribAuthor ">Mariusz  Milik</span>, <span class="hlFld-ContribAuthor ">Paulina  Węgrzyn</span>, <span class="hlFld-ContribAuthor ">Monika  Dobrzańska</span>, <span class="hlFld-ContribAuthor ">Krzysztof  Brzózka</span>, <span class="hlFld-ContribAuthor ">Piotr  Kowalczyk</span>. </span><span class="cited-content_cbyCitation_article-title">5-Keto-3-cyano-2,4-diaminothiophenes as selective maternal embryonic leucine zipper kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (4)
                                     , 607-613. <a href="https://doi.org/10.1016/j.bmcl.2018.12.051" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.12.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.12.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.12.051%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3D5-Keto-3-cyano-2%25252C4-diaminothiophenes%252Bas%252Bselective%252Bmaternal%252Bembryonic%252Bleucine%252Bzipper%252Bkinase%252Binhibitors%26aulast%3DBoutard%26aufirst%3DNicolas%26date%3D2019%26volume%3D29%26issue%3D4%26spage%3D607%26epage%3D613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon  Uzor</span>, <span class="hlFld-ContribAuthor ">Panagiota  Zorzou</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Bowler</span>, <span class="hlFld-ContribAuthor ">Sean  Porazinski</span>, <span class="hlFld-ContribAuthor ">Ian  Wilson</span>, <span class="hlFld-ContribAuthor ">Michael  Ladomery</span>. </span><span class="cited-content_cbyCitation_article-title">Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention. </span><span class="cited-content_cbyCitation_journal-name">Gene</span><span> <strong>2018,</strong> <em>670 </em>, 46-54. <a href="https://doi.org/10.1016/j.gene.2018.05.095" title="DOI URL">https://doi.org/10.1016/j.gene.2018.05.095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.gene.2018.05.095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.gene.2018.05.095%26sid%3Dliteratum%253Aachs%26jtitle%3DGene%26atitle%3DAutoregulation%252Bof%252Bthe%252Bhuman%252Bsplice%252Bfactor%252Bkinase%252BCLK1%252Bthrough%252Bexon%252Bskipping%252Band%252Bintron%252Bretention%26aulast%3DUzor%26aufirst%3DSimon%26date%3D2018%26volume%3D670%26spage%3D46%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dan  Zhu</span>, <span class="hlFld-ContribAuthor ">Shuichan  Xu</span>, <span class="hlFld-ContribAuthor ">Gordafaried  Deyanat-Yazdi</span>, <span class="hlFld-ContribAuthor ">Sophie X.  Peng</span>, <span class="hlFld-ContribAuthor ">Leo A.  Barnes</span>, <span class="hlFld-ContribAuthor ">Rama Krishna  Narla</span>, <span class="hlFld-ContribAuthor ">Tam  Tran</span>, <span class="hlFld-ContribAuthor ">David  Mikolon</span>, <span class="hlFld-ContribAuthor ">Yuhong  Ning</span>, <span class="hlFld-ContribAuthor ">Tao  Shi</span>, <span class="hlFld-ContribAuthor ">Ning  Jiang</span>, <span class="hlFld-ContribAuthor ">Heather K.  Raymon</span>, <span class="hlFld-ContribAuthor ">Jennifer R.  Riggs</span>, <span class="hlFld-ContribAuthor ">John F.  Boylan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G
              1
              –S Checkpoint. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2018,</strong> <em>17 </em>
                                    (8)
                                     , 1727-1738. <a href="https://doi.org/10.1158/1535-7163.MCT-17-1084" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-17-1084</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-17-1084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-17-1084%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DSynthetic%252BLethal%252BStrategy%252BIdentifies%252Ba%252BPotent%252Band%252BSelective%252BTTK%252Band%252BCLK1%25252F2%252BInhibitor%252Bfor%252BTreatment%252Bof%252BTriple-Negative%252BBreast%252BCancer%252Bwith%252Ba%252BCompromised%252BG%252B1%252B%2525E2%252580%252593S%252BCheckpoint%26aulast%3DZhu%26aufirst%3DDan%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D8%26spage%3D1727%26epage%3D1738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of TTK inhibitors reportedly in phase I clinical trials. The structure of S 81694 has not been published.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of phenotypic hit <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Disubstituted Pyrimidine Intermediates <b>4a</b>–<b>4u</b> and <b>6a</b>–<b>6g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) SEM-Cl, NaH, DMF, 0–22 °C; (b) R<sub>2</sub>-alcohol, 1, 4-dioxane, NaOtBu, 70–90 °C; (c) R<sub>1</sub>-boronate ester or acid, sodium carbonate in water, PdCl<sub>2</sub>(dppf)-CH<sub>2</sub>Cl<sub>2</sub> or Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, 1, 4-dioxane, 70–90 °C.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 2,4,5-Trisubstituted-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidines <b>7</b>–<b>44</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R<sub>3</sub>-amine, Pd<sub>2</sub>(dba)<sub>3</sub>, Xanphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, MW 150 °C; (b) TFA, DCM; (c) NH<sub>4</sub>OH, MeOH; (d) TBAF, THF, 50 °C.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Biochemical and cellular biomarker potency of compound <b>23</b>, confirming inhibition of TTK and CLK2 and phosphorylation of downstream substrates. (b) Compound <b>23</b> demonstrated preferential antiproliferative activities in TNBC lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Crystal structure of <b>23</b> bound in the TTK ATP pocket, and interactions with residues within 4.0 Å of the ligand are shown (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B4W">6B4W</a>). (b) TTK ATP binding pocket with the ordered portion of the activation loop shown in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vitro wash-out data in Cal-51 cell line of compound <b>23</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/medium/jm-2017-01223f_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cal-51 tumor xenograft studies with q3d (a) and q7d (b) dosing schedules of <b>23</b> (*<i>p</i> < 0.001, one way ANNOVA).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b01223/20171103/images/large/jm-2017-01223f_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01223&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i68">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81564" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81564" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 36 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Swinney, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, J.</span><span> </span><span class="NLM_article-title">How were new medicines discovered?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span><span class="refDoi"> DOI: 10.1038/nrd3480</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1038%2Fnrd3480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=21701501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlCmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=507-519&author=D.+C.+Swinneyauthor=J.+Anthony&title=How+were+new+medicines+discovered%3F&doi=10.1038%2Fnrd3480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">How were new medicines discovered?</span></div><div class="casAuthors">Swinney, David C.; Anthony, Jason</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">507-519</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Preclin. strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biol.-based approaches.  To investigate whether some strategies have been more successful than others in the discovery of new drugs, we analyzed the discovery strategies and the mol. mechanism of action (MMOA) for new mol. entities and new biologics that were approved by the US Food and Drug Administration between 1999 and 2008.  Out of the 259 agents that were approved, 75 were first-in-class drugs with new MMOAs, and out of these, 50 (67%) were small mols. and 25 (33%) were biologics.  The results also show that the contribution of phenotypic screening to the discovery of first-in-class small-mol. drugs exceeded that of target-based approaches - with 28 and 17 of these drugs coming from the two approaches, resp. - in an era in which the major focus was on target-based approaches.  We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE8Ah1iNz76bVg90H21EOLACvtfcHk0lgZ_6yf5HYA5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlCmsbs%253D&md5=7503620f8fbadb0a829f6ea2029936a2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd3480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3480%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26aulast%3DAnthony%26aufirst%3DJ.%26atitle%3DHow%2520were%2520new%2520medicines%2520discovered%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D507%26epage%3D519%26doi%3D10.1038%2Fnrd3480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Eder, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sedrani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span> </span><span class="NLM_article-title">The discovery of first-in-class drugs: origins and evolution</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">587</span><span class="refDoi"> DOI: 10.1038/nrd4336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1038%2Fnrd4336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=25033734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=577-587&author=J.+Ederauthor=R.+Sedraniauthor=C.+Wiesmann&title=The+discovery+of+first-in-class+drugs%3A+origins+and+evolution&doi=10.1038%2Fnrd4336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of first-in-class drugs: origins and evolution</span></div><div class="casAuthors">Eder, Jorg; Sedrani, Richard; Wiesmann, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">577-587</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Anal. of the origins of new drugs approved by the US Food and Drug Administration (FDA) from 1999 to 2008 suggested that phenotypic screening strategies had been more productive than target-based approaches in the discovery of first-in-class small-mol. drugs.  However, given the relatively recent introduction of target-based approaches in the context of the long time frames of drug development, their full impact might not yet have become apparent.  Here, we present an anal. of the origins of all 113 first-in-class drugs approved by the FDA from 1999 to 2013, which shows that the majority (78) were discovered through target-based approaches (45 small-mol. drugs and 33 biologics).  In addn., of 33 drugs identified in the absence of a target hypothesis, 25 were found through a chemocentric approach in which compds. with known pharmacol. served as the starting point, with only eight coming from what we define here as phenotypic screening: testing a large no. of compds. in a target-agnostic assay that monitors phenotypic changes.  We also discuss the implications for drug discovery strategies, including viewing phenotypic screening as a novel discipline rather than as a neoclassical approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqthEelveRWN7Vg90H21EOLACvtfcHk0liKXXxEL-FyYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7I&md5=b2061d96a71893a329b5b654acec5420</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd4336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4336%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DJ.%26aulast%3DSedrani%26aufirst%3DR.%26aulast%3DWiesmann%26aufirst%3DC.%26atitle%3DThe%2520discovery%2520of%2520first-in-class%2520drugs%253A%2520origins%2520and%2520evolution%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D577%26epage%3D587%26doi%3D10.1038%2Fnrd4336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Moffat, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, D.</span><span> </span><span class="NLM_article-title">Phenotypic screening in cancer drug discovery - past, present and future</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">588</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span><span class="refDoi"> DOI: 10.1038/nrd4366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1038%2Fnrd4366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=25033736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=588-602&author=J.+G.+Moffatauthor=J.+Rudolphauthor=D.+Bailey&title=Phenotypic+screening+in+cancer+drug+discovery+-+past%2C+present+and+future&doi=10.1038%2Fnrd4366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic screening in cancer drug discovery - past, present and future</span></div><div class="casAuthors">Moffat, John G.; Rudolph, Joachim; Bailey, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">588-602</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches.  Given that oncol. is currently the most active therapeutic area, and also one in which target-focused approaches have been particularly prominent in the past two decades, we investigated the contribution of phenotypic assays to oncol. drug discovery by analyzing the origins of all new small-mol. cancer drugs approved by the US Food and Drug Administration (FDA) over the past 15 years and those currently in clin. development.  Although the majority of these drugs originated from target-based discovery, we identified a significant no. whose discovery depended on phenotypic screening approaches.  We postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes.  However, tech. and biol. advances that enable such mechanistically informed phenotypic models have the potential to empower phenotypic drug discovery in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTWtoTIgWqvbVg90H21EOLACvtfcHk0liKXXxEL-FyYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7L&md5=0e8efed90e5bc4b47f959b83a6ab5b96</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd4366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4366%26sid%3Dliteratum%253Aachs%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DD.%26atitle%3DPhenotypic%2520screening%2520in%2520cancer%2520drug%2520discovery%2520-%2520past%252C%2520present%2520and%2520future%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D588%26epage%3D602%26doi%3D10.1038%2Fnrd4366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Lehmann, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanders, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarthy, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shyr, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietenpol, J. A.</span><span> </span><span class="NLM_article-title">Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">2750</span><span class="NLM_x">–</span> <span class="NLM_lpage">2767</span><span class="refDoi"> DOI: 10.1172/JCI45014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1172%2FJCI45014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=21633166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVKgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=2750-2767&author=B.+D.+Lehmannauthor=J.+A.+Bauerauthor=X.+Chenauthor=M.+E.+Sandersauthor=A.+B.+Chakravarthyauthor=Y.+Shyrauthor=J.+A.+Pietenpol&title=Identification+of+human+triple-negative+breast+cancer+subtypes+and+preclinical+models+for+selection+of+targeted+therapies&doi=10.1172%2FJCI45014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</span></div><div class="casAuthors">Lehmann, Brian D.; Bauer, Joshua A.; Chen, Xi; Sanders, Melinda E.; Chakravarthy, A. Bapsi; Shyr, Yu; Pietenpol, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2750-2767</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a highly diverse group of cancers, and subtyping is necessary to better identify mol.-based therapies.  In this study, we analyzed gene expression (GE) profiles from 21 breast cancer data sets and identified 587 TNBC cases.  Cluster anal. identified 6 TNBC subtypes displaying unique GE and ontologies, including 2 basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR) subtype.  Further, GE anal. allowed us to identify TNBC cell line models representative of these subtypes.  Predicted "driver" signaling pathways were pharmacol. targeted in these cell line models as proof of concept that anal. of distinct GE signatures can inform therapy selection.  BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines preferentially responded to cisplatin.  M and MSL subtypes were enriched in GE for epithelial-mesenchymal transition, and growth factor pathways and cell models responded to NVP-BEZ235 (a PI3K/mTOR inhibitor) and dasatinib (an abl/src inhibitor).  The LAR subtype includes patients with decreased relapse-free survival and was characterized by androgen receptor (AR) signaling.  LAR cell lines were uniquely sensitive to bicalutamide (an AR antagonist).  These data may be useful in biomarker selection, drug discovery, and clin. trial design that will enable alignment of TNBC patients to appropriate targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbhoQQUFogW7Vg90H21EOLACvtfcHk0liKXXxEL-FyYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVKgu78%253D&md5=c3681c79e0b972f16f6d5a5ecdc99fec</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1172%2FJCI45014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI45014%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DBauer%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSanders%26aufirst%3DM.%2BE.%26aulast%3DChakravarthy%26aufirst%3DA.%2BB.%26aulast%3DShyr%26aufirst%3DY.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DIdentification%2520of%2520human%2520triple-negative%2520breast%2520cancer%2520subtypes%2520and%2520preclinical%2520models%2520for%2520selection%2520of%2520targeted%2520therapies%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D2750%26epage%3D2767%26doi%3D10.1172%2FJCI45014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Calabrese, A. C.; Jeffy, B.; Robinson, D.; Zhu, D.; Huang, D.; Elsner, J.; Boylan, J.; Tehrani, L.; Nagy, M. A.; Raheja, R. K.; Erdman, P.; Narla, R. K.; Harris, R. L.; Tran, T. M.; Riggs, J.; Ning, Y.; Xu, S.</span><span> </span><span class="NLM_article-title">Substituted Pyrrolopyrimidine Compounds, Compositions Thereof, and Methods of Treatment Therewith</span>. U.S. Patent 9,346,812, May 24,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=A.+C.+Calabrese&author=B.+Jeffy&author=D.+Robinson&author=D.+Zhu&author=D.+Huang&author=J.+Elsner&author=J.+Boylan&author=L.+Tehrani&author=M.+A.+Nagy&author=R.+K.+Raheja&author=P.+Erdman&author=R.+K.+Narla&author=R.+L.+Harris&author=T.+M.+Tran&author=J.+Riggs&author=Y.+Ning&author=S.+Xu&title=Substituted+Pyrrolopyrimidine+Compounds%2C+Compositions+Thereof%2C+and+Methods+of+Treatment+Therewith"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCalabrese%26aufirst%3DA.%2BC.%26atitle%3DSubstituted%2520Pyrrolopyrimidine%2520Compounds%252C%2520Compositions%2520Thereof%252C%2520and%2520Methods%2520of%2520Treatment%2520Therewith%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Zhu, D.; Boylan, J.; Xu, S.; Riggs, J.; Shi, T.; Wurmser, A.; Mikolon, D.; Deyanat-Yazdi, G.</span><span> </span><span class="NLM_article-title">Methods of Treating a Cancer Using Substituted Pyrrolopyrimidine Compounds, Compositions Therof</span>. U.S. Patent 9,623,028, April 18,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=D.+Zhu&author=J.+Boylan&author=S.+Xu&author=J.+Riggs&author=T.+Shi&author=A.+Wurmser&author=D.+Mikolon&author=G.+Deyanat-Yazdi&title=Methods+of+Treating+a+Cancer+Using+Substituted+Pyrrolopyrimidine+Compounds%2C+Compositions+Therof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DD.%26atitle%3DMethods%2520of%2520Treating%2520a%2520Cancer%2520Using%2520Substituted%2520Pyrrolopyrimidine%2520Compounds%252C%2520Compositions%2520Therof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Hiruma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacristan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachis, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuijt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubbink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Castelmur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrakis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kops, G. J.</span><span> </span><span class="NLM_article-title">Cell division cycle. Competition between MPS1 and microtubules at kinetochores regulates spindle checkpoint signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">1264</span><span class="NLM_x">–</span> <span class="NLM_lpage">1267</span><span class="refDoi"> DOI: 10.1126/science.aaa4055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1126%2Fscience.aaa4055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=1264-1267&author=Y.+Hirumaauthor=C.+Sacristanauthor=S.+T.+Pachisauthor=A.+Adamopoulosauthor=T.+Kuijtauthor=M.+Ubbinkauthor=E.+von+Castelmurauthor=A.+Perrakisauthor=G.+J.+Kops&title=Cell+division+cycle.+Competition+between+MPS1+and+microtubules+at+kinetochores+regulates+spindle+checkpoint+signaling&doi=10.1126%2Fscience.aaa4055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaa4055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaa4055%26sid%3Dliteratum%253Aachs%26aulast%3DHiruma%26aufirst%3DY.%26aulast%3DSacristan%26aufirst%3DC.%26aulast%3DPachis%26aufirst%3DS.%2BT.%26aulast%3DAdamopoulos%26aufirst%3DA.%26aulast%3DKuijt%26aufirst%3DT.%26aulast%3DUbbink%26aufirst%3DM.%26aulast%3Dvon%2BCastelmur%26aufirst%3DE.%26aulast%3DPerrakis%26aufirst%3DA.%26aulast%3DKops%26aufirst%3DG.%2BJ.%26atitle%3DCell%2520division%2520cycle.%2520Competition%2520between%2520MPS1%2520and%2520microtubules%2520at%2520kinetochores%2520regulates%2520spindle%2520checkpoint%2520signaling%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D1264%26epage%3D1267%26doi%3D10.1126%2Fscience.aaa4055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Janssen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kops, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medema, R. H.</span><span> </span><span class="NLM_article-title">Targeting the mitotic checkpoint to kill tumor cells</span> <span class="citation_source-journal">Horm. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1007/s12672-010-0059-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1007%2Fs12672-010-0059-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=21475725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnot1Wkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=113-116&author=A.+Janssenauthor=G.+J.+Kopsauthor=R.+H.+Medema&title=Targeting+the+mitotic+checkpoint+to+kill+tumor+cells&doi=10.1007%2Fs12672-010-0059-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the mitotic checkpoint to kill tumor cells</span></div><div class="casAuthors">Janssen Aniek; Kops Geert J; Medema Rene H</div><div class="citationInfo"><span class="NLM_cas:title">Hormones & cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">One of the most common hallmarks of cancer cells is aneuploidy or an abnormal number of chromosomes.  This abnormal chromosome content is a consequence of chromosome missegregation during mitosis, a defect that is seen more frequently in tumor cell divisions as in normal cell divisions.  In fact, a large fraction of human tumors display a chromosome instable phenotype, meaning that they very frequently missegregate chromosomes.  This can cause variegated aneuploidy within the tumor tissue.  It has been argued that this hallmark of cancer could be exploited in anti-cancer therapies.  Here we test this hypothesis by inactivation of the mitotic checkpoint through RNAi-mediated depletion of an essential checkpoint component, Mps1.  The mitotic checkpoint delays segregation of chromosomes during mitosis until all chromosomes are properly attached to the mitotic spindle.  Its inactivation will therefore lead to increased segregation errors.  Indeed, we show that this can lead to increased cell death in tumor cells.  We demonstrate that increased cell death is associated with a dramatic increase in segregation errors.  This suggests that inhibition of the mitotic checkpoint might represent a useful anti-cancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTx5ZlxKChceNts4TFFB11gfW6udTcc2eYa5lRo6w2r27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnot1Wkug%253D%253D&md5=7ea1be16c9e26670ce447b0caca260c3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs12672-010-0059-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12672-010-0059-x%26sid%3Dliteratum%253Aachs%26aulast%3DJanssen%26aufirst%3DA.%26aulast%3DKops%26aufirst%3DG.%2BJ.%26aulast%3DMedema%26aufirst%3DR.%2BH.%26atitle%3DTargeting%2520the%2520mitotic%2520checkpoint%2520to%2520kill%2520tumor%2520cells%26jtitle%3DHorm.%2520Cancer%26date%3D2011%26volume%3D2%26spage%3D113%26epage%3D116%26doi%3D10.1007%2Fs12672-010-0059-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Colombo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldarelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mennecozzi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giorgini, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sola, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappella, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrera, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depaolini, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cucchi, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colotta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J.</span><span> </span><span class="NLM_article-title">Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">10255</span><span class="NLM_x">–</span> <span class="NLM_lpage">10264</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1158%2F0008-5472.CAN-10-2101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=21159646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGrt7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=10255-10264&author=R.+Colomboauthor=M.+Caldarelliauthor=M.+Mennecozziauthor=M.+L.+Giorginiauthor=F.+Solaauthor=P.+Cappellaauthor=C.+Perreraauthor=S.+R.+Depaoliniauthor=L.+Rusconiauthor=U.+Cucchiauthor=N.+Avanziauthor=J.+A.+Bertrandauthor=R.+T.+Bossiauthor=E.+Pesentiauthor=A.+Galvaniauthor=A.+Isacchiauthor=F.+Colottaauthor=D.+Donatiauthor=J.+Moll&title=Targeting+the+mitotic+checkpoint+for+cancer+therapy+with+NMS-P715%2C+an+inhibitor+of+MPS1+kinase&doi=10.1158%2F0008-5472.CAN-10-2101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase</span></div><div class="casAuthors">Colombo, Riccardo; Caldarelli, Marina; Mennecozzi, Milena; Giorgini, Maria Laura; Sola, Francesco; Cappella, Paolo; Perrera, Claudia; Depaolini, Stefania Re; Rusconi, Luisa; Cucchi, Ulisse; Avanzi, Nilla; Bertrand, Jay Aaron; Bossi, Roberto Tiberio; Pesenti, Enrico; Galvani, Arturo; Isacchi, Antonella; Colotta, Francesco; Donati, Daniele; Moll, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10255-10264</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">MPS1 kinase is a key regulator of the spindle assembly checkpoint (SAC), a mitotic mechanism specifically required for proper chromosomal alignment and segregation.  It has been found aberrantly overexpressed in a wide range of human tumors and is necessary for tumoral cell proliferation.  Here the authors report the identification and characterization of NMS-P715, a selective and orally bioavailable MPS1 small-mol. inhibitor, which selectively reduces cancer cell proliferation, leaving normal cells almost unaffected.  NMS-P715 accelerates mitosis and affects kinetochore components localization causing massive aneuploidy and cell death in a variety of tumoral cell lines and inhibits tumor growth in preclin. cancer models.  Inhibiting the SAC could represent a promising new approach to selectively target cancer cells.  Cancer Res; 70(24); 10255-64.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJeGyiQf0_uLVg90H21EOLACvtfcHk0lgYlsG6q_JwfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGrt7bK&md5=6478b34886d1d2f2a364d142bbd388fe</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2101%26sid%3Dliteratum%253Aachs%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DCaldarelli%26aufirst%3DM.%26aulast%3DMennecozzi%26aufirst%3DM.%26aulast%3DGiorgini%26aufirst%3DM.%2BL.%26aulast%3DSola%26aufirst%3DF.%26aulast%3DCappella%26aufirst%3DP.%26aulast%3DPerrera%26aufirst%3DC.%26aulast%3DDepaolini%26aufirst%3DS.%2BR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DCucchi%26aufirst%3DU.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DColotta%26aufirst%3DF.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DMoll%26aufirst%3DJ.%26atitle%3DTargeting%2520the%2520mitotic%2520checkpoint%2520for%2520cancer%2520therapy%2520with%2520NMS-P715%252C%2520an%2520inhibitor%2520of%2520MPS1%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D10255%26epage%3D10264%26doi%3D10.1158%2F0008-5472.CAN-10-2101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Maire, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldeyron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tesson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent-Salomon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gravier, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marty-Prouvost, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Koning, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigaill, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumont, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentien, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barillot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roman-Roman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruzalegui, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubois, T.</span><span> </span><span class="NLM_article-title">TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e63712</span><span class="refDoi"> DOI: 10.1371/journal.pone.0063712</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1371%2Fjournal.pone.0063712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=23700430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslamtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e63712&author=V.+Maireauthor=C.+Baldeyronauthor=M.+Richardsonauthor=B.+Tessonauthor=A.+Vincent-Salomonauthor=E.+Gravierauthor=B.+Marty-Prouvostauthor=L.+De+Koningauthor=G.+Rigaillauthor=A.+Dumontauthor=D.+Gentienauthor=E.+Barillotauthor=S.+Roman-Romanauthor=S.+Depilauthor=F.+Cruzaleguiauthor=A.+Pierreauthor=G.+C.+Tuckerauthor=T.+Dubois&title=TTK%2FhMPS1+is+an+attractive+therapeutic+target+for+triple-negative+breast+cancer&doi=10.1371%2Fjournal.pone.0063712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer</span></div><div class="casAuthors">Maire, Virginie; Baldeyron, Celine; Richardson, Marion; Tesson, Bruno; Vincent-Salomon, Anne; Gravier, Eleonore; Marty-Prouvost, Berengere; De Koning, Leanne; Rigaill, Guillem; Dumont, Aurelie; Gentien, David; Barillot, Emmanuel; Roman-Roman, Sergio; Depil, Stephane; Cruzalegui, Francisco; Pierre, Alain; Tucker, Gordon C.; Dubois, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e63712</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) represents a subgroup of breast cancers (BC) assocd. with the most aggressive clin. behavior.  No targeted therapy is currently available for the treatment of patients with TNBC.  In order to discover potential therapeutic targets, we searched for protein kinases that are overexpressed in human TNBC biopsies and whose silencing in TNBC cell lines causes cell death.  A cohort including human BC biopsies obtained at Institut Curie as well as normal tissues has been analyzed at a gene-expression level.  The data revealed that the human protein kinase monopolar spindle 1 (hMPS1), also known as TTK and involved in mitotic checkpoint, is specifically overexpressed in TNBC, compared to the other BC subgroups and healthy tissues.  We confirmed by immunohistochem. and reverse phase protein array that TNBC expressed higher levels of TTK protein compared to the other BC subgroups.  We then detd. the biol. effects of TTK depletion by RNA interference, through analyses of tumorigenic capacity and cell viability in different human TNBC cell lines.  We found that RNAi-mediated depletion of TTK in various TNBC cell lines severely compromised their viability and their ability to form colonies in an anchorage-independent manner.  Moreover, we obsd. that TTK silencing led to an increase in H2AX phosphorylation, activation of caspases 3/7, sub-G1 cell population accumulation and high annexin V staining, as well as to a decrease in G1 phase cell population and an increased aneuploidy.  Altogether, these data indicate that TTK depletion in TNBC cells induces apoptosis.  These results point out TTK as a protein kinase overexpressed in TNBC that may represent an attractive therapeutic target specifically for this poor prognosis assocd. subgroup of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCemS4PKt5pLVg90H21EOLACvtfcHk0ljuIINaSiyz2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslamtrs%253D&md5=21e30c2ca30b75839c07e13cdd19d897</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0063712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0063712%26sid%3Dliteratum%253Aachs%26aulast%3DMaire%26aufirst%3DV.%26aulast%3DBaldeyron%26aufirst%3DC.%26aulast%3DRichardson%26aufirst%3DM.%26aulast%3DTesson%26aufirst%3DB.%26aulast%3DVincent-Salomon%26aufirst%3DA.%26aulast%3DGravier%26aufirst%3DE.%26aulast%3DMarty-Prouvost%26aufirst%3DB.%26aulast%3DDe%2BKoning%26aufirst%3DL.%26aulast%3DRigaill%26aufirst%3DG.%26aulast%3DDumont%26aufirst%3DA.%26aulast%3DGentien%26aufirst%3DD.%26aulast%3DBarillot%26aufirst%3DE.%26aulast%3DRoman-Roman%26aufirst%3DS.%26aulast%3DDepil%26aufirst%3DS.%26aulast%3DCruzalegui%26aufirst%3DF.%26aulast%3DPierre%26aufirst%3DA.%26aulast%3DTucker%26aufirst%3DG.%2BC.%26aulast%3DDubois%26aufirst%3DT.%26atitle%3DTTK%252FhMPS1%2520is%2520an%2520attractive%2520therapeutic%2520target%2520for%2520triple-negative%2520breast%2520cancer%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De63712%26doi%3D10.1371%2Fjournal.pone.0063712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Huang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shieh, S. Y.</span><span> </span><span class="NLM_article-title">TTK/hMps1 mediates the p53-dependent postmitotic checkpoint by phosphorylating p53 at Thr18</span> <span class="citation_source-journal">Mol. Cell. Bio.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2935</span><span class="NLM_x">–</span> <span class="NLM_lpage">2944</span><span class="refDoi"> DOI: 10.1128/MCB.01837-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1128%2FMCB.01837-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=19332559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmvVCqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=2935-2944&author=Y.+F.+Huangauthor=M.+D.+Changauthor=S.+Y.+Shieh&title=TTK%2FhMps1+mediates+the+p53-dependent+postmitotic+checkpoint+by+phosphorylating+p53+at+Thr18&doi=10.1128%2FMCB.01837-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">TTK/hMps1 mediates the p53-dependent postmitotic checkpoint by phosphorylating p53 at Thr18</span></div><div class="casAuthors">Huang, Yi-Fu; Chang, Margaret Dah-Tsyr; Shieh, Sheau-Yann</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2935-2944</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Upon prolonged arrest in mitosis, cells undergo adaptation and exit mitosis without cell division.  These tetraploid cells are either eliminated by apoptosis or arrested in the subsequent G1 phase in a spindle checkpoint- and p53-dependent manner.  P53 has long been known to be activated by spindle poisons, such as nocodazole and Taxol, although the underlying mechanism remains elusive.  Here we present evidence that stabilization and activation of p53 by spindle disruption requires the spindle checkpoint kinase TTK/hMps1.  TTK/hMps1 phosphorylates the N-terminal domain of p53 at Thr18, and this phosphorylation disrupts the interaction with MDM2 and abrogates MDM2-mediated p53 ubiquitination.  Phosphorylation at Thr18 enhances p53-dependent activation of not only p21 but also Lats2, two mediators of the postmitotic checkpoint.  Furthermore, a phospho-mimicking substitution at Thr18 (T18D) is more competent than the phospho-deficient mutant (T18A) in rescuing the tetraploid checkpoint defect of p53-depleted cells.  Our findings therefore provide a mechanism connecting the spindle checkpoint with p53 in the maintenance of genome stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOjZaulBvOZrVg90H21EOLACvtfcHk0ljuIINaSiyz2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmvVCqsLw%253D&md5=608e4070bd4f5c6cf0d7f2767cdf49a9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FMCB.01837-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01837-08%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%2BF.%26aulast%3DChang%26aufirst%3DM.%2BD.%26aulast%3DShieh%26aufirst%3DS.%2BY.%26atitle%3DTTK%252FhMps1%2520mediates%2520the%2520p53-dependent%2520postmitotic%2520checkpoint%2520by%2520phosphorylating%2520p53%2520at%2520Thr18%26jtitle%3DMol.%2520Cell.%2520Bio.%26date%3D2009%26volume%3D29%26spage%3D2935%26epage%3D2944%26doi%3D10.1128%2FMCB.01837-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Yu, Z. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shieh, S. Y.</span><span> </span><span class="NLM_article-title">Requirement for human Mps1/TTK in oxidative DNA damage repair and cell survival through MDM2 phosphorylation</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1133</span><span class="NLM_x">–</span> <span class="NLM_lpage">1150</span><span class="refDoi"> DOI: 10.1093/nar/gkv1173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1093%2Fnar%2Fgkv1173" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=1133-1150&author=Z.+C.+Yuauthor=Y.+F.+Huangauthor=S.+Y.+Shieh&title=Requirement+for+human+Mps1%2FTTK+in+oxidative+DNA+damage+repair+and+cell+survival+through+MDM2+phosphorylation&doi=10.1093%2Fnar%2Fgkv1173"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkv1173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkv1173%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DZ.%2BC.%26aulast%3DHuang%26aufirst%3DY.%2BF.%26aulast%3DShieh%26aufirst%3DS.%2BY.%26atitle%3DRequirement%2520for%2520human%2520Mps1%252FTTK%2520in%2520oxidative%2520DNA%2520damage%2520repair%2520and%2520cell%2520survival%2520through%2520MDM2%2520phosphorylation%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2016%26volume%3D44%26spage%3D1133%26epage%3D1150%26doi%3D10.1093%2Fnar%2Fgkv1173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Laufer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brokx, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beletskaya, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotnikova, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awrey, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiarash, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madeira, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, H. W.</span><span> </span><span class="NLM_article-title">Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of tyrosine threonine kinase, TTK</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3562</span><span class="NLM_x">–</span> <span class="NLM_lpage">3566</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1016%2Fj.bmcl.2016.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=27335255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKgtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3562-3566&author=R.+Lauferauthor=S.+W.+Liauthor=Y.+Liuauthor=G.+Ngauthor=Y.+Langauthor=M.+Feherauthor=R.+Brokxauthor=I.+Beletskayaauthor=R.+Hodgsonauthor=G.+Maoauthor=O.+Plotnikovaauthor=D.+E.+Awreyauthor=J.+M.+Masonauthor=X.+Weiauthor=D.+C.+Linauthor=Y.+Cheauthor=R.+Kiarashauthor=B.+Madeiraauthor=G.+C.+Fletcherauthor=T.+W.+Makauthor=M.+R.+Brayauthor=H.+W.+Pauls&title=Discovery+of+4-%284-aminopyrazolo%5B1%2C5-a%5D%5B1%2C3%2C5%5Dtriazin-8-yl%29benzamides+as+novel%2C+highly+potent+and+selective%2C+orally+bioavailable+inhibitors+of+tyrosine+threonine+kinase%2C+TTK&doi=10.1016%2Fj.bmcl.2016.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK</span></div><div class="casAuthors">Laufer, Radoslaw; Li, Sze-Wan; Liu, Yong; Ng, Grace; Lang, Yunhui; Feher, Miklos; Brokx, Richard; Beletskaya, Irina; Hodgson, Richard; Mao, Guodong; Plotnikova, Olga; Awrey, Donald E.; Mason, Jacqueline M.; Wei, Xin; Lin, Dan Chi-Chia; Che, Yi; Kiarash, Reza; Madeira, Brian; Fletcher, Graham C.; Mak, Tak W.; Bray, Mark R.; Pauls, Henry W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3562-3566</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">TTK/Mps1 is a key kinase controlling progression of cell division via participation in the mitotic spindle assembly checkpoint and is overexpressed in a no. of human cancers.  Herein the authors report the discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as a potent, novel class of TTK inhibitors.  The series was identified by bioisosteric replacement of the related imidazopyrazine and imidazopyridazine scaffolds.  Optimization led to the identification of compds. with excellent potency (Ki = 0.8 nM) and exceptional kinase selectivity.  The SAR indicates a strong dependence of activity on the presence of the N-cyclopropyl-2-methylbenzamide moiety delineating the geometry for 11/2 type kinase inhibitor.  Mol. modeling indicates the extensive and optimal contacts, mediated through H-bonds and hydrophobic interactions, are responsible for the selectivity and potency of the inhibitors.  The compds. demonstrate a strong anti-proliferative activity in a panel of human cancer cell lines (HCT116 GIC50 <15 nM) and good rodent pharmacokinetics (oral %F 97%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTb2Z2xtkAWLVg90H21EOLACvtfcHk0lh5FegRPlvXfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKgtLnL&md5=d107d562ed4407d05bfbba57abcd6b98</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DNg%26aufirst%3DG.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DBrokx%26aufirst%3DR.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DMao%26aufirst%3DG.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DD.%2BC.%26aulast%3DChe%26aufirst%3DY.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DMadeira%26aufirst%3DB.%26aulast%3DFletcher%26aufirst%3DG.%2BC.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DBray%26aufirst%3DM.%2BR.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DDiscovery%2520of%25204-%25284-aminopyrazolo%255B1%252C5-a%255D%255B1%252C3%252C5%255Dtriazin-8-yl%2529benzamides%2520as%2520novel%252C%2520highly%2520potent%2520and%2520selective%252C%2520orally%2520bioavailable%2520inhibitors%2520of%2520tyrosine%2520threonine%2520kinase%252C%2520TTK%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3562%26epage%3D3566%26doi%3D10.1016%2Fj.bmcl.2016.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Laufer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awrey, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beletskaya, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotnikova, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiarash, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris-Brandts, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ban, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadeem, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirgadze, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, H. W.</span><span> </span><span class="NLM_article-title">Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4968</span><span class="NLM_x">–</span> <span class="NLM_lpage">4997</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.06.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1016%2Fj.bmc.2014.06.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=25043312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyjt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=4968-4997&author=R.+Lauferauthor=G.+Ngauthor=Y.+Liuauthor=N.+K.+Patelauthor=L.+G.+Edwardsauthor=Y.+Langauthor=S.+W.+Liauthor=M.+Feherauthor=D.+E.+Awreyauthor=G.+Leungauthor=I.+Beletskayaauthor=O.+Plotnikovaauthor=J.+M.+Masonauthor=R.+Hodgsonauthor=X.+Weiauthor=G.+Maoauthor=X.+Luoauthor=P.+Huangauthor=E.+Greenauthor=R.+Kiarashauthor=D.+C.+Linauthor=M.+Harris-Brandtsauthor=F.+Banauthor=V.+Nadeemauthor=T.+W.+Makauthor=G.+J.+Panauthor=W.+Qiuauthor=N.+Y.+Chirgadzeauthor=H.+W.+Pauls&title=Discovery+of+inhibitors+of+the+mitotic+kinase+TTK+based+on+N-%283-%283-sulfamoylphenyl%29-1H-indazol-5-yl%29-acetamides+and+carboxamides&doi=10.1016%2Fj.bmc.2014.06.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamides and carboxamides</span></div><div class="casAuthors">Laufer, Radoslaw; Ng, Grace; Liu, Yong; Patel, Narendra Kumar B.; Edwards, Louise G.; Lang, Yunhui; Li, Sze-Wan; Feher, Miklos; Awrey, Don E.; Leung, Genie; Beletskaya, Irina; Plotnikova, Olga; Mason, Jacqueline M.; Hodgson, Richard; Wei, Xin; Mao, Guodong; Luo, Xunyi; Huang, Ping; Green, Erin; Kiarash, Reza; Lin, Dan Chi-Chia; Harris-Brandts, Marees; Ban, Fuqiang; Nadeem, Vincent; Mak, Tak W.; Pan, Guohua J.; Qiu, Wei; Chirgadze, Nickolay Y.; Pauls, Henry W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4968-4997</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">TTK kinase was identified by inhouse siRNA screen and pursued as a tractable, novel target for cancer treatment.  A screening campaign and systematic optimization, supported by computer modeling led to an indazole core with key sulfamoylphenyl and acetamido moieties at positions 3 and 5, resp., establishing a novel chem. class culminating in identification of I (CFI-400936).  This potent inhibitor of TTK (IC50 = 3.6 nM) demonstrated good activity in cell based assay and selectivity against a panel of human kinases.  A complex TTK x-ray crystal structure and results of a xenograft study with TTK inhibitors from this class are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYMVdifCP5IrVg90H21EOLACvtfcHk0lh5FegRPlvXfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyjt7fK&md5=71dac8de6f21ee67d1c18fd4e521a4f9</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.06.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.06.027%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DNg%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPatel%26aufirst%3DN.%2BK.%26aulast%3DEdwards%26aufirst%3DL.%2BG.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DLeung%26aufirst%3DG.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DMao%26aufirst%3DG.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DGreen%26aufirst%3DE.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DD.%2BC.%26aulast%3DHarris-Brandts%26aufirst%3DM.%26aulast%3DBan%26aufirst%3DF.%26aulast%3DNadeem%26aufirst%3DV.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DPan%26aufirst%3DG.%2BJ.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DChirgadze%26aufirst%3DN.%2BY.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DDiscovery%2520of%2520inhibitors%2520of%2520the%2520mitotic%2520kinase%2520TTK%2520based%2520on%2520N-%25283-%25283-sulfamoylphenyl%2529-1H-indazol-5-yl%2529-acetamides%2520and%2520carboxamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D4968%26epage%3D4997%26doi%3D10.1016%2Fj.bmc.2014.06.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampson, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ban, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awrey, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beletskaya, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotnikova, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirgadze, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiarash, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madeira, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, H. W.</span><span> </span><span class="NLM_article-title">The discovery of orally bioavailable tyrosine threonine kinase (TTK) inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as anticancer agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3366</span><span class="NLM_x">–</span> <span class="NLM_lpage">3392</span><span class="refDoi"> DOI: 10.1021/jm501740a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501740a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3366-3392&author=Y.+Liuauthor=Y.+Langauthor=N.+K.+Patelauthor=G.+Ngauthor=R.+Lauferauthor=S.+W.+Liauthor=L.+Edwardsauthor=B.+Forrestauthor=P.+B.+Sampsonauthor=M.+Feherauthor=F.+Banauthor=D.+E.+Awreyauthor=I.+Beletskayaauthor=G.+Maoauthor=R.+Hodgsonauthor=O.+Plotnikovaauthor=W.+Qiuauthor=N.+Y.+Chirgadzeauthor=J.+M.+Masonauthor=X.+Weiauthor=D.+C.+Linauthor=Y.+Cheauthor=R.+Kiarashauthor=B.+Madeiraauthor=G.+C.+Fletcherauthor=T.+W.+Makauthor=M.+R.+Brayauthor=H.+W.+Pauls&title=The+discovery+of+orally+bioavailable+tyrosine+threonine+kinase+%28TTK%29+inhibitors%3A+3-%284-%28heterocyclyl%29phenyl%29-1H-indazole-5-carboxamides+as+anticancer+agents&doi=10.1021%2Fjm501740a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm501740a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501740a%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DPatel%26aufirst%3DN.%2BK.%26aulast%3DNg%26aufirst%3DG.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DEdwards%26aufirst%3DL.%26aulast%3DForrest%26aufirst%3DB.%26aulast%3DSampson%26aufirst%3DP.%2BB.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DBan%26aufirst%3DF.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DMao%26aufirst%3DG.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DChirgadze%26aufirst%3DN.%2BY.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DD.%2BC.%26aulast%3DChe%26aufirst%3DY.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DMadeira%26aufirst%3DB.%26aulast%3DFletcher%26aufirst%3DG.%2BC.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DBray%26aufirst%3DM.%2BR.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DThe%2520discovery%2520of%2520orally%2520bioavailable%2520tyrosine%2520threonine%2520kinase%2520%2528TTK%2529%2520inhibitors%253A%25203-%25284-%2528heterocyclyl%2529phenyl%2529-1H-indazole-5-carboxamides%2520as%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3366%26epage%3D3392%26doi%3D10.1021%2Fjm501740a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampson, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brokx, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beletskaya, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotnikova, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awrey, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirgadze, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiarash, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, H. W.</span><span> </span><span class="NLM_article-title">Discovery of pyrazolo[1,5-a]pyrimidine TTK inhibitors: CFI-402257 is a potent, selective, bioavailable anticancer agent</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">675</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00485</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00485" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC28Xntl2isLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=671-675&author=Y.+Liuauthor=R.+Lauferauthor=N.+K.+Patelauthor=G.+Ngauthor=P.+B.+Sampsonauthor=S.+W.+Liauthor=Y.+Langauthor=M.+Feherauthor=R.+Brokxauthor=I.+Beletskayaauthor=R.+Hodgsonauthor=O.+Plotnikovaauthor=D.+E.+Awreyauthor=W.+Qiuauthor=N.+Y.+Chirgadzeauthor=J.+M.+Masonauthor=X.+Weiauthor=D.+C.+Linauthor=Y.+Cheauthor=R.+Kiarashauthor=G.+C.+Fletcherauthor=T.+W.+Makauthor=M.+R.+Brayauthor=H.+W.+Pauls&title=Discovery+of+pyrazolo%5B1%2C5-a%5Dpyrimidine+TTK+inhibitors%3A+CFI-402257+is+a+potent%2C+selective%2C+bioavailable+anticancer+agent&doi=10.1021%2Facsmedchemlett.5b00485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent</span></div><div class="casAuthors">Liu, Yong; Laufer, Radoslaw; Patel, Narendra Kumar; Ng, Grace; Sampson, Peter B.; Li, Sze-Wan; Lang, Yunhui; Feher, Miklos; Brokx, Richard; Beletskaya, Irina; Hodgson, Richard; Plotnikova, Olga; Awrey, Donald E.; Qiu, Wei; Chirgadze, Nickolay Y.; Mason, Jacqueline M.; Wei, Xin; Lin, Dan Chi-Chia; Che, Yi; Kiarash, Reza; Fletcher, Graham C.; Mak, Tak W.; Bray, Mark R.; Pauls, Henry W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">671-675</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This work describes a scaffold hopping exercise that begins with known imidazo[1,2-a]pyrazines, briefly explores pyrazolo[1,5-a][1,3,5]triazines, and ultimately yields pyrazolo[1,5-a]pyrimidines as a novel class of potent TTK inhibitors.  An X-ray structure of a representative compd. is consistent with 11/2 type inhibition and provides structural insight to aid subsequent optimization of in vitro activity and physicochem. and pharmacokinetic properties.  Incorporation of polar moieties in the hydrophobic and solvent accessible regions modulates physicochem. properties while maintaining potency.  Compds. with enhanced oral exposure were identified for xenograft studies.  The work culminates in the identification of a potent (TTK Ki = 0.1 nM), highly selective, orally bioavailable anticancer agent (CFI-402257) for IND enabling studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8YPAge-MdqLVg90H21EOLACvtfcHk0lhyX3oKch2WsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xntl2isLo%253D&md5=3eb4e1971e0c0a73e6eee657ac9d6fe0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00485%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DN.%2BK.%26aulast%3DNg%26aufirst%3DG.%26aulast%3DSampson%26aufirst%3DP.%2BB.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DBrokx%26aufirst%3DR.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DChirgadze%26aufirst%3DN.%2BY.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DD.%2BC.%26aulast%3DChe%26aufirst%3DY.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DFletcher%26aufirst%3DG.%2BC.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DBray%26aufirst%3DM.%2BR.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DDiscovery%2520of%2520pyrazolo%255B1%252C5-a%255Dpyrimidine%2520TTK%2520inhibitors%253A%2520CFI-402257%2520is%2520a%2520potent%252C%2520selective%252C%2520bioavailable%2520anticancer%2520agent%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D671%26epage%3D675%26doi%3D10.1021%2Facsmedchemlett.5b00485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Mason, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiarash, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brokx, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beletskaya, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span> </span><span class="NLM_article-title">Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">3127</span><span class="NLM_x">–</span> <span class="NLM_lpage">3132</span><span class="refDoi"> DOI: 10.1073/pnas.1700234114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1073%2Fpnas.1700234114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=28270606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvVyjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=3127-3132&author=J.+M.+Masonauthor=X.+Weiauthor=G.+C.+Fletcherauthor=R.+Kiarashauthor=R.+Brokxauthor=R.+Hodgsonauthor=I.+Beletskayaauthor=M.+R.+Brayauthor=T.+W.+Mak&title=Functional+characterization+of+CFI-402257%2C+a+potent+and+selective+Mps1%2FTTK+kinase+inhibitor%2C+for+the+treatment+of+cancer&doi=10.1073%2Fpnas.1700234114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer</span></div><div class="casAuthors">Mason, Jacqueline M.; Wei, Xin; Fletcher, Graham C.; Kiarash, Reza; Brokx, Richard; Hodgson, Richard; Beletskaya, Irina; Bray, Mark R.; Mak, Tak W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3127-3132</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Loss of cell-cycle control is a hallmark of human cancer.  Cell-cycle checkpoints are essential for maintaining genome integrity and balanced growth and division.  They are specifically deregulated in cancer cells and contain regulators that represent potential therapeutic targets.  Monopolar spindle 1 (Mps1; also known as TTK protein kinase) is a core component of the spindle assembly checkpoint (SAC), a genome-surveillance mechanism that is important for cell survival, and has emerged as a candidate target for anticancer therapy.  Here, the authors report the cellular and antitumor effects of CFI-402257, a potent (Mps1 Ki = 0.09±0.02 nM; cellular Mps1 EC50 = 6.5±0.5 nM), highly selective, and orally active small-mol. inhibitor of Mps1 that was identified through a drug-discovery program.  Human cancer cells treated with CFI-402257 exhibit effects consistent with Mps1 kinase inhibition, specifically SAC inactivation, leading to chromosome missegregation, aneuploidy, and ultimately cell death.  Oral administration of CFI-402257 in monotherapy or in combination with an anti-programmed cell death 1 (PD-1) antibody in mouse models of human cancer results in inhibition of tumor growth at doses that are well-tolerated.  The authors' findings provide a rationale for the clin. evaluation of CFI-402257 in patients with solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFQJ3eg_c-qLVg90H21EOLACvtfcHk0lhyX3oKch2WsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvVyjsL8%253D&md5=bb9742c8d07314e7d3c322bef71ef0ff</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1700234114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1700234114%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DFletcher%26aufirst%3DG.%2BC.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DBrokx%26aufirst%3DR.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DBray%26aufirst%3DM.%2BR.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DFunctional%2520characterization%2520of%2520CFI-402257%252C%2520a%2520potent%2520and%2520selective%2520Mps1%252FTTK%2520kinase%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D3127%26epage%3D3132%26doi%3D10.1073%2Fpnas.1700234114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Faisal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, G. W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurden, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xavier, C. P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderhub, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innocenti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwood, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Haven Brandon, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Fee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">vanMontfort, R. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardopoulos, S.</span><span> </span><span class="NLM_article-title">Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">1166</span><span class="NLM_x">–</span> <span class="NLM_lpage">1176</span><span class="refDoi"> DOI: 10.1038/bjc.2017.75</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1038%2Fbjc.2017.75" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=28334731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVKht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2017&pages=1166-1176&author=A.+Faisalauthor=G.+W.+Y.+Makauthor=M.+D.+Gurdenauthor=C.+P.+R.+Xavierauthor=S.+J.+Anderhubauthor=P.+Innocentiauthor=I.+M.+Westwoodauthor=S.+Naudauthor=A.+Hayesauthor=G.+Boxauthor=M.+R.+Valentiauthor=A.+K.+De+Haven+Brandonauthor=L.+O%E2%80%99Feeauthor=J.+Schmittauthor=H.+L.+Woodwardauthor=R.+Burkeauthor=R.+L.+M.+vanMontfortauthor=J.+Blaggauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=S.+Hoelderauthor=S.+Linardopoulos&title=Characterisation+of+CCT271850%2C+a+selective%2C+oral+and+potent+MPS1+inhibitor%2C+used+to+directly+measure+in+vivo+MPS1+inhibition+vs+therapeutic+efficacy&doi=10.1038%2Fbjc.2017.75"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy</span></div><div class="casAuthors">Faisal, Amir; Mak, Grace W. Y.; Gurden, Mark D.; Xavier, Cristina P. R.; Anderhub, Simon J.; Innocenti, Paolo; Westwood, Isaac M.; Naud, Sebastien; Hayes, Angela; Box, Gary; Valenti, Melanie R.; De Haven Brandon, Alexis K.; O'Fee, Lisa; Schmitt, Jessica; Woodward, Hannah L.; Burke, Rosemary; van Montfort, Rob L. M.; Blagg, Julian; Raynaud, Florence I.; Eccles, Suzanne A.; Hoelder, Swen; Linardopoulos, Spiros</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1166-1176</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: The main role of the cell cycle is to enable error-free DNA replication, chromosome segregation and cytokinesis.  One of the best characterized checkpoint pathways is the spindle assembly checkpoint, which prevents anaphase onset until the appropriate attachment and tension across kinetochores is achieved.  MPS1 kinase activity is essential for the activation of the spindle assembly checkpoint and has been shown to be deregulated in human tumors with chromosomal instability and aneuploidy.  Therefore, MPS1 inhibition represents an attractive strategy to target cancers.  Methods: To evaluate CCT271850 cellular potency, two specific antibodies that recognize the activation sites of MPS1 were used and its antiproliferative activity was detd. in 91 human cancer cell lines.  DLD1 cells with induced GFP-MPS1 and HCT116 cells were used in in vivo studies to directly measure MPS1 inhibition and efficacy of CCT271850 treatment.  Results: CCT271850 selectively and potently inhibits MPS1 kinase activity in biochem. and cellular assays and in in vivo models.  Mechanistically, tumor cells treated with CCT271850 acquire aberrant nos. of chromosomes and the majority of cells divide their chromosomes without proper alignment because of abrogation of the mitotic checkpoint, leading to cell death.  We demonstrated a moderate level of efficacy of CCT271850 as a single agent in a human colorectal carcinoma xenograft model.  Conclusions: CCT271850 is a potent, selective and orally bioavailable MPS1 kinase inhibitor.  On the basis of in vivo pharmacodynamic vs efficacy relationships, we predict that more than 80% inhibition of MPS1 activity for at least 24 h is required to achieve tumor stasis or regression by CCT271850.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodu8v7zdjvabVg90H21EOLACvtfcHk0lhyX3oKch2WsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVKht74%253D&md5=656368a488e47677a8cb455de962371e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2017.75&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2017.75%26sid%3Dliteratum%253Aachs%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DMak%26aufirst%3DG.%2BW.%2BY.%26aulast%3DGurden%26aufirst%3DM.%2BD.%26aulast%3DXavier%26aufirst%3DC.%2BP.%2BR.%26aulast%3DAnderhub%26aufirst%3DS.%2BJ.%26aulast%3DInnocenti%26aufirst%3DP.%26aulast%3DWestwood%26aufirst%3DI.%2BM.%26aulast%3DNaud%26aufirst%3DS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DValenti%26aufirst%3DM.%2BR.%26aulast%3DDe%2BHaven%2BBrandon%26aufirst%3DA.%2BK.%26aulast%3DO%25E2%2580%2599Fee%26aufirst%3DL.%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DWoodward%26aufirst%3DH.%2BL.%26aulast%3DBurke%26aufirst%3DR.%26aulast%3DvanMontfort%26aufirst%3DR.%2BL.%2BM.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DHoelder%26aufirst%3DS.%26aulast%3DLinardopoulos%26aufirst%3DS.%26atitle%3DCharacterisation%2520of%2520CCT271850%252C%2520a%2520selective%252C%2520oral%2520and%2520potent%2520MPS1%2520inhibitor%252C%2520used%2520to%2520directly%2520measure%2520in%2520vivo%2520MPS1%2520inhibition%2520vs%2520therapeutic%2520efficacy%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2017%26volume%3D116%26spage%3D1166%26epage%3D1176%26doi%3D10.1038%2Fbjc.2017.75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Innocenti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solanki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwood, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faisal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Fee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saville, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matijssen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardopoulos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span> </span><span class="NLM_article-title">Rapid discovery of pyrido[3,4-d]pyrimidine inhibitors of monopolar spindle kinase 1 (MPS1) using a structure-based hybridization approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3671</span><span class="NLM_x">–</span> <span class="NLM_lpage">3688</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01811</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01811" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsF2qsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3671-3688&author=P.+Innocentiauthor=H.+L.+Woodwardauthor=S.+Solankiauthor=S.+Naudauthor=I.+M.+Westwoodauthor=N.+Croninauthor=A.+Hayesauthor=J.+Robertsauthor=A.+T.+Henleyauthor=R.+Bakerauthor=A.+Faisalauthor=G.+W.+Makauthor=G.+Boxauthor=M.+Valentiauthor=A.+De+Haven+Brandonauthor=L.+O%E2%80%99Feeauthor=H.+Savilleauthor=J.+Schmittauthor=B.+Matijssenauthor=R.+Burkeauthor=R.+L.+van+Montfortauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=S.+Linardopoulosauthor=J.+Blaggauthor=S.+Hoelder&title=Rapid+discovery+of+pyrido%5B3%2C4-d%5Dpyrimidine+inhibitors+of+monopolar+spindle+kinase+1+%28MPS1%29+using+a+structure-based+hybridization+approach&doi=10.1021%2Facs.jmedchem.5b01811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach</span></div><div class="casAuthors">Innocenti, Paolo; Woodward, Hannah L.; Solanki, Savade; Naud, Sebastien; Westwood, Isaac M.; Cronin, Nora; Hayes, Angela; Roberts, Jennie; Henley, Alan T.; Baker, Ross; Faisal, Amir; Mak, Grace Wing-Yan; Box, Gary; Valenti, Melanie; De Haven Brandon, Alexis; O'Fee, Lisa; Saville, Harry; Schmitt, Jessica; Matijssen, Berry; Burke, Rosemary; van Montfort, Rob L. M.; Raynaud, Florence I.; Eccles, Suzanne A.; Linardopoulos, Spiros; Blagg, Julian; Hoelder, Swen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3671-3688</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monopolar spindle 1 (MPS1) plays a central role in the transition of cells from metaphase to anaphase and is one of the main components of the spindle assembly checkpoint.  Chromosomally unstable cancer cells rely heavily on MPS1 to cope with the stress arising from abnormal nos. of chromosomes and centrosomes and are thus more sensitive to MPS1 inhibition than normal cells.  We report the discovery and optimization of a series of new pyrido[3,4-d]pyrimidine based inhibitors via a structure-based hybridization approach from our previously reported inhibitor CCT251455 and a modestly potent screening hit.  Compds. in this novel series display excellent potency and selectivity for MPS1, which translates into biomarker modulation in an in vivo human tumor xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr42v6loNvM1bVg90H21EOLACvtfcHk0lhzOcY5PYkTKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsF2qsro%253D&md5=dd858ed11744e0b036061baf5e2c181a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01811%26sid%3Dliteratum%253Aachs%26aulast%3DInnocenti%26aufirst%3DP.%26aulast%3DWoodward%26aufirst%3DH.%2BL.%26aulast%3DSolanki%26aufirst%3DS.%26aulast%3DNaud%26aufirst%3DS.%26aulast%3DWestwood%26aufirst%3DI.%2BM.%26aulast%3DCronin%26aufirst%3DN.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DJ.%26aulast%3DHenley%26aufirst%3DA.%2BT.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DMak%26aufirst%3DG.%2BW.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DDe%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Fee%26aufirst%3DL.%26aulast%3DSaville%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DMatijssen%26aufirst%3DB.%26aulast%3DBurke%26aufirst%3DR.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DLinardopoulos%26aufirst%3DS.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DRapid%2520discovery%2520of%2520pyrido%255B3%252C4-d%255Dpyrimidine%2520inhibitors%2520of%2520monopolar%2520spindle%2520kinase%25201%2520%2528MPS1%2529%2520using%2520a%2520structure-based%2520hybridization%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3671%26epage%3D3688%26doi%3D10.1021%2Facs.jmedchem.5b01811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Kusakabe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ide, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daigo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashizume, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nozu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagashira, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashino, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanazawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishioka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baba, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span> </span><span class="NLM_article-title">Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1760</span><span class="NLM_x">–</span> <span class="NLM_lpage">1775</span><span class="refDoi"> DOI: 10.1021/jm501599u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501599u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2it7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1760-1775&author=K.+Kusakabeauthor=N.+Ideauthor=Y.+Daigoauthor=T.+Itohauthor=T.+Yamamotoauthor=H.+Hashizumeauthor=K.+Nozuauthor=H.+Yoshidaauthor=G.+Tadanoauthor=S.+Tagashiraauthor=K.+Higashinoauthor=Y.+Okanoauthor=Y.+Satoauthor=M.+Inoueauthor=M.+Iguchiauthor=T.+Kanazawaauthor=Y.+Ishiokaauthor=K.+Dohiauthor=Y.+Kidoauthor=S.+Sakamotoauthor=S.+Andoauthor=M.+Maedaauthor=M.+Higakiauthor=Y.+Babaauthor=Y.+Nakamura&title=Discovery+of+imidazo%5B1%2C2-b%5Dpyridazine+derivatives%3A+selective+and+orally+available+Mps1+%28TTK%29+kinase+inhibitors+exhibiting+remarkable+antiproliferative+activity&doi=10.1021%2Fjm501599u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Imidazo[1,2-b]pyridazine Derivatives: Selective and Orally Available Mps1 (TTK) Kinase Inhibitors Exhibiting Remarkable Antiproliferative Activity</span></div><div class="casAuthors">Kusakabe, Ken-ichi; Ide, Nobuyuki; Daigo, Yataro; Itoh, Takeshi; Yamamoto, Takahiko; Hashizume, Hiroshi; Nozu, Kohei; Yoshida, Hiroshi; Tadano, Genta; Tagashira, Sachie; Higashino, Kenichi; Okano, Yousuke; Sato, Yuji; Inoue, Makiko; Iguchi, Motofumi; Kanazawa, Takayuki; Ishioka, Yukichi; Dohi, Keiji; Kido, Yasuto; Sakamoto, Shingo; Ando, Shigeru; Maeda, Masahiro; Higaki, Masayo; Baba, Yoshiyasu; Nakamura, Yusuke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1760-1775</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monopolar spindle 1 (Mps1) is an attractive oncol. target due to its high expression level in cancer cells as well as the correlation of its expression levels with histol. grades of cancers.  An imidazo[1,2-a]pyrazine 10a was identified during an HTS campaign.  Although 10a exhibited good biochem. activity, its moderate cellular as well as antiproliferative activities needed to be improved.  The cocrystal structure of an analog of 10a guided our lead optimization to introduce substituents at the 6-position of the scaffold, giving the 6-aryl substituted 21b which had improved cellular activity but no oral bioavailability in rat.  Property-based optimization at the 6-position and a scaffold change led to the discovery of the imidazo[1,2-b]pyridazine-based 27f, an extremely potent (cellular Mps1 IC50 = 0.70 nM, A549 IC50 = 6.0 nM), selective Mps1 inhibitor over 192 kinases, which could be orally administered and was active in vivo.  This 27f demonstrated remarkable antiproliferative activity in the nanomolar range against various tissue cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8D9nRl5vWabVg90H21EOLACvtfcHk0lhzOcY5PYkTKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2it7g%253D&md5=bee62a50247a363dc3e35fcdeac6a64f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm501599u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501599u%26sid%3Dliteratum%253Aachs%26aulast%3DKusakabe%26aufirst%3DK.%26aulast%3DIde%26aufirst%3DN.%26aulast%3DDaigo%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DNozu%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DTadano%26aufirst%3DG.%26aulast%3DTagashira%26aufirst%3DS.%26aulast%3DHigashino%26aufirst%3DK.%26aulast%3DOkano%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DIguchi%26aufirst%3DM.%26aulast%3DKanazawa%26aufirst%3DT.%26aulast%3DIshioka%26aufirst%3DY.%26aulast%3DDohi%26aufirst%3DK.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DSakamoto%26aufirst%3DS.%26aulast%3DAndo%26aufirst%3DS.%26aulast%3DMaeda%26aufirst%3DM.%26aulast%3DHigaki%26aufirst%3DM.%26aulast%3DBaba%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520imidazo%255B1%252C2-b%255Dpyridazine%2520derivatives%253A%2520selective%2520and%2520orally%2520available%2520Mps1%2520%2528TTK%2529%2520kinase%2520inhibitors%2520exhibiting%2520remarkable%2520antiproliferative%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1760%26epage%3D1775%26doi%3D10.1021%2Fjm501599u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Uitdehaag, J. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Man, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willemsen-Seegers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinsen, M. B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libouban, M. A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterrenburg, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Wit, J. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vetter, J. R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Roos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buijsman, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaman, G. J. R.</span><span> </span><span class="NLM_article-title">Target residence time-guided optimization on TTK kinase results in inhibitors with potent anti-proliferative activity</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">429</span><span class="NLM_x">, </span> <span class="NLM_fpage">2211</span><span class="NLM_x">–</span> <span class="NLM_lpage">2230</span><span class="refDoi"> DOI: 10.1016/j.jmb.2017.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1016%2Fj.jmb.2017.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=28539250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1Wiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=429&publication_year=2017&pages=2211-2230&author=J.+C.+M.+Uitdehaagauthor=J.+de+Manauthor=N.+Willemsen-Seegersauthor=M.+B.+W.+Prinsenauthor=M.+A.+A.+Liboubanauthor=J.+G.+Sterrenburgauthor=J.+J.+P.+de+Witauthor=J.+R.+F.+de+Vetterauthor=J.+de+Roosauthor=R.+C.+Buijsmanauthor=G.+J.+R.+Zaman&title=Target+residence+time-guided+optimization+on+TTK+kinase+results+in+inhibitors+with+potent+anti-proliferative+activity&doi=10.1016%2Fj.jmb.2017.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity</span></div><div class="casAuthors">Uitdehaag, Joost C. M.; de Man, Jos; Willemsen-Seegers, Nicole; Prinsen, Martine B. W.; Libouban, Marion A. A.; Sterrenburg, Jan Gerard; de Wit, Joeri J. P.; de Vetter, Judith R. F.; de Roos, Jeroen A. D. M.; Buijsman, Rogier C.; Zaman, Guido J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">429</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2211-2230</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The protein kinase threonine tyrosine kinase (TTK; also known as Mps1) is a crit. component of the spindle assembly checkpoint and a promising drug target for the treatment of aggressive cancers, such as triple neg. breast cancer.  While the first TTK inhibitors have entered clin. trials, little is known about how the inhibition of TTK with small-mol. compds. affects cellular activity.  The authors studied the selective TTK inhibitor NTRC 0066-0, which was developed in the authors' own lab., together with 11 TTK inhibitors developed by other companies, including Mps-BAY2b, BAY 1161909, BAY 1217389 (Bayer), TC-Mps1-12 (Shionogi), and MPI-0479605 (Myrexis).  Parallel testing shows that the cellular activity of these TTK inhibitors correlates with their binding affinity to TTK and, more strongly, with target residence time.  TTK inhibitors are therefore an example where target residence time dets. activity in in vitro cellular assays.  X-ray structures and thermal stability expts. reveal that the most potent compds. induce a shift of the glycine-rich loop as a result of binding to the catalytic lysine at position 553.  This "lysine trap" disrupts the catalytic machinery.  Based on these insights, the authors developed TTK inhibitors, based on a (5,6-dihydro)pyrimido[4,5-e]indolizine scaffold, with longer target residence times, which further exploit an allosteric pocket surrounding Lys 553.  Their binding mode is new for kinase inhibitors and can be classified as hybrid Type I/Type III.  These inhibitors have very potent anti-proliferative activity that rivals classic cytotoxic therapy.  The authors' findings will open up new avenues for more applications for TTK inhibitors in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT_6mZVMoVTrVg90H21EOLACvtfcHk0liQsCVG4NLUUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1Wiuro%253D&md5=c02b149e673dec7b0212b37a4c7b0831</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2017.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2017.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DUitdehaag%26aufirst%3DJ.%2BC.%2BM.%26aulast%3Dde%2BMan%26aufirst%3DJ.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DPrinsen%26aufirst%3DM.%2BB.%2BW.%26aulast%3DLibouban%26aufirst%3DM.%2BA.%2BA.%26aulast%3DSterrenburg%26aufirst%3DJ.%2BG.%26aulast%3Dde%2BWit%26aufirst%3DJ.%2BJ.%2BP.%26aulast%3Dde%2BVetter%26aufirst%3DJ.%2BR.%2BF.%26aulast%3Dde%2BRoos%26aufirst%3DJ.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%2BR.%26atitle%3DTarget%2520residence%2520time-guided%2520optimization%2520on%2520TTK%2520kinase%2520results%2520in%2520inhibitors%2520with%2520potent%2520anti-proliferative%2520activity%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2017%26volume%3D429%26spage%3D2211%26epage%3D2230%26doi%3D10.1016%2Fj.jmb.2017.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Jemaa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galluzzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kepp, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senovilla, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brands, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boemer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koppitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lienau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prechtl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siemeister, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wengner, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mumberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziegelbauer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrieu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castedo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitale, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroemer, G.</span><span> </span><span class="NLM_article-title">Characterization of novel MPS1 inhibitors with preclinical anticancer activity</span> <span class="citation_source-journal">Cell Death Differ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1532</span><span class="NLM_x">–</span> <span class="NLM_lpage">1545</span><span class="refDoi"> DOI: 10.1038/cdd.2013.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1038%2Fcdd.2013.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=23933817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2gurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1532-1545&author=M.+Jemaaauthor=L.+Galluzziauthor=O.+Keppauthor=L.+Senovillaauthor=M.+Brandsauthor=U.+Boemerauthor=M.+Koppitzauthor=P.+Lienauauthor=S.+Prechtlauthor=V.+Schulzeauthor=G.+Siemeisterauthor=A.+M.+Wengnerauthor=D.+Mumbergauthor=K.+Ziegelbauerauthor=A.+Abrieuauthor=M.+Castedoauthor=I.+Vitaleauthor=G.+Kroemer&title=Characterization+of+novel+MPS1+inhibitors+with+preclinical+anticancer+activity&doi=10.1038%2Fcdd.2013.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of novel MPS1 inhibitors with preclinical anticancer activity</span></div><div class="casAuthors">Jemaa, M.; Galluzzi, L.; Kepp, O.; Senovilla, L.; Brands, M.; Boemer, U.; Koppitz, M.; Lienau, P.; Prechtl, S.; Schulze, V.; Siemeister, G.; Wengner, A. M.; Mumberg, D.; Ziegelbauer, K.; Abrieu, A.; Castedo, M.; Vitale, I.; Kroemer, G.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1532-1545</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Monopolar spindle 1 (MPS1), a mitotic kinase that is overexpressed in several human cancers, contributes to the alignment of chromosomes to the metaphase plate as well as to the execution of the spindle assembly checkpoint (SAC).  Here, we report the identification and functional characterization of three novel inhibitors of MPS1 of two independent structural classes, N-(4-{2-[(2-cyanophenyl)amino][1,2,4]triazolo[1,5-a]pyridin-6-yl}phenyl)-2-phenylacetamide (Mps-BAY1) (a triazolopyridine), N-cyclopropyl-4-{8-[(2-methylpropyl)amino]-6-(quinolin-5-yl)imidazo[1,2-a]pyrazin-3-yl}benzamide (Mps-BAY2a) and N-cyclopropyl-4-{8-(isobutylamino)imidazo[1,2-a]pyrazin-3-yl}benzamide (Mps-BAY2b) (two imidazopyrazines).  By selectively inactivating MPS1, these small inhibitors can arrest the proliferation of cancer cells, causing their polyploidization and/or their demise.  Cancer cells treated with Mps-BAY1 or Mps-BAY2a manifested multiple signs of mitotic perturbation including inefficient chromosomal congression during metaphase, unscheduled SAC inactivation and severe anaphase defects.  Videomicroscopic cell fate profiling of histone 2B-green fluorescent protein-expressing cells revealed the capacity of MPS1 inhibitors to subvert the correct timing of mitosis as they induce a premature anaphase entry in the context of misaligned metaphase plates.  Hence, in the presence of MPS1 inhibitors, cells either divided in a bipolar (but often asym.) manner or entered one or more rounds of abortive mitoses, generating gross aneuploidy and polyploidy, resp.  In both cases, cells ultimately succumbed to the mitotic catastrophe-induced activation of the mitochondrial pathway of apoptosis.  Of note, low doses of MPS1 inhibitors and paclitaxel (a microtubular poison) synergized at increasing the frequency of chromosome misalignments and missegregations in the context of SAC inactivation.  This resulted in massive polyploidization followed by the activation of mitotic catastrophe.  A synergistic interaction between paclitaxel and MPS1 inhibitors could also be demonstrated in vivo, as the combination of these agents efficiently reduced the growth of tumor xenografts and exerted superior antineoplastic effects compared with either compd. employed alone.  Altogether, these results suggest that MPS1 inhibitors may exert robust anticancer activity, either as standalone therapeutic interventions or combined with microtubule-targeting chems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHoriIGxHO_rVg90H21EOLACvtfcHk0liQsCVG4NLUUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2gurjI&md5=867fb902b15b6df0f7049b069bd47a4c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2013.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2013.105%26sid%3Dliteratum%253Aachs%26aulast%3DJemaa%26aufirst%3DM.%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DKepp%26aufirst%3DO.%26aulast%3DSenovilla%26aufirst%3DL.%26aulast%3DBrands%26aufirst%3DM.%26aulast%3DBoemer%26aufirst%3DU.%26aulast%3DKoppitz%26aufirst%3DM.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DPrechtl%26aufirst%3DS.%26aulast%3DSchulze%26aufirst%3DV.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DAbrieu%26aufirst%3DA.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DCharacterization%2520of%2520novel%2520MPS1%2520inhibitors%2520with%2520preclinical%2520anticancer%2520activity%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2013%26volume%3D20%26spage%3D1532%26epage%3D1545%26doi%3D10.1038%2Fcdd.2013.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Wengner, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siemeister, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koppitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosemund, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoeckigt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuhaus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lienau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prechtl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raschke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frisk, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Ahsen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michels, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreft, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Nussbaum, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brands, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mumberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziegelbauer, K.</span><span> </span><span class="NLM_article-title">Novel Mps1 kinase inhibitors with potent antitumor activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">583</span><span class="NLM_x">–</span> <span class="NLM_lpage">592</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1158%2F1535-7163.MCT-15-0500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=26832791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVSqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=583-592&author=A.+M.+Wengnerauthor=G.+Siemeisterauthor=M.+Koppitzauthor=V.+Schulzeauthor=D.+Kosemundauthor=U.+Klarauthor=D.+Stoeckigtauthor=R.+Neuhausauthor=P.+Lienauauthor=B.+Baderauthor=S.+Prechtlauthor=M.+Raschkeauthor=A.+L.+Friskauthor=O.+von+Ahsenauthor=M.+Michelsauthor=B.+Kreftauthor=F.+von+Nussbaumauthor=M.+Brandsauthor=D.+Mumbergauthor=K.+Ziegelbauer&title=Novel+Mps1+kinase+inhibitors+with+potent+antitumor+activity&doi=10.1158%2F1535-7163.MCT-15-0500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity</span></div><div class="casAuthors">Wengner, Antje M.; Siemeister, Gerhard; Koppitz, Marcus; Schulze, Volker; Kosemund, Dirk; Klar, Ulrich; Stoeckigt, Detlef; Neuhaus, Roland; Lienau, Philip; Bader, Benjamin; Prechtl, Stefan; Raschke, Marian; Frisk, Anna-Lena; von Ahsen, Oliver; Michels, Martin; Kreft, Bertolt; von Nussbaum, Franz; Brands, Michael; Mumberg, Dominik; Ziegelbauer, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">583-592</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Monopolar spindle 1 (Mps1) has been shown to function as the key kinase that activates the spindle assembly checkpoint (SAC) to secure proper distribution of chromosomes to daughter cells.  Here, we report the structure and functional characterization of two novel selective Mps1 inhibitors, BAY 1161909 and BAY 1217389, derived from structurally distinct chem. classes.  BAY 1161909 and BAY 1217389 inhibited Mps1 kinase activity with IC50 values below 10 nmol/L while showing an excellent selectivity profile.  In cellular mechanistic assays, both Mps1 inhibitors abrogated nocodazole-induced SAC activity and induced premature exit from mitosis ("mitotic breakthrough"), resulting in multinuclearity and tumor cell death.  Both compds. efficiently inhibited tumor cell proliferation in vitro (IC50 nmol/L range).  In vivo, BAY 1161909 and BAY 1217389 achieved moderate efficacy in monotherapy in tumor xenograft studies.  However, in line with its unique mode of action, when combined with paclitaxel, low doses of Mps1 inhibitor reduced paclitaxel-induced mitotic arrest by the weakening of SAC activity.  As a result, combination therapy strongly improved efficacy over paclitaxel or Mps1 inhibitor monotreatment at the resp. MTDs in a broad range of xenograft models, including those showing acquired or intrinsic paclitaxel resistance.  Both Mps1 inhibitors showed good tolerability without adding toxicity to paclitaxel monotherapy.  These preclin. findings validate the innovative concept of SAC abrogation for cancer therapy and justify clin. proof-of-concept studies evaluating the Mps1 inhibitors BAY 1161909 and BAY 1217389 in combination with antimitotic cancer drugs to enhance their efficacy and potentially overcome resistance.  Mol Cancer Ther; 15(4); 583-92. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGZQmIvWHFcLVg90H21EOLACvtfcHk0liQsCVG4NLUUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVSqt7g%253D&md5=f2b5cf0daf178088479be4be2aefa6b7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0500%26sid%3Dliteratum%253Aachs%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DKoppitz%26aufirst%3DM.%26aulast%3DSchulze%26aufirst%3DV.%26aulast%3DKosemund%26aufirst%3DD.%26aulast%3DKlar%26aufirst%3DU.%26aulast%3DStoeckigt%26aufirst%3DD.%26aulast%3DNeuhaus%26aufirst%3DR.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DBader%26aufirst%3DB.%26aulast%3DPrechtl%26aufirst%3DS.%26aulast%3DRaschke%26aufirst%3DM.%26aulast%3DFrisk%26aufirst%3DA.%2BL.%26aulast%3Dvon%2BAhsen%26aufirst%3DO.%26aulast%3DMichels%26aufirst%3DM.%26aulast%3DKreft%26aufirst%3DB.%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DBrands%26aufirst%3DM.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26atitle%3DNovel%2520Mps1%2520kinase%2520inhibitors%2520with%2520potent%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D583%26epage%3D592%26doi%3D10.1158%2F1535-7163.MCT-15-0500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Yomoda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muraki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kataoka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosoya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagiwara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span> </span><span class="NLM_article-title">Combination of Clk family kinase and SRp75 modulates alternative splicing of adenovirus E1A</span> <span class="citation_source-journal">Genes Cells</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">233</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span><span class="refDoi"> DOI: 10.1111/j.1365-2443.2008.01163.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1111%2Fj.1365-2443.2008.01163.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=18298798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVensrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=233-244&author=J.+Yomodaauthor=M.+Murakiauthor=N.+Kataokaauthor=T.+Hosoyaauthor=M.+Suzukiauthor=M.+Hagiwaraauthor=H.+Kimura&title=Combination+of+Clk+family+kinase+and+SRp75+modulates+alternative+splicing+of+adenovirus+E1A&doi=10.1111%2Fj.1365-2443.2008.01163.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of Clk family kinase and SRp75 modulates alternative splicing of adenovirus E1A</span></div><div class="casAuthors">Yomoda, Jun-ichiro; Muraki, Michiko; Kataoka, Naoyuki; Hosoya, Takamitsu; Suzuki, Masaaki; Hagiwara, Masatoshi; Kimura, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Genes to Cells</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">233-244</span>CODEN:
                <span class="NLM_cas:coden">GECEFL</span>;
        ISSN:<span class="NLM_cas:issn">1356-9597</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Inc.</span>)
        </div><div class="casAbstract">SR proteins are non-snRNP splicing factors harboring a domain rich in Arg-Ser repeats, which are extensively phosphorylated by several kinases.  We performed a comparative study of different SR kinases, including SRPK, Clk, PRP4 and DYRK, and found that only Clks efficiently altered 5' splice site selection of Adenovirus E1A.  The phosphorylation state of SR proteins was examd. using a phospho-SR specific antibody mAb1H4 and a 75 kDa protein was most evidently hyperphosphorylated by Clks.  Administration of TG003, a specific inhibitor for the Clk family members, specifically and rapidly induced dephosphorylation of 75 kDa SR protein.  Imaging with mRFP-SRp75 in living cells revealed that its nuclear distribution was rapidly altered upon inhibition of the Clk activity by TG003.  Co-transfection expts. demonstrated that HA-tagged SRp75 was hyperphosphorylated by Clk family members, but not by other SR kinases.  These results indicate that Clks specifically hyperphosphorylate SRp75.  Furthermore, SRp75 over-expression promoted the selection of 12S 5' splice site in E1A pre-mRNA, which is stimulated by co-expression of Clks.  These results suggest that the specific combination of SR protein and SR kinase plays a distinct role in alternative splicing through dynamic balance of phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuPpVncHxTVLVg90H21EOLACvtfcHk0lgTEty0V-fitQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVensrY%253D&md5=cbf3231037575ed191494dd01cc4c1be</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2443.2008.01163.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2443.2008.01163.x%26sid%3Dliteratum%253Aachs%26aulast%3DYomoda%26aufirst%3DJ.%26aulast%3DMuraki%26aufirst%3DM.%26aulast%3DKataoka%26aufirst%3DN.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DHagiwara%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DH.%26atitle%3DCombination%2520of%2520Clk%2520family%2520kinase%2520and%2520SRp75%2520modulates%2520alternative%2520splicing%2520of%2520adenovirus%2520E1A%26jtitle%3DGenes%2520Cells%26date%3D2008%26volume%3D13%26spage%3D233%26epage%3D244%26doi%3D10.1111%2Fj.1365-2443.2008.01163.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Aubol, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plocinik, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagopian, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGlone, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandyopadhyay, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, X. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. A.</span><span> </span><span class="NLM_article-title">Partitioning RS domain phosphorylation in an SR protein through the CLK and SRPK protein kinases</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">425</span><span class="NLM_x">, </span> <span class="NLM_fpage">2894</span><span class="NLM_x">–</span> <span class="NLM_lpage">2909</span><span class="refDoi"> DOI: 10.1016/j.jmb.2013.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1016%2Fj.jmb.2013.05.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=425&publication_year=2013&pages=2894-2909&author=B.+E.+Aubolauthor=R.+M.+Plocinikauthor=J.+C.+Hagopianauthor=C.+T.+Maauthor=M.+L.+McGloneauthor=R.+Bandyopadhyayauthor=X.+D.+Fuauthor=J.+A.+Adams&title=Partitioning+RS+domain+phosphorylation+in+an+SR+protein+through+the+CLK+and+SRPK+protein+kinases&doi=10.1016%2Fj.jmb.2013.05.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2013.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2013.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DAubol%26aufirst%3DB.%2BE.%26aulast%3DPlocinik%26aufirst%3DR.%2BM.%26aulast%3DHagopian%26aufirst%3DJ.%2BC.%26aulast%3DMa%26aufirst%3DC.%2BT.%26aulast%3DMcGlone%26aufirst%3DM.%2BL.%26aulast%3DBandyopadhyay%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DX.%2BD.%26aulast%3DAdams%26aufirst%3DJ.%2BA.%26atitle%3DPartitioning%2520RS%2520domain%2520phosphorylation%2520in%2520an%2520SR%2520protein%2520through%2520the%2520CLK%2520and%2520SRPK%2520protein%2520kinases%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2013%26volume%3D425%26spage%3D2894%26epage%3D2909%26doi%3D10.1016%2Fj.jmb.2013.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Yoshida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carver, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weremowicz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mei, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polyak, K.</span><span> </span><span class="NLM_article-title">CLK2 Is an oncogenic kinase and splicing regulator in breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1516</span><span class="NLM_x">–</span> <span class="NLM_lpage">1526</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-2443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1158%2F0008-5472.CAN-14-2443" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1516-1526&author=T.+Yoshidaauthor=J.+H.+Kimauthor=K.+Carverauthor=Y.+Suauthor=S.+Weremowiczauthor=L.+Mulveyauthor=S.+Yamamotoauthor=C.+Brennanauthor=S.+Meiauthor=H.+Longauthor=J.+Yaoauthor=K.+Polyak&title=CLK2+Is+an+oncogenic+kinase+and+splicing+regulator+in+breast+cancer&doi=10.1158%2F0008-5472.CAN-14-2443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-2443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-2443%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DCarver%26aufirst%3DK.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DWeremowicz%26aufirst%3DS.%26aulast%3DMulvey%26aufirst%3DL.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DC.%26aulast%3DMei%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DPolyak%26aufirst%3DK.%26atitle%3DCLK2%2520Is%2520an%2520oncogenic%2520kinase%2520and%2520splicing%2520regulator%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D1516%26epage%3D1526%26doi%3D10.1158%2F0008-5472.CAN-14-2443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Araki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dairiki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashita, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwatani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, O.</span><span> </span><span class="NLM_article-title">Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0116929</span><span class="refDoi"> DOI: 10.1371/journal.pone.0116929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1371%2Fjournal.pone.0116929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=25581376" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0116929&author=S.+Arakiauthor=R.+Dairikiauthor=Y.+Nakayamaauthor=A.+Muraiauthor=R.+Miyashitaauthor=M.+Iwataniauthor=T.+Nomuraauthor=O.+Nakanishi&title=Inhibitors+of+CLK+protein+kinases+suppress+cell+growth+and+induce+apoptosis+by+modulating+pre-mRNA+splicing&doi=10.1371%2Fjournal.pone.0116929"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0116929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0116929%26sid%3Dliteratum%253Aachs%26aulast%3DAraki%26aufirst%3DS.%26aulast%3DDairiki%26aufirst%3DR.%26aulast%3DNakayama%26aufirst%3DY.%26aulast%3DMurai%26aufirst%3DA.%26aulast%3DMiyashita%26aufirst%3DR.%26aulast%3DIwatani%26aufirst%3DM.%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DNakanishi%26aufirst%3DO.%26atitle%3DInhibitors%2520of%2520CLK%2520protein%2520kinases%2520suppress%2520cell%2520growth%2520and%2520induce%2520apoptosis%2520by%2520modulating%2520pre-mRNA%2520splicing%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0116929%26doi%3D10.1371%2Fjournal.pone.0116929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><div class="note"><p class="first last">SelectScreen Kinase Profiling Services: Thermo Fisher Scientific, M., WI, USA.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=SelectScreen+Kinase+Profiling+Services%3A+Thermo+Fisher+Scientific%2C+M.%2C+WI%2C+USA."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Naud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwood, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faisal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldrake, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bavetsias, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atrash, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAndrew, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matijssen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardopoulos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span> </span><span class="NLM_article-title">Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">10045</span><span class="NLM_x">–</span> <span class="NLM_lpage">10065</span><span class="refDoi"> DOI: 10.1021/jm401395s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401395s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVShsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=10045-10065&author=S.+Naudauthor=I.+M.+Westwoodauthor=A.+Faisalauthor=P.+Sheldrakeauthor=V.+Bavetsiasauthor=B.+Atrashauthor=K.+M.+Cheungauthor=M.+Liuauthor=A.+Hayesauthor=J.+Schmittauthor=A.+Woodauthor=V.+Choiauthor=K.+Boxallauthor=G.+Makauthor=M.+Gurdenauthor=M.+Valentiauthor=A.+de+Haven+Brandonauthor=A.+Henleyauthor=R.+Bakerauthor=C.+McAndrewauthor=B.+Matijssenauthor=R.+Burkeauthor=S.+Hoelderauthor=S.+A.+Ecclesauthor=F.+I.+Raynaudauthor=S.+Linardopoulosauthor=R.+L.+van+Montfortauthor=J.+Blagg&title=Structure-based+design+of+orally+bioavailable+1H-pyrrolo%5B3%2C2-c%5Dpyridine+inhibitors+of+mitotic+kinase+monopolar+spindle+1+%28MPS1%29&doi=10.1021%2Fjm401395s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Orally Bioavailable 1H-Pyrrolo[3,2-c]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1)</span></div><div class="casAuthors">Naud, Sebastien; Westwood, Isaac M.; Faisal, Amir; Sheldrake, Peter; Bavetsias, Vassilios; Atrash, Butrus; Cheung, Kwai-Ming J.; Liu, Manjuan; Hayes, Angela; Schmitt, Jessica; Wood, Amy; Choi, Vanessa; Boxall, Kathy; Mak, Grace; Gurden, Mark; Valenti, Melanie; de Haven Brandon, Alexis; Henley, Alan; Baker, Ross; McAndrew, Craig; Matijssen, Berry; Burke, Rosemary; Hoelder, Swen; Eccles, Suzanne A.; Raynaud, Florence I.; Linardopoulos, Spiros; van Montfort, Rob L. M.; Blagg, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10045-10065</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The protein kinase MPS1 is a crucial component of the spindle assembly checkpoint signal and is aberrantly overexpressed in many human cancers.  MPS1 is one of the top 25 genes overexpressed in tumors with chromosomal instability and aneuploidy.  PTEN-deficient breast tumor cells are particularly dependent upon MPS1 for their survival, making it a target of significant interest in oncol.  The authors report the discovery and optimization of potent and selective MPS1 inhibitors based on the 1H-pyrrolo-[3,2-c]-pyridine scaffold, guided by structure-based design and cellular characterization of MPS1 inhibition, leading to CCT251455.  This potent and selective chem. tool stabilizes an inactive conformation of MPS1 with the activation loop ordered in a manner incompatible with ATP and substrate-peptide binding; it displays a favorable oral pharmacokinetic profile, shows dose-dependent inhibition of MPS1 in an HCT116 human tumor xenograft model, and is an attractive tool compd. to elucidate further the therapeutic potential of MPS1 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVRsRcyzCEBLVg90H21EOLACvtfcHk0liXYy-85VarNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVShsLzO&md5=6564efe14dec83774e94c355be756845</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm401395s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401395s%26sid%3Dliteratum%253Aachs%26aulast%3DNaud%26aufirst%3DS.%26aulast%3DWestwood%26aufirst%3DI.%2BM.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DSheldrake%26aufirst%3DP.%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DAtrash%26aufirst%3DB.%26aulast%3DCheung%26aufirst%3DK.%2BM.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DChoi%26aufirst%3DV.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DMak%26aufirst%3DG.%26aulast%3DGurden%26aufirst%3DM.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DMcAndrew%26aufirst%3DC.%26aulast%3DMatijssen%26aufirst%3DB.%26aulast%3DBurke%26aufirst%3DR.%26aulast%3DHoelder%26aufirst%3DS.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DLinardopoulos%26aufirst%3DS.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DBlagg%26aufirst%3DJ.%26atitle%3DStructure-based%2520design%2520of%2520orally%2520bioavailable%25201H-pyrrolo%255B3%252C2-c%255Dpyridine%2520inhibitors%2520of%2520mitotic%2520kinase%2520monopolar%2520spindle%25201%2520%2528MPS1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D10045%26epage%3D10065%26doi%3D10.1021%2Fjm401395s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0liXYy-85VarNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storoni, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span> </span><span class="NLM_article-title">Phaser crystallographic software</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span><span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0liXYy-85VarNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohkamp, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Features and development of Coot</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0li5RiOLAgvIXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skubak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebedev, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pannu, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholls, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span> </span><span class="NLM_article-title">REFMAC5 for the refinement of macromolecular crystal structures</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span><span class="refDoi"> DOI: 10.1107/S0907444911001314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1107%2FS0907444911001314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=21460454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=355-367&author=G.+N.+Murshudovauthor=P.+Skubakauthor=A.+A.+Lebedevauthor=N.+S.+Pannuauthor=R.+A.+Steinerauthor=R.+A.+Nichollsauthor=M.+D.+Winnauthor=F.+Longauthor=A.+A.+Vagin&title=REFMAC5+for+the+refinement+of+macromolecular+crystal+structures&doi=10.1107%2FS0907444911001314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">REFMAC5 for the refinement of macromolecular crystal structures</span></div><div class="casAuthors">Murshudov, Garib N.; Skubak, Pavol; Lebedev, Andrey A.; Pannu, Navraj S.; Steiner, Roberto A.; Nicholls, Robert A.; Winn, Martyn D.; Long, Fei; Vagin, Alexei A.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">355-367</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">This paper describes various components of the macromol. crystallog. refinement program REFMAC5, which is distributed as part of the CCP4 suite.  REFMAC5 utilizes different likelihood functions depending on the diffraction data employed (amplitudes or intensities), the presence of twinning and the availability of SAD/SIRAS exptl. diffraction data.  To ensure chem. and structural integrity of the refined model, REFMAC5 offers several classes of restraints and choices of model parameterization.  Reliable models at resolns. at least as low as 4 Å can be achieved thanks to low-resoln. refinement tools such as secondary-structure restraints, restraints to known homologous structures, automatic global and local NCS restraints, 'jelly-body' restraints and the use of novel long-range restraints on at. displacement parameters (ADPs) based on the Kullback-Leibler divergence.  REFMAC5 addnl. offers TLS parameterization and, when high-resoln. data are available, fast refinement of anisotropic ADPs.  Refinement in the presence of twinning is performed in a fully automated fashion.  REFMAC5 is a flexible and highly optimized refinement package that is ideally suited for refinement across the entire resoln. spectrum encountered in macromol. crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Jq-i2qIq5rVg90H21EOLACvtfcHk0li5RiOLAgvIXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqtbk%253D&md5=f8f3202d246908500057ad7c71015b7b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1107%2FS0907444911001314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444911001314%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DSkubak%26aufirst%3DP.%26aulast%3DLebedev%26aufirst%3DA.%2BA.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DSteiner%26aufirst%3DR.%2BA.%26aulast%3DNicholls%26aufirst%3DR.%2BA.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DLong%26aufirst%3DF.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26atitle%3DREFMAC5%2520for%2520the%2520refinement%2520of%2520macromolecular%2520crystal%2520structures%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D355%26epage%3D367%26doi%3D10.1107%2FS0907444911001314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Halgren, T. A.</span><span> </span><span class="NLM_article-title">Identifying and characterizing binding sites and assessing druggability</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">389</span><span class="refDoi"> DOI: 10.1021/ci800324m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800324m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1OhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=377-389&author=T.+A.+Halgren&title=Identifying+and+characterizing+binding+sites+and+assessing+druggability&doi=10.1021%2Fci800324m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying and Characterizing Binding Sites and Assessing Druggability</span></div><div class="casAuthors">Halgren, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">377-389</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification and characterization of binding sites is key in the process of structure-based drug design.  In some cases there may not be any information about the binding site for a target of interest.  In other cases, a putative binding site has been identified by computational or exptl. means, but the druggability of the target is not known.  Even when a site for a given target is known, it may be desirable to find addnl. sites whose targeting could produce a desired biol. response.  A new program, called SiteMap, is presented for identifying and analyzing binding sites and for predicting target druggability.  In a large-scale validation, SiteMap correctly identifies the known binding site as the top-ranked site in 86% of the cases, with best results (>98%) coming for sites that bind ligands with subnanomolar affinity.  In addn., a modified version of the score employed for binding-site identification allows SiteMap to accurately classify the druggability of proteins as measured by their ability to bind passively absorbed small mols. tightly.  In characterizing binding sites, SiteMap provides quant. and graphical information that can help guide efforts to critically assess virtual hits in a lead-discovery application or to modify ligand structure to enhance potency or improve phys. properties in a lead-optimization context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfAt0-gvcXDLVg90H21EOLACvtfcHk0li5RiOLAgvIXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1OhsA%253D%253D&md5=f03c7b27e30ae03d10e4127ed1f1ed3c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fci800324m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800324m%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26atitle%3DIdentifying%2520and%2520characterizing%2520binding%2520sites%2520and%2520assessing%2520druggability%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D377%26epage%3D389%26doi%3D10.1021%2Fci800324m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-ref35_1"><span><span class="NLM_contrib-group">Halgren, T. A.</span><span> </span><span class="NLM_article-title">New method for fast and accurate binding-site identification and analysis</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00483.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/ref35_1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1111%2Fj.1747-0285.2007.00483.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/ref35_1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=17381729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/ref35_1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkt1OnsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2007&pages=146-148&author=T.+A.+Halgren&title=New+method+for+fast+and+accurate+binding-site+identification+and+analysis&doi=10.1111%2Fj.1747-0285.2007.00483.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_ref35_1R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">New method for fast and accurate binding-site identification and analysis</span></div><div class="casAuthors">Halgren, Tom</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-148</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Structure-based drug design seeks to exploit the structure of protein-ligand or protein-protein binding sites, but the site is not always known at the outset.  Even when the site is known, the researcher may wish to identify alternative prospective binding sites that may result in different biol. effects or new class of compds.  It is also vital in lead optimization to clearly understand the degree to which known binders or docking hits satisfy or violate complementarity to the receptor.  SiteMap is a new technique for identifying potential binding sites and for predicting their druggability in lead-discovery applications and for characterizing binding sites and critically assessing prospective ligands in lead-optimization applications.  In large-scale validation tests, SiteMap correctly identifies the known binding site in > 96% of the cases, with best results (> 98%) coming for sites that bind ligands tightly.  It also accurately distinguishes between sites that bind ligands and sites that don't.  In binding-site anal., SiteMap provides a wealth of quant. and graphical information that can help guide efforts to modify ligand structure to enhance potency or improve phys. properties.  These attributes allow SiteMap to nicely complement techniques such as docking and computational lead optimization in structure-base drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr245hmZWXilrVg90H21EOLACvtfcHk0lhWqh4HyPCBdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkt1OnsLg%253D&md5=c233276ba9580393b282f255781f9ce6</span></div><a href="/servlet/linkout?suffix=ref35_1&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00483.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00483.x%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26atitle%3DNew%2520method%2520for%2520fast%2520and%2520accurate%2520binding-site%2520identification%2520and%2520analysis%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D69%26spage%3D146%26epage%3D148%26doi%3D10.1111%2Fj.1747-0285.2007.00483.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Patricelli, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomanbhoy, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagannathan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okerberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herring, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozarich, J. W.</span><span> </span><span class="NLM_article-title">In situ kinase profiling reveals functionally relevant properties of native kinases</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">699</span><span class="NLM_x">–</span> <span class="NLM_lpage">710</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2011.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=10.1016%2Fj.chembiol.2011.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=21700206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVejtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=699-710&author=M.+P.+Patricelliauthor=T.+K.+Nomanbhoyauthor=J.+Wuauthor=H.+Brownauthor=D.+Zhouauthor=J.+Zhangauthor=S.+Jagannathanauthor=A.+Abanauthor=E.+Okerbergauthor=C.+Herringauthor=B.+Nordinauthor=H.+Weissigauthor=Q.+Yangauthor=J.+D.+Leeauthor=N.+S.+Grayauthor=J.+W.+Kozarich&title=In+situ+kinase+profiling+reveals+functionally+relevant+properties+of+native+kinases&doi=10.1016%2Fj.chembiol.2011.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases</span></div><div class="casAuthors">Patricelli, Matthew P.; Nomanbhoy, Tyzoon K.; Wu, Jiangyue; Brown, Heidi; Zhou, David; Zhang, Jianming; Jagannathan, Subadhra; Aban, Arwin; Okerberg, Eric; Herring, Chris; Nordin, Brian; Weissig, Helge; Yang, Qingkai; Lee, Jiing-Dwan; Gray, Nathanael S.; Kozarich, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">699-710</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Protein kinases are intensely studied mediators of cellular signaling, yet important questions remain regarding their regulation and in vivo properties.  Here, we use a probe-based chemoprotemics platform to profile several well studied kinase inhibitors against >200 kinases in native cell proteomes and reveal biol. targets for some of these inhibitors.  Several striking differences were identified between native and recombinant kinase inhibitory profiles, in particular, for the Raf kinases.  The native kinase binding profiles presented here closely mirror the cellular activity of these inhibitors, even when the inhibition profiles differ dramatically from recombinant assay results.  Addnl., Raf activation events could be detected on live cell treatment with inhibitors.  These studies highlight the complexities of protein kinase behavior in the cellular context and demonstrate that profiling with only recombinant/purified enzymes can be misleading.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopb21npuaC_rVg90H21EOLACvtfcHk0lhWqh4HyPCBdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVejtbo%253D&md5=dda091b895850c95131f80c3aba9e8c7</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DJagannathan%26aufirst%3DS.%26aulast%3DAban%26aufirst%3DA.%26aulast%3DOkerberg%26aufirst%3DE.%26aulast%3DHerring%26aufirst%3DC.%26aulast%3DNordin%26aufirst%3DB.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BD.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKozarich%26aufirst%3DJ.%2BW.%26atitle%3DIn%2520situ%2520kinase%2520profiling%2520reveals%2520functionally%2520relevant%2520properties%2520of%2520native%2520kinases%26jtitle%3DChem.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D699%26epage%3D710%26doi%3D10.1016%2Fj.chembiol.2011.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B4W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B4W','PDB','6B4W'); return false;">PDB: 6B4W</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3NR9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3NR9','PDB','3NR9'); return false;">PDB: 3NR9</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i63"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01223">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_83088"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01223">10.1021/acs.jmedchem.7b01223</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">In vitro and cellular kinase selectivity data for compound <b>23</b>, additional TTK crystal structure views, docked structure of <b>23</b> in CLK2, experimental procedures for intermediates (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01223/suppl_file/jm7b01223_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01223/suppl_file/jm7b01223_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01223/suppl_file/jm7b01223_si_001.pdf">jm7b01223_si_001.pdf (1.26 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01223/suppl_file/jm7b01223_si_002.csv">jm7b01223_si_002.csv (3.81 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01223&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-21%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01223%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01223" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a420e1b2e3c52","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
